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1. BACKGROUND AND SIGNIFICANCE 
 
1.1 Ovarian Cancer Etiology 
 Ovarian cancer is the most prevalent and deadly gynecologic malignancy in the United 
States, and, as the fifth most common cause of cancer death in women, accounts for 
approximately 16,000 deaths per year [1].  Nearly all ovarian cancers originate from the 
epithelial cells comprising the outermost surface of the ovary.  There are four major subtypes of 
epithelial ovarian cancers (EOC) which are categorized by their histopathologic characteristics 
[2].  EOC variability is present not only in the morphology of histopathologic samples, but also in 
the wide variety of unique karyotypes, and the numerous low frequency genetic abnormalities 
associated with this disease.  Specific genetic alterations tend to be inconsistent between 
studies, but include changes on many levels including DNA sequence, copy number, 
methylation status, and miRNA levels [3-4].  Features on each level have been correlated with 
resistance to chemotherapy and with differing patient survival rates [5].  Despite an increased 
knowledge of the etiology of this disease, improvements in surgical techniques, advancements 
in chemotherapeutic treatments, and the characterization of ovarian cancer genomes at many 
levels [5-6], the morbidity and mortality associated with EOC overall has remained largely 
unchanged (0.39 in 1980–1989 to 0.43 in 1990–1997) [7].  EOC is often asymptomatic in its 
earliest stages and strategies with sufficient sensitivity and specificity to detect early-stage 
disease are currently not available.  As a result, most patients are diagnosed with late-stage 
disseminated EOC which typically becomes resistant to both standard and combination 
chemotherapies [7-9] and carries a prognosis of only 20% survival over five years [7].  
Therefore, the specific challenges presented by the heterogeneous and clinically insidious 
nature of EOC underlie the rationale for continued focus on these areas of research to improve 
upon the high morbidity and mortality currently associated with this disease. 
 Due to the paucity of early-stage clinical samples, the initiating events in ovarian cancer 
transformation are not well understood.  It is widely believed that the vast majority of ovarian 
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cancers originate from the single layer of simple cuboidal to low pseudostratified columnar 
epithelial cells encasing the mammalian ovary [10-11].  The genetic and morphologic 
heterogeneity seen in transformed EOC cells has been postulated as a mechanism by which 
the early homogeneous surface epithelial cells could and differentiate from their common origin 
to form the multiple malignant ovarian cancer subtypes.  The resulting cancers are clinically 
categorized into four distinct histopathologic categories with the following distribution of 
incidence: 1) papillary serous (50-60%), 2) endometrioid (25%), 3) mucinous (4%), 4) and clear 
cell (4%) [12-14].  These subtypes are distinguished by their morphologic features, which 
resemble those of the specialized epithelia of the reproductive tract that derive from the 
Müllerian ducts. Specifically, papillary serous cancers resemble cancers of the fallopian tube, 
endometrioid ovarian cancers are characterized by endometrial-like glands, and mucinous 
ovarian cancer types resemble endocervical and intestinal epithelial cells [15-16].  The ability of 
the ovarian surface epithelium (OSE) to assume these varying Müllerian-like features has 
recently been linked to the inappropriate activation of homeobox (HOX) genes that control 
patterning of the reproductive tract [17-19].  This finding adds yet another regulatory level by 
which ovarian cancer may generate heterogeneity by phenotype.  The dynamic interactions 
between the multiple regulatory systems that govern differentiation and spontaneous neoplastic 
transformation from a normal epithelial cell to one of many tumorigenic ovarian cancer 
phenotypes are beginning to be explored. As improvements in prevention and early detection 
will likely have a significant impact on morbidity and mortality of this disease, emphasis is 
placed on expanding the knowledge bases of the early transformative events. 
The specific mechanisms underlying spontaneous transformation in EOC are not well 
understood.  Epidemiologic data have provided valuable clues as well as data supporting 
several seemingly paradoxical theories that explain precisely how ovarian cancer might form. 
Three major interrelated theories have been proposed to explain the epidemiologic data 
associated with ovarian cancer susceptibility [20-21].  The first of these is based on the link 
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between ovarian cancer risk and the number of ovulatory cycles and is thus termed the 
incessant ovulation hypothesis.  It is based on the concept that repetitive wounding and cell 
proliferation in postovulatory repair of the ovarian surface epithelium results in an accumulation 
of genetic abnormalities that promote cellular transformation [20].  If these damaged epithelial 
cells are invaginated into the tumor-promoting stromal environment, aberrant autocrine and 
paracrine stimulation by trophic hormones, phospholipids, and vascular endothelial growth 
factor are thought to accelerate cellular transformation during post-ovulatory growth and 
epithelial regeneration [15-16].  These putative mechanisms are incongruent in a temporal 
sense with the findings that stoppage of ovulation for a disproportionately short time interval 
significantly reduces the lifetime risk of ovarian cancer.  Short-term stoppges in the ovulatory 
cycle reflect less than 1/40 of a woman's total lifetime ovulations and include the carriage of a 
single full-term pregnancy, less than one year of breast feeding, or as little as 6 months of oral 
contraceptive usage [22].  An alternative transformation mechanism has been hypothesized that 
centers on the reduction in pituitary gonadotropin levels occuring with these same protective 
events.  This theory implicates surges of pituitary gonadotropins occurring at ovulation and 
persistent high gonadotropin levels following menopause in the activation of mitogenic pathways 
and the resulting accumulation of genetic changes leading to carcinogenesis [23-25].  The third 
theory for ovarian cancer causation states that inflammation and changes in redox potential in 
the setting of ovulation and OSE repair account for the increased risk of ovarian cancer 
associated with pro-inflammatory conditions.  These include talc/asbestos exposure, 
endometriosis, pelvic inflammatory disease, and mumps infection [26-27].  Together, these 
theories are largely based on altered incidence rates generated from physiologic and 
epidemiologic data with some molecular and cellular correlates.  Each of these theories explains 
a portion of disease causation in terms of modifiable risk factors, however, optimal minimization 
or elimination of these factors does not prevent EOC completely.  Therefore these variables 
likely serve as cofactors for underlying events resulting in cellular transformation. 
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At the molecular level, studies in cell biology demonstrate that the epithelial cells 
adjacent to the site of follicular rupture sustain sub-lethal oxidative DNA damage and are more 
likely in healing to give rise to cells with genetic alterations and a transformed phenotype [28].  
This is supported by clinical reports that have documented cellular atypia including metaplasia, 
hyperplasia, and ovarian intraepithelial neoplasia of the surface epithelium adjacent to invasive 
carcinoma [29-31].  Despite this knowledge, our current understanding of the mechanisms of 
surface epithelial cell transformation is limited by the paucity of early stage clinical samples [32].  
This is particularly true in the characterization of how early-stage transformative events lead to 
progression and eventually tumorigenesis.  Increased understanding of how the initiating events 
underlying the transformation process and the inherent plasticity of the ovarian surface 
epithelium could link to later transformative stages will likely reduce the morbidity and mortality 
currently associated with ovarian cancer through the identification of new strategies for 
detection, diagnosis, and treatment. 
1.2 Animal Models of Ovarian Cancer 
 A number of in vitro and in vivo murine models have been developed to study the 
characteristics and behavior of EOC, each with its own set of strengths and limitations.  
Chemically induced cellular transformation models mark some of the first successful attempts to 
induce EOC in laboratory mice and rats and, with varying success and timelines, linked DNA 
damage by 1,3-butadiene [33], and dimethlybenz(a)anthracene (DMBA) 20-methylcholanthrene 
[34], to EOC.  The applicability of data from carcinogenic induction models is unclear, as 
evidence supporting the association of chemical carcinogenesis and ovarian cancer etiology in 
humans is largely absent [3]. 
 In addition to chemical models of DNA damage, genetically induced ovarian epithelial tumor 
models have also provided valuable information regarding gene alterations linked to 
tumorigenesis.  One of the first genetically induced models was created through the cross 
breeding of transgenic mice expressing the avian retroviral receptor (TVA) with p53-/- mice.  The 
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induction of transformation by oncogenic alteration of any two of three (c-myc, Kras, and Akt) 
oncogenes on the p53-/- background was sufficient to increase the rate of tumorigenesis [35].  A 
second approach demonstrated that injection of the simian virus 40 T-antigen (SV40 T-Ag) into 
the male pronucleus of half-day old embryos was sufficient to generate ovarian tumors.  
 However, tumor outcomes differed significantly from human EOC because, despite linking of 
the SV40 Tag to the epithelial ovarian surface with the Müllerian Inhibitory Substance Type II 
Receptor (MISIIR) promoter, uterine masses and polycystic kidneys also developed [36].  In a 
third model, the targeted expression of murine PIK3CA under the MISIIR promoter resulted in 
mouse ovarian surface epithelial cell (MOSEC) hyperplasia, but cells were not tumorigenic after 
18 months.  However, both PIK3CA and mutant K-ras were still thought hold promise for 
spontaneous transformation models as they were shown to increase anchorage-independent 
growth of cultured MOSEC [37].  A fourth model used transient (21 day) inactivation of p53 and 
Rb by adenoviral infection within the ovarian bursa.  These experiments demonstrated that early 
causative events in ovarian cancer transformation need not be maintained for tumorigenesis as 
early transient inactivation resulted in ovarian tumors in 33/34 mice at ~225 days [38].  
Adenoviral administration was also utilized for in a fifth genetic model that showed that alteration 
of Pten when paired with K-ras [39] or Apc  [40] generates invasive primary ovarian 
endometrioid adenocarcinomas.  Because of its strong association with inherited risk for ovarian 
cancer [41] the conditional inactivation of Brca1 in the MOSEC was speculated to increase 
ovarian cancer formation.  Additionally, the Brca1 protein is involved in diverse cellular events 
and functions related to genomic instability, including homology-directed DNA repair [42], 
transcriptional regulation [43-44], chromatin remodeling [45] ubiquitin ligation [46], and 
centrosome amplification [47].  However in this seventh genetic model, conditional inactivation 
of Brca1 introns 5-13 (Brca1Δ55-13) using AdCre administration in the ovarian bursa resulted in 
surface epithelium hyperplasia and the formation of inclusion cysts but not in tumor formation 
after 240 days in vivo.  Conditional deletion of Brca1 in vitro resulted in slowed growth that was 
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reversed by p53 deletion, as well as increased sensitivity to the DNA damaging agent cisplatin 
[48].  The last relevant genetic model showed that Brca1 inactivation coupled with either p53 or 
Rb inactivation also failed to yield epithelial tumors.  Unpredictably, leiomyosarcomas formed in 
adjacent cells and showed more rapid progression with concomitant inactivation of Brca1 and 
p53, but not Rb and p53 [38].  Considering the relative successes of these eight MOSEC 
models for genetically induced transformation, the unpredictability of success and the limitations 
of each, coupled with the fact that most human EOCs are not predictably linked to a specific 
genetic alteration, brings into question the utility and significance of genetic models for 
comparison with human EOC. 
 Animal models that most closely mimic the human disease are vital not only in furthering our 
understanding of the biological and genetic factors that influence disease phenotype, but also 
serve as the basis for the development and of detection and treatment strategies.  As early-
stage human ovarian cancer samples are rarely available, and human OSE do not 
spontaneously transform in culture, animal models are heavily relied upon as investigative tools.  
These models afford investigators the opportunity to study the mechanisms underlying cellular 
transformation longitudinally and from its earliest events.  Considering the various chemical and 
genetic animal models currently available for ovarian cancer, very few develop ovarian tumors 
spontaneously. Low tumor prevalence and extended time to first occurrence of tumors also 
renders many of these models impractical for experimental studies [49-51].  Each MOSEC 
model that incorporates genetic alteration in the induction of tumorigenesis has proven 
somewhat paradoxical, as the action of gene alteration using MOSEC in vitro does not equate 
to EOC causation in vivo.  Together, these models suggest that either ex vivo manipulation or 
embryonic transgene expression do not accurately represent human epithelial ovarian cancer 
(EOCs), which arise spontaneously and in a vast majority of cases are linked to age and to the 
total number of ovulatory cycles.  Additionally the significance of data generated from studies 
where transformed human cells are injected into immune-compromised mice is confounded by 
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the absence of immune regulatory mechanisms known to block tumor growth and immune 
mediated tumor-stromal interactions. 
1.3 Utility of MOSEC Model 
 More recently, syngeneic rodent models have been developed where ovarian surface 
epithelial cells were transformed in vitro. Transfused cells were then injected into the peritoneal 
cavity of immune competent animals in vivo to study tumorigenesis.  Initially, spontaneous 
transformation of OSE in vitro was shown to occur in a matter of weeks in rat [52-53], with 
multiple divergent cytogenetic changes in each transformed cell line.  A syngeneic mouse model 
was developed soon after by Roby et al. [54] with significantly slower transformative properties 
that facilitated the characterization of  key transformative stages.  Similar to the rat model, in the 
mouse ovarian surface epithelial cell (MOSEC) transformation occurred spontaneously in vitro 
with repeated passages, and the cells proved tumorigenic in C57BL6 mice.  Variations on this 
model have since been used by numerous investigators to study the transformation process and 
the tumorigenic features of ovarian cancer, including cytoskeletal and adhesion protein 
alterations, tumor stromal interactions, proliferation, differential activation of survival and 
apoptosis pathways, and endothelial growth factor expression [55-59].   
 The similarity of genetic alterations between late stage transformed cells of the MOSEC 
model and genetic alterations previously characterized from human ovarian cancers provides 
further support for the appropriateness of this model.  For example, array comparative genomic 
hybridization (array-CGH) of late-stage transformed MOSEC revealed 80% conservation of 
synteny between the MOSEC and human ovarian malignancies of epithelial origin [57]. Parallel 
pathways of karyotypic change were also reported between species [57].  Additionally, genome-
wide transcriptional profiles of late-stage tumorigenic MOSEC lines revealed a similar gene 
expression pattern to human carcinomas of varying cell morphological, behavioral, and 
prognoses [60].  These include a high percentage of shared, differentially expressed genes, 
similar alterations in major signal transduction pathways, and common alterations in pathways 
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of cellular metabolism [61].  The MOSEC model mimics human ovarian cancer in its abnormal 
distribution of the actin cytoskeleton and of the adhesion proteins necessary for dissemination of 
the primary tumor from the surface of the ovary into the peritoneal cavity [55].  Together, these 
morphologic and genomic analyses provide evidence that the MOSEC disease model as an 
accurate parallel in vitro and in vivo system with which to study of human ovarian cancer 
initiation and progression. 
 The MOSEC timeline also closely mimics human EOC because transformation arises over 
relatively a long period of time and requires repeated long-term growth and passaging.  
Continuous culture of the MOSEC is intended to mimic the repeated growth and repair cycles 
theorized to contribute to ovarian cancer causation in humans [54-55].  This model is similar to 
human EOC because significant variability between and within MOSEC cell lines is well 
established [54-55].  Additionally, histopathologic heterogeneity is also seen in tumors formed 
from late stage injected MOSEC in vivo [54-55].  Until a mechanism for induction of EOC within 
the mouse ovary in vivo is established, the MOSEC model remains a highly relevant syngeneic 
animal model for hypothesis testing in transformation and tumorigenesis of the ovarian surface 
epithelium. 
 Taken together, MOSEC model is particularly well suited for modeling cellular transformation 
in ovarian cancer because it offers the following advantages:  1) A long timeline (12-18 months) 
for the analysis of neoplastic transformation, 2) spontaneous transformation without viral or 
genetic alteration, 3) the generation of late stage cells with transcriptomic and behavioral 
similarity to the human disease, 4) tumor establishment in immune competent syngeneic mice.  
Additionally, the MOSEC model is superior to previously established immortalized human 
ovarian epithelial cell lines as it allows for continuous tracking of the transformation process 
across the gamut of clearly defined stages without viral alteration or carcinogenic induction of 
DNA damage.   Additionally, this model allows for in vivo biomarker detection of tumors 
following transformed MOSEC xenografting and subsequently for efficacy studies of both 
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chemotherapeutic treatment regimens and chemo preventive strategies in syngeneic immune 
competent mice. 
1.4 Genomic Heterogeneity in Ovarian Cancer 
 Like the vast majority of solid tumors, human ovarian carcinomas have near-diploid to highly 
aneuploid karyotypes and many contain complex combinations of structural and numeric 
chromosomal aberrations that parallel tumor grade [62].  Additional cytogenetic analyses of five 
human ovarian surface epithelial cell lines immortalized by HPV16-E6E7 viral oncogenes 
revealed a high number of chromosomal imbalances including +1q, +3q, +8q, and +20q, -4q, -
5q, -8p, -17p, -18q, and -22q, only one of which was universally present among the lines (+19q 
(5/5 lines) [63].  Additional reported non-clonal chromosome imbalances with variable 
prevalence marked heterogeneity among the cell lines and included -13q (4/5 lines), +5q, +20q -
22q (3/5 lines each), +1q +11q, -2p, -4q, -8p, -10p and -11q (2/5 lines each).  This level of 
variability was documented despite the selective omission of chromosomal imbalances present 
in only one line.  Most important is the realization that each transformed cell line was 
characterized by a unique set of imbalances, and that only 1/12 (+19q) of the imbalances was 
universally detected across all transformed lines [64].  A second, independent study found 
different karyotype alterations when forming a second set of transformed ovarian cancer cell 
lines [65].  This result demonstrates diversity in the karyotypic alterations is permissive to the 
tumorigenic phenotype of human OSE, and supports the concept that multiple combinations of 
genomic alterations can result phenotypically similar cellular transformations. 
 Heterogeneity among tumors is commonly reported, and ranges from a high degree of 
structural aberrations to only low frequency of relatively simple rearrangements [66-70].  This is 
significant to cancer transformation as karyotype heterogeneity can have many gene based and 
non-gene causes including dysregulation of cell cycle checkpoints [71-75], the presence of 
structural aberrations caused by errors in homologous and nonhomologous end-joining of 
double-stranded DNA, and telomere shortening [76-78].  Independent of the mechanism, the 
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variability that arises from karyotype level change likely provides the basis for selection and 
evolution of cancer cell populations.  Previously, intra-tumor  "heterogeneity" has been defined 
as metaphase-to-metaphase variations among the 50 quantified for each transitional stage, but 
the complexity of such variations within a single tumor or cell line has eluded quantification [79].  
Recently, a method developed by Castro et. Al. [80] showed how inter-tumor diversity among 
patient samples could be quantified for non-normally distributed data sets by applying the 
Shannon Index to quantify the heterogeneity of chromosome count data for various tumor types 
[80].  As a measure of genomic instability, we have adapted this method and applied the 
Shannon Index to measure the diversity contributed by each whole and aberrant chromosome 
to the cell population.  The indices for each chromosome are summed to generate a summed 
index for the karyotype of a given cell. 
  Chromosome instability and aneuploidy result in large scale DNA copy number variations by 
whole chromosome that can significantly influence the transcription profiles of cancer cells.  
Several investigations into cancer genomes suggest that nearly all cellular genes may be 
expressed in proportion to the dosage of the corresponding chromosomes [81-83].  These 
studies support the notion that cancer karyotypes have significant impact on gene expression 
and therefore for cell phenotype.  Oppositely, in human disease of inherited autosomal 
trisomies, matching of whole chromosome copy number proportional to the cellular 
transcriptome does not usually occur or is cell type specific [84-85].  Understanding how this 
mechanism of gene regulation may function in cancer cell macro evolution and selection by 
genome system would further define the chromosome-transcriptome relationship of the cancer 
cell genome.  The inherent property of spontaneous transformation in the MOSEC model is 
important as it eliminates the artificial induction of immortalization by the use of viral or other 
methods required to transform human cells [63].  Although these methods have become 
commonplace tools for molecular cell biologists, the generation and usage of genetically altered 
clones to study cellular transformation presents several significant challenges that warrant 
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further discussion.  The first challenge lies in the determination of whether the change in cell 
phenotype should be attributed to the intended gene-level alteration in transcription, translation, 
and protein synthesis of the desired gene product, or, alternatively, reflects the inevitable 
disruption of the host genome sequence, structure, and spatial relationship of all other genes on 
that chromosome.  Secondly, the selection pressure needed to isolate stably expressing cells 
creates an “evolutionary bottleneck” in which individual cellular clones are picked and are 
individually subcultured in vitro.  The use of virally transformed cells as a model for this disease 
does not align well with our current understanding of human ovarian cancer formation in situ as 
there is no known viral link to this disease.  Depending on the site of insertion, it is also possible 
that disruption of the host genome may increase genomic instability, subsequently increasing 
the chance for transformation by this mechanism [86]. 
 High-degrees of karyotypic heterogeneity have consistently marked genomic instability in 
OECs and cancer cell lines from both humans and mice [87].  Currently, neither the timing nor 
the extent of this genomic instability has been characterized.  Genetic models for MOSEC tumor 
induction may not mimic spontaneous disease and have limited ability to form epithelial ovarian 
cancer in vivo. Additionally, previous attempts at long-term culture of human ovarian epithelial 
cells have failed to spontaneously generate tumorigenic cells, and tumorigenesis of transformed 
human lines can only be tested in immune compromised mice.   Therefore, the MOSEC model 
is well suited in this regard to investigate several aspects of genomic instability as it relates to 
the key transformative stages of transformation and tumorigenesis. 
 
1.5 Specific Aims 
 Using the MOSEC model of spontaneous transformation and tumorigenesis in syngeneic 
C57BL6 mice together with a longitudinal study design, genome-wide multivariate analysis was 
facilitated at several key transformative stages.  With the understanding that cancer cell 
populations have the properties of a complex adaptive system, our experimental design 
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accounted for the possibility that these cell populations may work as a dynamic network 
comprised of many parallel agents that act in a non-linear fashion.  Therefore, the following 
study emphasizes a holistic approach to experimental design that encompasses the possibility 
of stochastic, non-linear change. To this end, data collection and analysis was performed on cell 
populations such that the degree of karyotypic variability from cell to cell is characterized at 
each transitional stage.  Using these means under the genome centered paradigm, the 
relationships among gene expression profiles, cellular phenotype cellular behavior and 
karyotype heterogeneity can be elucidated.  The current study thereby provides evidence 
supporting an alternate hypothesis of cancer formation that emphasizes genome level variability 
and cellular selection over the current widely held gene-based theory for cancer causation and 
stepwise clonal evolutionary theory of tumorigenesis. 
 These specific aims are designed to provide insight into current major challenges in the 
diagnosis and treatment of epithelial ovarian cancer which stem from the paucity of early stage 
samples, the heterogeneity of the disease, and the ability of OSEC to differentiate to a number 
of heterogeneous subtypes: 1) characterization of genomic instability and the onset of macro-
evolutionary change from the earliest stages of spontaneous transformation from the diploid 
genome 2) definition of the relationship between karyotype heterogeneity and the cell 
phenotype of each key transformative stage  3) comparing phenotypes and karyotype 
heterogeneity between spontaneously transformed cells and genetically induced models of 
cellular transformation 4) quantifying the differences in karyotype profiles between late-stage 
injected cells and the tumors which evolved in vivo  5) identification and profiling of differentially 
expressed genes between stages and between tumorigenic and non-tumorigenic cell lines 6) 
defining the role of whole chromosome copy number change in gene regulation by evaluating 
the genome-transcriptome relationship at each key transformative stage.  
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2. METHODS 
2.1 Experimental Overview 
 To determine the pattern of karyotype variability and its relationship to spontaneous cellular 
transformation over time, mouse ovarian surface epithelial cells (MOSEC) were grown 
continuously in culture from primary cells to their eventual transformation to the malignant 
phenotype. Population karyotype, senescence, and morphologic data were collected at the 
earliest transformative stages.  Subsequent key transformative stages were determined by cell 
phenotype and by repeat testing of the MOSEC in vitro using traditional and organotypic models.  
Genome level change was measured at several levels including spectral karyotype analysis for 
MOSEC populations, array comparative genomic hybridization (aCGH) for DNA copy number, 
and RNA transcript abundance for transcriptional change (Figure 1).  To confirm the 
tumorigenicity of MOSEC, late stage day 528 cells were compared to day 245 cells in vivo by 
allograft followed by histopahologic and karyotype evaluation of harvested tumors  
 All analyses were performed real-time with the exception of the microarray analyses. The 
selection of key transitional stages was based on previously established patterns of in vitro 
phenotype change in this model [54-55].  These included ranges of passage number, size, 
density, growth rate, anchorage-independent growth efficiency in soft agar, invasiveness in 
matrigel culture, and depth of invasion on collagen rafts.  
 
2.2 Cell Culture 
2.2.1 Establishment of Spontaneously Transforming Primary Cells 
 Primary MOSEC were generated from a single ovary from a 6-week-old C57BL6 female 
mouse.  To avoid the possibility that heterogeneity was generated from the establishment of cell 
lines from multiple mice, primary cultures were attempted using cells from the single ovary, but 
viability was low using this method (1:20).  Cultures were discarded if they failed to show viability 
by day 30.    The ovaries were resected, and residual remnants of the oviducts and bursa were 
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removed.  Each ovary was individually incubated for 20 minutes in a 20 mm dish with 50 µl of 
0.25% trypsin and was rolled gently with a toothpick to help dislodge the surface epithelial cells.  
For each ovary, cells were resuspended in MOSEC growth medium (low glucose DMEM with 
4% fetal bovine serum, 100 µg/ml each of penicillin and streptomycin, 5 µg/ml insulin, 5 µg/ml 
transferrin, and 5 ng/ml sodium selenite (Invitrogen, Carlsbad, CA) were plated in one well each 
of standard 6-well tissue culture plates (Becton-Dickinson, Oakville, ON, Canada). 
2.2.2 Conditional Inactivation of Brca1 
  To determine cell phenotype and the extent of karyotype heterogeneity in genetically 
induced versus spontaneously arising transformation models, MOSEC cells from mice bearing 
loxP sites in introns 4 and 13 of the Brca1 gene (Brca1loxP/loxP [FVB;129-Brca1tm2Brn]) were 
provided as a generous gift from investigators Clark-Knowles and Vanderhyden [48].  Following 
the initial establishment of the primary cells MOSEC as above (30 days), targeted inactivation of 
Brca1 was achieved via adenoviral delivery of Cre recombinase to MOSEC using recombinant 
adenoviruses Ad5CMVCre (AdCre), (Vector Development Laboratory, Houston, TX, USA).  
Mitotic cells were passaged only enough times to assure mitotic activity sufficient for SKY 
analysis of metaphase spreads (20 days post AdCre administration). 
2.2.3 Routine Cell Culture Conditions 
 Cells were passaged in MOSEC medium and were split at varying ratios, depending on their 
growth rate (1:2 - 1:12 ratios).  For growth rate analyses, cells were seeded at densities of 1 x 
104 and 5 x 104 cells, and subconfluent cell counts were determined at different times 
postseeding.  Cell doubling times were estimated from the formula: doubling time = 
(T)ln2/ln(Xe/Xb), where Xe is the cell number determined at the endpoint, Xb is the cell number at 
the beginning time point, and T is the total elapsed time (in hours). Transitional states of 
carcinogenesis were captured by preparing frozen cell stocks every three to five passages. 
Stocks were stored in liquid nitrogen and preservation of cell phenotype was verified and 
population karyotype analyses were shown to be >95% similar in re-seeded cells from frozen 
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stocks.  Freezing medium contained 50% fetal bovine serum, 40% low glucose DMEM, and 10% 
DMSO.  All analyses were performed on transitional stages real time using never-frozen cells 
with the exception of the collection of mRNA for analysis of transcript abundance.    
 
2.3 In vitro invasion, proliferation, and migration assays 
2.3.1 Soft Agar Proliferation Assay 
 MOSEC (1.5 x 104) were suspended in 1.0 ml of 0.5% Bactoagar (Difco Laboratories, 
Detroit, MI) in the MOSEC growth medium at 42°C, layered over 1 ml of 0.8% Bactoagar in 
DMEM in 6-well dishes, and cultured in 5% CO2 in a humidified chamber.   After 15 days of 
growth monitoring, colonies were stained with cresyl violet, sized using a 10x calibrated 
eyepiece and were counted if they exceeded >10 µm in diameter. 
2.3.2 Migration Assay 
 MOSEC were trypsinized and resuspended at 105 cells per 0.3 ml serum-free media and 
migratory capacity was tested using 6-well invasion chambers with 8 µl Matrigel coated trans-
well filter inserts (BD Biosciences) and 8 µl uncoated controls.  Cell suspension was added to 
the upper chambers and the lower chamber contained 0.8 ml serum-containing media.  After 4 h 
in a humidified 37°C incubator, the inserts were removed, the upper surface of the filters was 
cleaned thoroughly with cotton swabs, and the lower surface was fixed with 4% 
paraformaldehyde for 10 min and stained with 0.5% crystal violet in 20% methanol for 5 min.  
Membranes were mounted on glass slides and images were captured using a light microscope 
with 20x objective and were counted in a blinded fashion.  Values reported are normalized to 
controls as follows: Migration = migratory cells matrigel/ migratory cells control. 
2.3.3 Three dimensional growth in Matrigel 
 MOSEC (2 x 104 cells/well) were embedded directly in Matrigel (BD Biosciences, Franklin 
Lakes, NJ) diluted 1:1 with the MOSEC growth medium.  Following solidification of the Matrigel, 
cultures were incubated at 37°C and monitored for up to 15 days.  Phase contrast images of 
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colonies grown in Matrigel were captured with a Nikon Coolpix 990 digital camera attached to a 
Nikon Diaphot microscope using 20x objectives.  Invasiveness was scored by branching 
morphology as 1) number of branches/ cell and 2) branching cells/ total cells.  Two hundred cells 
were counted per assay. 
2.3.4 Organotypic Collagen Raft Cultures 
 Organotypic collagen raft cultures were prepared essentially as described by Gregoire et al. 
[63], with minor modifications.  Briefly, collagen plugs (2.5 ml of 1.63 mg/ml rat tail collagen; BD 
Biosciences) were prepared in trans-well filter inserts (BD Biosciences) and were equilibrated 
with the MOSEC growth medium prior to seeding the cells.  Cells (5 x 105) were seeded onto 
collagen plugs and allowed to grow to confluency at 37°C in a humidified incubator with 5% CO2 
for 1-2 days.  After removing the medium from the top chamber, raft cultures were maintained 
with sufficient medium for cells to grow at the air/ liquid interface for 14-21 days. Cell growth was 
monitored and cells were fed by changing the medium every 2 to 3 days from the bottom 
chamber.  Rafts and their associated cultures were carefully transferred into 10% neutral 
buffered zinc formalin (Thermo Fisher Scientific Inc.) for processing by routine histopathologic 
analysis. 
 
2.4 Senescence Associated Beta Galactosidase Activity 
 Senescence Associated Beta Galactosidase Activity (SA-βgal) was measured from MOSEC 
cells grown on glass slides under standard culture conditions.  Slides were removed from culture 
dishes, rinsed twice with phosphate buffered saline (PBS), and were fixed in 2% formaldehyde, 
0.2% glutaraldehyde in PBS at room temperature for 10 minutes.  Cells were rinsed twice again 
with PBS, covered with fresh staining solution (400 nM citric acid, sodium phosphate pH 6.0 1.5 
mM NaCl, 200 mM MgCl2, 50 nM potassium ferrocyanide, 50 nM potassium fericyanide, 20 mg/ 
ml X-gal in DMF), and  incubated without light for 12-24 hours at 37°C.  SA-βgal images were 
captured with an Olympus BX41 microscope at 40x with DP72 camera.  Cells were counted with 
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the investigator was blinded to their identity using NIH Image (U.S. National Institutes of Health 
and available at http://rsb.info.nih.gov/nih-image/). 
 
2.5. Population Karyotype Analysis 
2.5.1 Spectral Karyotype Analysis (SKY) 
Painting and detection of metaphase cells from key transitional stages was performed 
following overnight treatment with colcemid and collection using mitotic shake-off.  
Chromosomes were prepared using standard hypotonic treatment, fixation, and air drying [88].  
After pepsin treatment and fixation with formaldehyde followed by dehydration, the slides were 
denatured in 70% formamide and 2x SSC and hybridized with denatured mouse painting probes 
(Sky Paint, Applied Spectral Imaging, Vista, CA) for over 48 hours at 37°C.  Following two 
additional washes in 2x SSC, the slides were mounted in an anti-fade solution (Vectashield; 
Vector Laboratories, Burlingame, CA) with 4,6-diamidino-2-phenylindole (DAPI).  Image 
acquisition was performed using an SD200 Spectracube (Applied Spectral Imaging, Carlsbad, 
CA) mounted on a Leica DMRXA microscope (Leica, Wetzlar, Germany).  Applied Spectral 
Imaging software (Spectral Imaging and SkyView) was used for image acquisition and analysis 
of cell populations at each key transitional stage.  Typically, multi-color SKY karyotype 
descriptions are based on only five to ten mitotic figures with the emphasis on tracing clonality of 
the cell line [79].  The current data set was generated by capture of 50 mitotic figures with clearly 
defined boundaries and minimal chromosome overlap [89] for each population of interest.  
Chromosomes were organized into a karyotype table according to their color and size using SKY 
viewer software [90].  Results were verified by a second investigator who was blinded to the 
sample identity and concordance was ~97% for whole and aberrant chromosome identification. 
 Results were tabulated for all whole chromosome copy number change and derivative 
chromosomes.  Chromosomal aberrations were considered clonal if present in >20% of the 
metaphases, (> 30% of metaphases for chromosome loss), according to established 
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International System for Chromosome Nomenclature (ISCN) conventions.  Aberrations found in 
<20% of metaphases were termed, “nonclonal.” 
2.5.2 Quantifying karyotype heterogeneity within a key transformative stage 
 To obtain a quantitative measure for karyotypic diversity of cells at each key transitional 
stage, an adaptation of the Shannon Index was calculated using methods of adapted systematic 
cytogenetic analysis adapted from Castro et. al. [80].  This method has been widely used by 
ecologists to calculate population diversity and has been validated for tumor heterogeneity by 
total chromosome count by Castro et. al. [80].  Population diversity at each key transitional stage 
was quantified by summation of Shannon indices (H′) [91] for each whole (1-19) and aberrant 
(der) chromosome according to the following equations: 
 
 
equation 1 
 
 
 
equation 2  
 
equation 3  
 
 Where ni is the number of cells with chromosome count i (the abundance of chromosome 
count i), S the number if unique chromosome counts in the population, pi the relative abundance 
of each chromosome count (calculated as the proportion of cells with that count).  It can be 
shown that for any population, there is a maximum possible H based on the number of different 
chromosome counts, where Hmax = ln S.  This occurs when all counts for a given chromosome 
19 
 
are equally distributed within the population.  The X chromosome was omitted from all Shannon 
Index calculations as Barr body inactivation is likely dysregulated and its impact on X 
chromosome variability is an unknown potentially confounding variable for the current data and 
to future comparisons with male genomes. 
  
2.6 Whole Genome Analysis of mRNA Transcript Abundance 
2.6.1 Sample Collection, Labeling, Hybridization, and Scanning 
 Total RNA was isolated from biological triplicates of cells grown to 75% confluency in T-75 
flasks at key transformative stages days 170, 245, 450, and 528.  RNA extraction was performed 
from with Trizol reagent (Invitrogen, Carlsbad, CA) followed by clean-up using an RNeasy mini 
kit (Qiagen, Valencia, CA) in accordance with the manufacturers’ instructions.  First strand cDNA 
synthesis, second strand synthesis, clean-up, and in vitro amplification of biotin-labeled cRNA 
fragments were performed using an original starting amount of 1µg RNA for each biological 
replicate. The hybridization cocktail containing 10μg fragmented RNA and probe array controls 
was bound to Illumina MouseRef-8 v2.0 expression bead chips.  By design, one array on each 
chip served as a technical replicate to account for between-chip variation and was determined to 
have a correlation coefficient of >0.996.  Beadchips were scanned on the Illumina BeadArray 
Reader confocal scanner for 90 min and initial quality assessments were performed according to 
the manufacturer’s instructions.  Procedures were carried out by personnel in the Applied 
Genomics Technology Center (AGTC, Wayne State University). 
 
2.6.2 Preprocessing and Normalization 
 High density microarray image files were interpreted and quality was assessed of both the 
internal controls and the between-chip technical replicate.  Microarray data pre-processing 
including background subtraction, cubic-splines based normalization, and quantification of 
differential expression compared to negative controls were performed using Illumina Genome 
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Studio Software.  Probesets were excluded from the outputs of time course and differential 
expression analyses if they failed to meet the following criteria for at least one of the arrays: 
significant differential expression above background p >0.1, and signal intensity greater than 3x 
background (signal intensity >420). 
 
2.6.3 Time Course Analysis of Differential Gene Expression 
 To identify differentially expressed genes throughout spontaneous transformation, time-
course microarray data analysis was performed using Extraction of Differential Gene Expression 
(EDGE) software [92].  EDGE utilizes a series of cubic splines to model within class temporal 
gene expression.  A statistic is calculated for each gene that quantifies the goodness of fit 
between the null hypothesis (Ho is defined as constant expression over time, where the sum of 
squares is minimized among all possible flat lines) and the alternative hypothesis (a curve that 
minimizes the sum of squares among a general class of cubic-spline curves).  A significance cut-
off was applied to the statistics by using a false discovery rate criterion where the null distribution 
of the statistic is based on genes with no differential expression.   These analyses were 
implemented using the Optimal Discovery Procedure for simultaneous significance testing of 
differential expression [93] using C++ extensions with the open source R version 2.7.1 Statistical 
Environment (www.r-project.org) [94].  Differential gene expression was considered significant 
where q < 0.01. 
 
2.6.4 Profile Fitting for Differentially Expressed Genes 
 Time-course based profile analysis of the differentially expressed genes was performed 
using Short Time Expression Miner (STEM) [95].  Genes were assigned to model temporal 
expression profiles based on maximization of the correlation coefficient between the model 
profile and the actual gene expression.  The number of genes expected to be assigned to a 
profile was estimated by random permutation of the original time point values and assignment of 
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genes most closely matching model profiles.  The process was repeated for a large number of 
permutations.  The statistical significance of the number of assigned versus expected genes for 
each profile was computed, and model profiles were grouped to form clusters of profiles.  
Profiles were assigned based on unfiltered relative expression levels from the previously 
generated list of differentially expressed genes using EDGE.  Settings were kept at the original 
defaults with the exception that maximums were set to 5 unit change between time points, 50 
theoretical profiles, and correlation of 0.9 among profiles and among clusters.  Genes were 
included in a given profile at a significance level of p <0.05. The Benjamini and Hochberg 
method [96] was used for multiple testing correction of the false discovery rate.  The biological, 
molecular, and cellular functions for each cluster of genes were interpreted using Gene 
Ontologies [97] as indicated below.   
 
2.6.5 Biological Significance of Microarray Data 
 The biological significance of sets of genes assigned to lists or expression profiles of interest 
was assessed using Gene Ontologies (GO) enrichment analysis.  Differentially expressed genes 
were classified by their enrichment for corresponding GO categories, and the observed number 
of genes in each of these GO categories was recorded. Genes represented on the Illumina 
MouseRef-8 v2.0 expression bead chip served as the reference gene list. The expected number 
of genes in each GO category corresponds to the number of genes falling into that GO category 
in the reference gene list.  A given GO category was considered enriched when the observed 
number of genes in that category was significantly greater than the expected number.  A 
Bonferroni corrected p-value, p <0.05 was used for lists generated by SAM analyses.  For STEM 
data, annotations for biological processes, molecular function and cellular componentry were 
determined at a depth of three annotation levels for Gene Ontologies, requiring a minimum of 
five genes per annotation and annotation significance was determined where p <0.05 after 
correction for multiple hypothesis testing by randomization. 
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2.7 Validation of Spectral Karyotype Data by Array Comparative Genomic Hybridization (aCGH) 
2.7.1 DNA Isolation, Labeling, and Hybridization 
 DNA copy number analyses for interphase and mitotic-enriched MOSEC at key transitional 
stages (days 245, 450 and 528) were measured on Agilent Mouse 4 x 44K arrays.  Interphase 
cells were cultured using standard MOSEC conditions, mitotic enriched cells were harvested 
after 8 hours treatment with Colcemid and were shaken off.  Genomic DNA (gDNA) was isolated 
using the DNeasy Tissue kit (Qiagen, Inc., Valencia, CA) following the supplier’s protocol. DNA 
quantity and quality were assessed by UV/Vis spectrophotometry using the ND-1000 
Spectrophotometer (NanoDrop Technologies, Rockland, DE).  CGH labeling was performed in 
accordance with the chip manufacturer’s instructions (Protocol v3.1, 2009, Agilent Technologies, 
Santa Clara, CA).  Briefly, gDNA (3 μg/ sample) from the reference (Promega Mouse Genomic 
(XY/XX pooled) DNA, Madison, WI) and from day 245, 450 and 528 cells were heat fragmented 
and denatured at 95° C for 10 minutes.  The DNAs were labeled with ULS- Cy3 (reference) or 
ULS- Cy5 (test) using the Agilent Genomic DNA Labeling Kit Plus (Agilent Technologies).  
Labeled DNA products were purified with Microcon YM-30 filtration devices (Millipore, Inc., 
Bedford, MA).  For hybridization, the appropriate Cy3 and Cy5-labeled DNA sample pairs were 
combined and then mixed with mouse Cot-1 DNA (Invitrogen Carlsbad, CA), Agilent Blocking 
Agent, and Agilent Hybridization Buffer.  Prior to hybridization, the samples were heated at 95°C 
for 3 minutes and then incubated for 30 minutes at 37°C.  The labeled target solution was then 
hybridized to the arrays using Agilent SureHyb chambers.  The hybridization chambers were 
placed in a 65°C rotisserie oven set at 15 rotations per minute for 40 hours.  Post-hybridization, 
the microarrays were washed and dried according to the manufacturer’s protocol and were 
scanned immediately using an Agilent microarray scanner.   
2.7.2 Normalization and Pre-processing 
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 Microarray data for the individual features including log2 ratios and quality metrics (median 
signal intensity, background noise, signal-to-noise ratio, reproducibility of replicate probes, and 
probe-to-probe log ratio noise were extracted from the scan image using Agilent Feature 
Extraction software (v 9.1.3.2). 
 As cancer genomes are universally known for aneuploidy and variable chromosome copy 
number imbalances, the prerequisites for conventional normalization methods (that nearly all of 
the DNA copy numbers are homogeneous and nearly equal to the diploid genome) were not 
met.  As chromosome copy number correlated with intensity, a novel strategy for array-CGH 
data was implemented.  Data normalization using a custom adaptation of PopLowess [98] with 
the open source R Statistical Environment (www.r-project.org) was performed using libraries 
from the Bioconductor Project (www.bioconductor.org).  This normalization method accounts for 
the presence of variable whole chromosome copy number change prior to segmentation and 
calling of small amplified or deleted regions.  A maximum of five subpopulations with a merge 
cluster criteria for the subpopulations of 0.3 was utilized. The k-means clustering algorithm was 
adapted to incorporate the weighted means for each cluster.  Following zero-centering to the 
largest subpopulation, the median value for the cluster with the lowest chromosome copy 
number was added as a constant to the M value for each probe.  With this correction, data were 
centered with the assumption that the cluster with the lowest median M was assumed to have a 
chromosome copy number count of two. 
2.7.3 Analysis of DNA Copy Number Change 
 Whole chromosome copy number change for validation of SKY analyses and detection of 
genomic gains and losses was determined using PopLowess to rank chromosomes by cluster 
median for comparison with median chromosome counts from SKY analyses.  Copy number for 
sub-chromosomal regions was assessed after normalization using PopLowess and was 
determined using Agilent’s CGH Analytics v3.5 software with statistical algorithm ADM-1, 
sensitivity threshold 6.0, and a moving average window of 1 Mb.  Copy number change for 
24 
 
chromosomal sub-regions was called by locus if a positive call was made by ADM-1 testing and 
≥10 consecutive probes were seen with ≥1.5-fold change. 
 
2.8 In vivo Tumorigenesis 
2.8.1 Determination of Tumorigenicity in vivo 
 To determine the relative tumorigenicity of day 245 versus day 528 cells in vivo, six-week-
old female C57BL6 mice were purchased from syngeneic immune competent C57BL6 mice and 
in nod-SCID-gamma (NSG) immune-compromised mice (Charles River Laboratories, 
Wilmington, MA) and  from JAX® Mice strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (Jackson 
Laboratories Bar Harbor, ME). 
 Following five days of acclimatization, each mouse received a total of three injections.  
Intraperitoneal injections consisted of 5x106 MOSEC in 0.2 ml DMEM with 0.25% Matrigel, and 
bilateral subcutaneous injections of 1x105 in 0.1 ml DMEM with 25% matrigel were administered 
bilaterally on the back.  Cell types were divided as follows so that each mouse received only one 
cell type (n=7 day 245, n=7 day 528, n=2 positive control (ID8) cells from one of 10 previously 
established tumorigenic MOSEC late stage clones from the discoverer of this model system [54], 
n=2 negative control acellular Matrigel mixed 1:1 with DMEM).  Mice were weighed and tumor 
size was approximated by diameter using calipers once per week.  Mice were sacrificed at day 
70 when tumor locations, weights, and sizes were documented.  All animal investigations were 
conducted in accordance within the guidelines and with approval from the Wayne State 
University Institutional Animal Care and Use Committee. 
2.8.2 Tumor Histopathology 
 The location and amount of intraperitoneal tumor formation was scored where 1 point 
was given for positivity in each of the following:  pancreas, liver, peritoneal fat, reproductive 
organs, lymph node, spleen, small intestine, large intestine, diaphragm, hemorrhagic ascites 
(max=10).  Subcutaneous findings were scored based on invasiveness and severity where 1 
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point was given for positivity: dermis, subcutaneous fat, muscle, diffuse, necrotic (max= 5 each 
side, 10 total).  Tumor implants and the surrounding tissues were collected from multiple sites, 
fixed overnight in 4% paraformaldehyde and embedded in paraffin for routine hematoxylin and 
eosin staining (Beaumont Hospital Tissue Biobank, Royal Oak, MI).  After de-identifying the 
tumor and tissue specimens, each was evaluated by a clinical pathologist (RR). 
 
2.9 Statistical Analyses  
 Counts of morphological features in the ovarian surface epithelial are expressed as the 
mean ± SEM (standard error of the mean) of the number of morphological features per section in 
five non-consecutive ovarian sections for n ovaries, where n is the number of ovaries examined. 
In vitro cell counts are expressed as the mean ± SEM of three independent experiments 
performed in triplicate. The predictive value of chromosome ID, time and Shannon Index was 
determined using general linear mixed model.  For each sub-population, chromosome count was 
compared using a paired t-test.  The probability of significant differences upon comparison of 
only two groups was determined by Student's t test. When multiple groups were analyzed, 
statistical comparisons were made by analysis of variance (ANOVA). Bonferroni's post hoc 
correction for multiple comparisons was applied in the determination of significant differences 
between specific groups when whole group differences were detected by ANOVA.  Alpha was 
set at a value of 0.05 and all p-values are two-sided. The proportion of variance in SA-βgal 
accounted for by time was estimated by calculation of R-squared.  The link between senescence 
by SA-βgal and nuclear abnormality was tested using the chi-squared statistic.  Statistical 
analyses were performed using NCSS (Kaysville, Utah).
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3. RESULTS 
3.1 Timeline and Experimental Overview 
3.1.1 Whole Genome Analysis of Key Stages of Transformation and Tumorigenesis 
 Mouse ovarian surface epithelial cells (MOSEC) were seeded from a single ovary from a 
healthy 6-week old C57BL6 mouse and were repeatedly passaged until reaching a tumorigenic 
phenotype similar to positive control cells (ID8) in vitro.  Tumorigenicity testing of day 245 versus 
day 528 MOSEC in vivo was performed by allograft injection of select transformative stages and 
tracking of tumor formation for 70 days in vivo.  Tumorigenicity in vivo correlated well with 
phenotype analyses in vitro and confirmed the ability for this cell type to transform 
spontaneously and without out viral transfection or carcinogenic insult [54-55].  Using this model, 
data was acquired longitudinally from five key transformative stages, beginning with primary 
cells in culture until malignant characteristics were eventually acquired at day 528.  Cell culture 
was continued until the characteristics of the malignant phenotype were acquired and the 
MOSEC performed similarly to positive control ID8 MOSEC in several types of in vitro and in 
vivo measures of proliferation, invasion, migration, and tumorigenicity (Figure1, Table1).  Real-
time analyses of MOSEC were performed for all assays except for measuring tumorigenesis in 
vivo in which cells were retrieved from prepared frozen stocks.  This experimental design is 
unique as it successfully facilitated the longitudinal study of ovarian cancer transformation real-
time and allowed for the comparison of cellular phenotype with global genomic profiles at 
multiple levels including cytogenetic abnormalities, population karyotype analysis, mRNA 
transcript abundance, and array comparative genomic hybridization (Figure 1).   
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3.1.2 Establishment and Selection of Primary Ovarian Surface Epithelial Cells 
 Primary cells were difficult to establish in culture and the survival rate was approximately 
5%.  The high prevalence of cellular senescence and the low frequency of mitotic events in 
these cells likely accounts for their low viability and the difficulty incurred in establishing these 
lines in culture from small numbers of seeded cells.  Five lines were established past day 30, 
two of these lost viability before day 100 (“non-viable A”, “non-viable B”) and three of these 
progressed to transformation (“Longitudinal”, “Replicate 1”, “Replicate 2”).  Whole-genome data 
was acquired from the “Longitudinal” line including repeated measures of spectral karyotype 
data, microarray analyses, and tumorigenicity testing and is presented from here forward as 
MOSEC. Importantly, “Replicate” lines displayed similarly elevated chromosome counts, cellular 
variability and altered 
cellular morphology 
throughout transformation.  
The frequency of 
aneuploid cells was not 
different among lines from 
the viable and non-viable 
groups, but each was 
different from a the normal 
diploid karyotype at first 
measure (day 76,82, and 
170) where chi-squared 
<0.01 for each of three 
lines sampled before day 
200, (Figure 2). 
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3.2 Senescence and Nuclear Abnormalities of Early Stage Interphase Cells 
 The earliest observations of the MOSEC in vitro revealed a heterogeneous pattern of 
cellular morphologies.  At day 40, large, ballooned cells with diverse morphotypes and low cell 
densities typical of senescent cell populations occupied the majority of the surface of the culture 
dish.  Within this population lay pockets of mixed cuboidal and refractile cells.  These pockets 
are more typical of the phenotype of MOSEC at later transformative stages (Figure 3A).  Further 
evidence for the senescence phenotype of these large ballooned cells was generated by the bi-
weekly assaying for senescence-associated β-galactosidase (SA β-gal) activity from day 28 to 
day 170.  The percentage of SA β-gal positive cells averaged 94 ± 3%) at day 28 and fell 
logarithmically with routine passaging over time to reach <5% from day 100 onwards, R2 = 0.83 
(Figure 3B, C).  Nuclear abnormalities including blebs, micronuclei, and lagging chromosomes 
were noted with increased frequency at day 28, 40, and 70 in SA β-gal positive versus negative 
cells (chi-square analysis: p=0.04, 0.02, and 0.02 respectively, Figure 3D, 3E).  From day 28-
70, the frequency of abnormal nuclear morphology was unchanged in normal and SA β-gal 
positive cell populations, despite the largest decline in the prevalence of SA β-gal positive cells. 
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3.3 Early Stage Abnormalities of Cell Division 
 The early stage (day<40) MOSEC were slow-growing and cytogenetic preparation for 
spectral karyotype analysis revealed the presence of several types of nuclear and cytogenetic 
abnormalities.  Typical examples from classes of nuclear and cytogenetic abnormality are 
depicted from colcemid treated SKY painted cells that provide evidence for early genomic 
instability and cell cycle checkpoint insufficiency (Figure 4).  When late-stage metaphase cells 
enter mitosis in the presence of colcemid, unpairing of centromeres can occur without spindle 
formation and is termed late c-metaphase [99].  During cellular division when the centromeres 
are visible, discondensed chromosomes are seen that comprise individual circular blebs with 
the aforementioned split centromere morphology (Figure 4A, B).  SKY analyses of these cells 
clearly shows that many of the individual blebs contain DNA from a single chromosome with 
separated centromeres, whereas other images show coalescence of further discondensed 
chromosomes with unclear centromere morphology (Figure 4C).  Images of nuclear 
outpouchings and macro-nuclear formations were additionally captured where DNA from at 
least three different chromosomes is seen to be contained within the rounded outpouchings 
protruding from the normal nuclear domain (~4% of interphase cells, Figure 4C).  Metaphase 
cells with well condensed chromosomes and clearly defined single centromeres also show 
chromosomal abnormalities including multiple breaks, fusions, and other structural 
abnormalities (Figure 4D-F).  In total, early signs of genomic instability and cell cycle checkpoint 
insufficiency including defects in chromosome condensation, segregation, and nuclear 
morphologic abnormalities such as those depicted occurred in day <40 cells at a frequency of 
19 ± 6%. 
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3.4 Morphologic and Phenotypic Features Defining the Key Transformative Stages in vitro 
 Several distinct phenotypic changes characterizing the MOSEC key transformative stages 
were captured in two-dimensional, three-dimensional, and organotypic culture scenarios (Table 
1, Figure 5).  Day 170 MOSEC divide more slowly than all subsequent stages, maintain a large 
surface area, low cell density, and slightly elongated morphology compared to day 245 cells.  
The day 245 cells are characterized by increased cell density compared to day 170 and have 
acquired the typical cobble-stone appearance of epithelial cells grown in vitro.  Day 450 and day 
528 MOSEC continue to increase cell density until transitioning to a phenotype of tightly packed 
cells with regions of overlap (Figure 5A).  Three-dimensional cell growth in matrigel shows 
parallel morphologic changes and a phenotype of increasing branching that was significantly 
greater at each transformative stage (170;2%-528;96%, p=0.01).  Day 170 cells have limited 
branching and invasion capabilities as seen by their growth limitation to one plane on the 
substrate surface.  In comparison, the day 245 and later stage cells show a progressive 
increase in proliferation, branching, and invasion into the deeper layers of the three-dimensional 
substrate.  Day 528 cells show increased frequency of branching and superior ability to grow 
within the three-dimensional medium (93 ± 6% branching cells, Figure 5B, Table 1).  
Organotypic collagen raft assays demonstrate the contact inhibited monolayer growth on the raft 
surface without invasion at day 170.  The acquisition of invasive capabilities began with day 245 
cells, which demonstrated focal invasion of cells viable cells with atypical and heterogeneous 
nuclei (height 1, depth 1, pattern focal).  Day 450 cells showed a diffuse pattern invasion to a 
depth of ~6 cells in most areas and increased cell density at the raft surface (Figure 5C).  Day 
528 cells additionally acquired the capacity for multilayered upward growth and stratification of 
cell layers, typically resulting in a cell height of ~6 cells or more above the raft surface.  Invasion 
morphology was changed in the day 450 cells to now include both focal and diffuse patterns 
with atypical nuclear morphologies (Figure 5C).  Cell phenotype alterations were compared with 
previous reports and, based on the total information gleaned from the in vitro studies, were 
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considered weakly positive for the transformed phenotype at day 245.  MOSEC were 
considered certainly positive for the transformed phenotype at day 528, having acquired all 
characteristics previously linked to strong tumorigenicity in vivo. 
Table 1. Characteristics of mouse ovarian surface epithelial cell key transformative stages 
170 245 450 528 ID8 
PROLIFERATION 
doubling time 1 (hours)  36 ± 6 24 ± 4* 17 ± 2* 11 ± 1* 13 ± 2 
colony forming units in agar 2 (%)  0.44 ± 0.21 2.6 ± 1.1* 8.5 ± 1.7* 16.8 ± 2.9* 14 ±3.5 
INVASION  
‡ raft culture 3 (height/ depth/ 
pattern)  
1/ 0/ 0 1/4 /  F 1/ 6/ D 6/ 6/ FD 6/ 6.5/ D 
branching cells 4 (%)  2 ± 1 43 ± 4* 63 ± 7* 93 ±  6* 96 ± 8 
MIGRATION  
trans-well filter inserts 5  2.1 ± 1.2 6.6 ± 2.8* 42 ± 17* 54 ± 9* 89 ± 16* 
TUMORIGENICITY  
subcutaneous tumors 6 (% positive)  N 25% N 50% 100% 
subcutaneous tumors (mm)  N 1 N 10 10 
subcutaneous tumors 7 (score/10)  N 1/10 N 6/10 7/10 
intraperitoneal tumors (% positive)  N - N 50% 100% 
intraperitoneal tumor 8 (score/10)  N - N 4/10 2/10 
1) Doubling time =(T)ln2/ln(Xe/Xb), where Xn is the cell number determined at the beginning (Xb) and 
end (Xe) time poinst, and T is the total elapsed time (hours), seeding of 1 x104 and 5 x104 cells were 
harvested at 70% confluency.  2) Colony forming units in soft agar = mean colony count / number of 
cells seeded x 100%.  3) Organotypic collagen raft culture: height= number of cells above, depth= 
number of cells below the collagen. Pattern: D=diffuse, F=focal, 0=none.  4) Three-dimensional 
Matrigel branching = branched cells/ total cells.  5) Tran swell filter insert migration =(cells crossing 
matrigel / total cells) / (cells crossing open pores / total cells)  6) Tumor positive/ injected sites in 
eighteen syngeneic C57BL6 mice (245:n=7, 528:n=7, ID8: n=2, vehicle:  n=2).  Each mouse at each of 
3 sites (left and right subcutaneous flank (1E5) and intraperitoneal 1E6) at day 70.  7) Average bilateral 
subcutaneous tumor invasion (dermis, muscle, subcutaneous fat, diffuse: 1point each/ 10 total).  8) 
Intraperitoneal tumorigenicity organ involvement and pattern (pancreas, liver, peritoneum, reproductive 
organs, lymph node, spleen, intestine, lung, heart, infiltrative, 1 point each/ 10 total).  
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3.5 Population Based Karyotype Analysis of Key Transformative Stages 
3.5.1 Summary Characteristics of Cell Populations by Transformative Stage  
 Spectral karyotype analysis of MOSEC key transformative stages was meticulously 
performed on 30-50 metaphase cells, resulting in ~1000 data points per transformative stage.  
These raw karyotype data are presented for comparative evaluation among MOSEC key 
transformative stages, tumor cells, and Brca1Δ5–13 MOSEC to characterize the variability, as well 
as more standard cytogenetic reports including cell ploidy and the incidence of clonal and non-
clonal chromosome aberrations (Table 2).  Histogram reporting of raw data shows the 
expansion of variability acquired by the MOSEC from day 170-528 (Table 2).  The first clonal 
chromosome aberration (CCA, ≥20% of cells) was seen at day 245 and these small pieces of 
chromosome 11 were without centromere (min 11) and persisted until day 528.  Additional 
clonal chromosome aberrations arose at day 450 t4;3 and t6;15 (~30% of cells) and several 
(t4;3 t4;5 t5;4, min19) that were common to tumor 1 and 2.  Interestingly neither t4;3 nor t5;16 
were present at day 528.  Non-clonal chromosome aberrations (<20% of cells) were present at 
each transformative stage and consisted predominantly of chromosomes linked by centromere 
at day 170, but expanded to include all types of aberrations from day 245 onwards.   
 
3.5.2 Spectral Karyotype Analysis for Population Based Karyotype Heterogeneity 
Karyotype heterogeneity at each transformative stage was measured using an 
adaptation of concepts published by Castro et. al. [80] for measuring tumor diversity among 
patient samples and applies the Shannon Index to chromosome count data.  The method allows 
diversity to be quantified for normal or abnormally distributed data at each whole or aberrant 
chromosome and can be summed to generate an index for the entire karyotype (methods).  This 
measure was applied to karyotypes of varying heterogeneity and served as a surrogate 
measure of genomic instability for each MOSEC transitional stage.  The Shannon Index of 
diversity was calculated for each chromosome and is reported as the sum for whole  
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Table 2. Karyotype and variability of key transformative stages, Brca1 ∆5-13, and for harvested tumors 
CHROM 
ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 X CCA NCCA 
DAY 
170 
1(1) 
2(27) 
4(3) 
2(28) 
3(2) 
4(1) 
2(29) 
3(1) 
4(1) 
1(2) 
2(27) 
4(2) 
2(29) 
3(1) 
4(1) 
2(28) 
4(3) 
1(1) 
2(28) 
4(2) 
0(1) 
2(27) 
3(1) 
4(2) 
1(1) 
2(29) 
4(1) 
1(2) 
2(26) 
3(1) 
4(2) 
0(1) 
2(27) 
3(1) 
4(2) 
2(28) 
4(3) 
1(1) 
2(26) 
3(2) 
4(2) 
2(27) 
3(2) 
4(2) 
1(1) 
2(26) 
3(2) 
4(2) 
1(2) 
2(26) 
3(1) 
4(2) 
1(3) 
2(25) 
4(3) 
1(1) 
2(27) 
4(3) 
1(2) 
2(25) 
3(2) 
4(2) 
2(28) 
3(2) 
4(1) 
- 
t2, t13, t19, t7, t12;16, t12;19, t10;14, t10, 
t3=3, t5=5, t8=8, t9=9, t11=11, t13=13, , 
t14=14, tX=X, t1=1, t2=2, 
min(4, 8, 10, 15, 17, 19) 
∑H’= 12= 0.5 0.4 0.3 0.5 0.4 0.6 0.5 0.6 0.4 0.7 0.5 0.5 0.6 0.4 0.5 0.5 0.5 0.5 0.7 0.5 + 4 H’der 
DAY 
245 
0(1) 
1(3) 
2(11) 
3(22) 
4(3) 
6(1) 
1(1) 
2(8) 
3(12) 
4(13) 
5(3) 
6(2) 
7(1) 
8(1) 
1(3) 
2(7) 
3(9) 
4(18) 
5(2) 
6(2) 
1(1) 
2(9) 
3(20) 
4(5) 
5(3) 
6(3) 
2(8) 
3(10) 
4(12) 
5(6) 
6(5) 
1(2) 
2(9) 
3(15) 
4(9) 
5(3) 
6(2) 
7(1) 
1(1) 
2(10) 
3(18) 
4(7) 
5(4) 
7(1) 
3(7) 
4(20) 
5(10) 
6(1) 
7(1) 
11(1) 
16(1) 
1(2) 
2(6) 
3(19) 
4(10) 
5(3) 
6(1) 
1(1) 
2(12) 
3(11) 
4(10) 
5(6) 
6(1) 
1(2) 
2(3) 
3(15) 
4(10) 
5(9) 
6(2) 
1(5) 
2(27) 
3(4) 
4(4) 
6(1) 
1(3) 
2(7) 
3(21) 
4(8) 
5(1) 
6(1) 
0(1) 
1(2) 
2(11) 
3(13) 
4(9) 
5(1) 
6(3) 
7(1) 
1(1) 
2(7) 
3(11) 
4(9) 
5(12) 
6(1) 
1(1) 
2(7) 
3(17) 
4(8) 
5(6) 
6(1) 
7(1) 
1(1) 
2(3) 
3(4) 
4(20) 
5(10) 
6(1) 
7(1) 
9(1) 
1(2) 
2(11) 
3(20) 
4(7) 
6(1) 
1(2) 
2(10) 
3(18) 
4(8) 
5(2) 
6(1) 
0(2) 
2(3) 
3(8) 
4(11) 
5(10) 
6(4) 
7(3) 
min 11 
der10*, der11*, der16*, der5*, der10*, 
der12*, der5*, t12;19, t13;19, t14;17, 
t16;3, t17;15, 
t19;18, t7;14, t8;20, t9;12, t9;15, t3=3, 
t4=16, 4, 4*, 
min(5, 7, 10, 12, 15, 16, 18, 19) 
∑H’= 23= 1.3 1.7 1.5 1.4 1.6 1.6 1.4 1.4 1.4 1.5 1.5 1.1 1.3 1.7 1.5 1.5 1.5 1.2 1.4 1.8 + 7 H’der 
DAY 
450 
1(1) 
2(7) 
3(38) 
4(3) 
5(1) 
1(1) 
2(9) 
3(13) 
4(18) 
5(9) 
1(2) 
2(2) 
3(13) 
4(27) 
5(6) 
2(12) 
3(22) 
4(15) 
7(1) 
2(3) 
3(9) 
4(22) 
5(16) 
2(3) 
3(10) 
4(25) 
5(9) 
6(3) 
1(2) 
2(9) 
3(23) 
4(13) 
5(3) 
2(1) 
3(8) 
4(30) 
5(9) 
6(2) 
2(13) 
3(19) 
4(13) 
5(5) 
2(10) 
3(21) 
4(15) 
5(4) 
1(1) 
2(3) 
3(17) 
4(17) 
5(11) 
6(1) 
0(2) 
1(3) 
2(39) 
3(6) 
1(2) 
2(15) 
3(30) 
4(2) 
7(1) 
1(1) 
2(17) 
3(21) 
4(9) 
5(1) 
6(1) 
1(1) 
2(2) 
3(8) 
4(27) 
5(10) 
6(2) 
2(12) 
3(24) 
4(11) 
5(3) 
2(3) 
3(20) 
4(20) 
5(6) 
6(1) 
1(4) 
2(12) 
3(30) 
4(4) 
1(1) 
2(5) 
3(16) 
4(26) 
5(2) 
1(1) 
2(1) 
3(4) 
4(11) 
5(12) 
6(15) 
7(3) 
8(3) 
der4;3, 
der6;15, 
min11 
t12, t12;17, t13=13, t16;10, t17;19, 
t17=17, t7=12, t8;11, t8;14, t8;19, t9, 
t7=12, 
min(2, 1, 7, 10, 12, 13, 14, 15, 16, 17, 19, 
X) 
∑H’= 22= 0.8 1.4 1.2 1.2 1.2 1.3 1.3 1.1 1.3 1.2 1.4 0.7 1.0 1.3 1.3 1.2 1.2 1.1 1.1 1.7 + 6 H’der 
DAY 
528 
1(2) 
2(28) 
3(18) 
4(1) 
6(1) 
0(1) 
2(9) 
3(13) 
4(17) 
5(8) 
7(1) 
8(1) 
1(2) 
2(5) 
3(16) 
4(12) 
5(12) 
6(2) 
10(1) 
1(3) 
2(16) 
3(18) 
4(10) 
5(2) 
6(1) 
1(1) 
2(7) 
3(10) 
4(26) 
5(3) 
6(2) 
7(1) 
1(1) 
2(8) 
3(17) 
4(20) 
5(3) 
7(1) 
1(4) 
2(17) 
3(13) 
4(15) 
9(1) 
2(6) 
3(2) 
4(20) 
5(14) 
6(5) 
7(1) 
8(1) 
14(1) 
1(1) 
2(15) 
3(17) 
4(14) 
5(2) 
7(1) 
0(1) 
1(1) 
2(12) 
3(14) 
4(10) 
5(9) 
6(2) 
8(1) 
0(1) 
1(3) 
2(8) 
3(11) 
4(19) 
5(6) 
6(1) 
11(1) 
0(1) 
1(8) 
2(31) 
3(7) 
4(2) 
5(1) 
1(4) 
2(17) 
3(23) 
4(3) 
5(2) 
6(1) 
1(3) 
2(15) 
3(23) 
4(8) 
8(1) 
1(1) 
2(10) 
3(10) 
4(20) 
5(7) 
6(1) 
8(1) 
0(1) 
1(1) 
2(16) 
3(22) 
4(6) 
5(3) 
6(1) 
1(3) 
2(5) 
3(13) 
4(24) 
5(4) 
8(1) 
1(5) 
2(18) 
3(18) 
4(7) 
5(1) 
6(1) 
1(3) 
2(5) 
3(18) 
4(13) 
5(8) 
6(3) 
1(1) 
2(5) 
3(7) 
4(13) 
5(11) 
6(10) 
7(2) 
8(1) 
min11 
t14;8, der15, t4;3, t7;15, derX, t15, der5, 
t15;14, t18*, t18^, t2;1, t2;14, t2;19, t2;5, 
der4, 
t4=12, 
min( 3, 4, 12, 17, 18) 
∑H’= 19= 1.0 1.6 1.6 1.4 1.4 1.4 1.4 1.6 1.4 1.7 1.7 1.2 1.3 1.3 1.5 1.4 1.4 1.4 1.6 1.8 + 5 H’der 
Brca1 
Δ4-13 
1(3) 
2(4) 
3(37) 
4(1) 
6(3) 
2(2) 
3(3) 
4(16) 
5(18) 
6(5) 
7(2) 
10(1) 
12(1) 
2(4) 
3(5) 
4(17) 
5(12) 
6(5) 
7(2) 
9(2) 
13(1) 
1(1) 
2(5) 
3(34) 
4(5) 
6(2) 
7(1) 
2(1) 
3(8) 
4(19) 
5(14) 
6(2) 
7(3) 
14(1) 
2(1) 
3(7) 
4(17) 
5(15) 
6(3) 
7(2) 
8(1) 
9(1) 
11(1) 
1(3) 
2(7) 
3(32) 
4(4) 
6(1) 
7(1) 
2(2) 
3(3) 
4(33) 
5(5) 
6(2) 
7(2) 
9(1) 
2(5) 
3(21) 
4(17) 
5(2) 
7(2) 
10(1) 
3(2) 
4(19) 
5(17) 
6(5) 
7(4) 
8(1) 
3(1) 
4(5) 
5(16) 
6(15) 
7(5) 
8(4) 
10(1) 
13(1) 
1(1) 
2(4) 
3(23) 
4(15) 
5(2) 
6(2) 
8(1) 
2(1) 
3(7) 
4(9) 
5(21) 
6(6) 
7(1) 
10(2) 
11(1) 
2(6) 
3(14) 
4(19) 
5(5) 
6(1) 
7(1) 
8(2) 
0(1) 
2(1) 
3(2) 
4(7) 
5(17) 
6(11) 
7(6) 
9(1) 
12(1) 
14(1) 
3(8) 
4(26) 
5(6) 
6(3) 
7(1) 
8(1) 
10(2) 
12(1) 
2(1) 
3(6) 
4(21) 
5(15) 
6(2) 
8(2) 
9(1) 
2(3) 
3(13) 
4(21) 
5(8) 
7(2) 
11(1) 
1(1) 
2(1) 
3(1) 
4(4) 
5(22) 
6(13) 
7(2) 
8(2) 
11(1) 
12(1) 
1(1) 
2(12) 
3(12) 
4(12) 
5(5) 
6(4) 
9(1) 
10(1) 
- 
der10, der11, der14, der16, der1, der5, 
der7, der4*, derX*, der12*,der13, der^7, 
t7;10, t4=4, t19=19t12;9, t13;15, t15;10, 
t18;8, t3;4, t3;4, t4=4;X, 
min(4, 7, 10) 
∑H’= 15= 0.8 1.2 1.4 0.4 1.2 1.3 0.9 1.3 1.1 1.4 1.4 1.0 1.1 1.5 1.3 1.6 0.9 1.6 1.2 1.5 + 3 H’der 
TUMOR 
1 
0(1) 
1(1) 
2(28) 
3(15) 
4(2) 
5(3) 
2(6) 
3(16) 
4(16) 
5(1) 
6(7) 
8(3) 
10(1) 
0(1) 
1(1) 
2(14) 
3(18) 
4(7) 
5(4) 
6(2) 
7(2) 
8(1) 
2(18) 
3(21) 
4(6) 
5(3) 
6(2) 
1(3) 
2(8) 
3(17) 
4(15) 
5(4) 
6(1) 
7(2) 
2(7) 
3(17) 
4(18) 
5(6) 
7(1) 
8(1) 
2(14) 
3(20) 
4(8) 
5(4) 
6(3) 
7(1) 
2(1) 
3(2) 
4(22) 
5(11) 
6(3) 
7(1) 
8(5) 
9(2) 
10(1) 
11(1) 
13(1) 
1(4) 
2(20) 
3(18) 
4(3) 
5(2) 
6(3) 
0(1) 
1(1) 
2(7) 
3(18) 
4(12) 
5(5) 
6(3) 
7(1) 
10(1) 
14(1) 
1(1) 
2(9) 
3(15) 
4(10) 
5(7) 
6(2) 
7(4) 
8(2) 
1(4) 
2(25) 
3(7) 
4(9) 
5(2) 
6(1) 
8(2) 
2(23) 
3(11) 
4(9) 
5(1) 
6(3) 
8(1) 
10(1) 
14(1) 
1(6) 
2(18) 
3(11) 
4(13) 
5(1) 
6(1) 
1(2) 
2(4) 
3(18) 
4(18) 
5(3) 
6(2) 
7(2) 
10(1) 
2(3) 
3(19) 
4(16) 
5(5) 
6(3) 
7(2) 
8(1) 
9(1) 
3(12) 
4(25) 
5(3) 
6(1) 
7(6) 
8(2) 
9(1) 
1(1) 
2(9) 
3(19) 
4(10) 
5(4) 
6(2) 
7(4) 
11(1) 
1(5) 
2(7) 
3(7) 
4(20) 
5(4) 
6(2) 
7(5) 
2(4) 
3(6) 
4(18) 
5(8) 
6(5) 
7(2) 
8(4) 
9(2) 
10(1) 
t4;5 
t5;4 
t4;3* 
t11;13 
min 19 
t14;8, der15, t7;15, derX, der5, t15;14, 
t18*, t18^, t2;1, t2;14, t2;19, t2;5, der4, 
t4=12, 
min( 3, 4, 12, 17, 18) 
∑H’= 23= 1.1 1.6 1.7 1.3 1.6 1.4 1.5 1.7 1.4 1.8 1.8 1.5 1.5 1.5 1.6 1.6 1.4 1.7 1.7 1.9 + 7 H’der 
TUMOR 
2 
1(1) 
2(6) 
3(30) 
4(8) 
5(3) 
6(1) 
10(1) 
2(7) 
3(11) 
4(14) 
5(10) 
6(3) 
7(2) 
8(1) 
10(2) 
1(1) 
2(3) 
3(21) 
4(14) 
5(6) 
6(1) 
7(1) 
8(2) 
10(1) 
0(1) 
1(3) 
2(14) 
3(13) 
4(13) 
5(3) 
6(1) 
7(1) 
8(1) 
2(12) 
3(20) 
4(13) 
5(2) 
6(2) 
7(1) 
2(8) 
3(22) 
4(9) 
5(6) 
7(3) 
8(1) 
9(1) 
0(1) 
1(1) 
2(8) 
3(23) 
4(9) 
5(3) 
6(1) 
7(2) 
8(2) 
1(1) 
2(6) 
3(8) 
4(17) 
5(9) 
6(5) 
8(3) 
9(1) 
0(1) 
1(4) 
2(15) 
3(11) 
4(11) 
5(4) 
6(3) 
7(1) 
1(2) 
2(12) 
3(12) 
4(13) 
5(3) 
6(3) 
7(3) 
9(1) 
12(1) 
0(1) 
1(1) 
2(5) 
3(15) 
4(12) 
5(7) 
6(1) 
7(6) 
9(1) 
10(1) 
0(1) 
1(5) 
2(25) 
3(8) 
4(5) 
5(2) 
6(3) 
8(1) 
0(1) 
1(3) 
2(24) 
3(13) 
4(6) 
5(1) 
6(1) 
8(1) 
1(2) 
2(23) 
3(12) 
4(7) 
5(1) 
6(3) 
7(1) 
8(1) 
2(4) 
3(10) 
4(26) 
5(6) 
8(3) 
11(1) 
1(2) 
2(2) 
3(24) 
4(9) 
5(7) 
6(3) 
8(2) 
9(1) 
0(1) 
1(1) 
2(5) 
3(12) 
4(19) 
5(5) 
6(1) 
7(5) 
10(1) 
1(2) 
2(12) 
3(23) 
4(8) 
5(3) 
8(1) 
12(1) 
0(1) 
1(2) 
2(13) 
3(16) 
4(8) 
5(4) 
6(4) 
8(1) 
12(1) 
1(1) 
2(8) 
3(8) 
4(11) 
5(9) 
6(3) 
7(5) 
8(3) 
10(1) 
12(1) 
t4;3, t5;4, 
t4;5, 
min(10, 
11, 13, 
19, X) 
der10, der11, der14, der16, der1, der5, 
der7, der4*, derX*, der12*,der13, der^7, 
t7;10, 
t4=4, t19=19t12;9, t13;15, t15;10, t18;8, 
t3;4, t4=4;X, min(4, 7) 
∑H’= 29= 1.3 1.8 1.6 1.7 1.4 1.5 1.6 1.8 1.8 1.8 1.9 1.6 1.4 1.5 1.4 1.6 1.7 1.4 1.8 2.0 + 13 H’der 
Chromosome ID by column header, key transformative stage or cell type  by row end (left).  Chromosome count data 
for:  count (frequency), derivative chromosomes: * telomeric aberration, ^ centromeric aberration; translocations (t, 
where “;” for chromosome arm, “=“ centromeric linkage), double minute (min), clonal chromosome aberration 
(CCA≥20% of cells), non-clonal chromosome aberration (NCCA<20% of cells, Normalized Shannon Index of 
Variability (H').  
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chromosomes, sum for aberrant chromosomes, and the total of both indices.  Population 
karyotype characteristics are summarized for chromosome counts, ploidy distribution Shannon 
indices of variability, CCAs and NCCAs in Table 3.  Day 170 cells were the only stage 
characterized by 2n ploidy status.  Ploidy increased to double this (4n) in day 245, 450, and was 
3n in day 528 cells and tumor derived MOSEC.  Brca1Δ5–13 also displayed high ploidy level (4n) 
despite their short time in culture (50 days).  Karyotype abnormalities were detected in early 
stage day 170 cells at a frequency of 48% abnormal karyotypes (Table 3).  The median count 
for each chromosome at day 170 was 1.9 (x¯  = 2.1; range = 2.1-2.2), with 32% of the cells 
containing at least one whole chromosome imbalance. This increased to day 450, and 
decreased slightly at day 528.  In contrast to the early passage MOSEC, whole chromosome 
analyses at subsequent time points revealed aneuploidy in 98-100% of cells.  The Shannon 
index values (H' whole chromosome, ∑H') were elevated in day 245, 450, and 528 cells 
compared to day 170 cells, and followed a similar pattern of elevation until day 450, with a small 
but significant reduction in day 528 cells. 
The Shannon Index for whole chromosome diversity ranged from 10 to 29, climbing to 
reach a maximum of H=29 at day 245 and 528, falling slightly at day 450.  The total Shannon 
Index (H) follows a similar trend, as it is largely driven by whole chromosome heterogeneity.  
The Shannon Index for derivative chromosomes begins at 2 at day 170, rises to 4 at day 450, 
and falls again to 2 at day 528 with a similar pattern to ∑H' values.  The Shannon Index value 
(H') is corrected for maximum variability (H'=H/ lnS).  In descriptive terms, H' is a measure 
randomness within the constraints of the variability inherent in the population at that time with a 
limited range (0 ≤ H' ≤ 1 for each whole and derivative chromosome).  At day 170, ∑H' was at a 
minimum (∑H'=13), and showed significant increase over day170 values at each subsequent 
stage (245, ∑H'=35; 450, ∑H'= 31, 528, ∑H'=29, Table 2 and Figure 6). 
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3.5.3 Characterizing the extent of cell-to-cell heterogeneity by karyotype 
A visual impression of the relationship between cellular heterogeneity and key 
transformative stage during spontaneous MOSEC transformation is seen in the karyograph 
plots (Figure 6).  By using three-dimensional plots of complete karyotype data for each 
transitional stage, the dynamic changes in the karyotype profiles and the extent of the 
karyotypic heterogeneity at each stage are readily apparent.  Each line on the karyograph 
shows chromosome count data for normal and derivative chromosomes, thus presenting data in 
a format that preserves its relationship to the individual cell.  Normal and abarrent chromosomes 
are identified along the x-axis, corresponding counts for each chromosome are plotted on the y-
axis, and metaphase number (M1,M50) on the z-axis.  The predominant karyotype at day 170 is 
diploid (2n) and, with the exception of some rare peaks and infrequent tetraploid cells, is 
remarkably similar to the normal mouse genome.  Rare changes in whole chromosome copy 
number and in occasional derivative chromosomes are seen in several cells (Figure 6A).  There 
is little to no inherent noise in the SKY data at this stage.  Metaphase spreads from day 245 
cells showed an increased median chromosome number and a significant increase in variability 
of chromosome count at each position (Figure 6B).  Total un-normalized karyotype 
heterogeneity fell slightly in day 450 cells (∑H=35, Figure 6C), when the occurrence of clonal 
4;3 and 6;15 translocations appeared in addition to the clonal min11 double minute noted in the 
previous stage.  These translocations were found at a frequency of ~30% (Figure 6C).  Neither 
clonal chromosome aberration was seen in the late stage day 450 MOSEC (∑H=32, Figure 6D). 
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3.5.4  Comparing the distribution of count data by chromosome across the key transformative 
stages 
 To demonstrate the variability contributed by varying distributions of each chromosome 
measured in the population karyotype data, violin plots of chromosome counts and the 
distribution for each are presented across the transitional stages (Figure 7A-D).  The median 
chromosome count (y-axis, right) for each whole chromosome and the sum of all derivative 
chromosomes is shown (gray circles x-axis), with 95% confidence intervals for each (black lines 
within curve), maxima and minima by the thin lines projecting from each curve, and distribution 
of each chromosome count by the width of the curve at that count.  From these analyses, 
certain patterns can be recognized over time that are not clear from the karyograph plots.  For 
example, the uniformity of chromosome count distribution is better seen in this plot.  
Additionally, the findings that certain chromosomes (chromosome 12) and chromosome 1 
approached significance as chromosomes that did not undergo significant change in count over 
time can also be seen (Figure 7, B-D).  Chromosomes 1 and 12, showing little change over time 
additionally have the lowest Shannon Index at each key transitional stage, indicating stability of 
that chromosome over time is related to the diversity of chromosome count measured at each 
transitional stage.  Oppositely the X chromosome has the largest and most persistent increase 
in chromosome counts and a high Shannon Index (Figure 7A-D, Table 2). The difference in 
distribution profiles between the Brca1 and the spontaneously derived line can also be seen.  
Finally, the increase in the maximum chromosome count for day 528, Brca1, Tumor 1 and 
Tumor 2 is seen by the height of these upward going lines from the body of the violin plot as 
compared to the earlier stage (day 170, 245, 450) spontaneously transforming lines. 
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Table 3. Population karyotype characteristics for mouse ovarian surface epithelial cell stages and lines. 
170 245 450 528 Brca1Δ5–13 TUMOR 1 TUMOR 2 
chromosome count          mode 40 75† 71 67  82‡ 62 61 
min-max 36 - 77 26 - 120† 45 - 84† 31 - 148† 43 - 165 42 - 129 37 - 159 
median  1.9 3.2 3.6 3.4 4.2 3.2 3.3 
ploidy range 2.1 - 2.2 3.3 - 3.4 3.4 - 3.4 3.2 - 3.3 4.3 - 4.4 3.6 - 3.7 3.6 - 3.6 
ploidy best fit 2n 4n 4n 3n 4n 3n 3n 
whole chromosome            loss 0 1 13 9 5 6 4 
gain 0 12 4 14 10 13 11 
change 0 13 16 20 15 18 14 
2n (%) 90 7 2 14 4 2 4 
3n (%) 3 49 36 42 4 74 66 
4n (%) 6 37 62 42 81 4 18 
5n (%) 0 5 0 0 2 6 4 
>5n (%) 0 2 0 2 8 14 8 
aneuploid cells (%) 48 100 100 98 100 100 100 
H                                     (1-19) 10 29† 24† 29 29 31 33 
(der) 2 3 4 2 3 3 6 
 (min) 1 3 3 2 0 4 6 
∑ H  13 35 31 32 32 38 44 
H'                                    (1-19) 8 16† 15† 15† 14 16 14 
(der) 3 4 3 3 4 7‡ 1‡ 
(min) 1 3 3 2 1 6 3 
∑ H'  12 23† 22† 19† 19 29‡ 18‡ 
CCA               translocation (%) 0 0 30 0 0 96 98 
 linked (%) 0 0 0 0 0 0 0 
minute (%) 0 44 30 34 0 90 0 
∑CCA (%) 0 44 54 34 0 98 98 
NCCA            translocation (%) 19 41 20 24 19 6 58 
 linked (%) 19 5 2 2 2 22 0 
minute (%) 0 29 32 16 3 22 0 
∑NCCA (%) 32 59 46 40 20 42 58 
 
Percentages indicate the percentage of metaphase cells belonging to that category. 
Ploidy best fit defined by modal chromosome number (m), "n" is defined such that "m" falls within 20n ±10. 
Whole chromosome loss and gain defined as the difference between the predicted (best fit ploidy) count and the 
actual chromosome count.  CCA, clonal chromosome aberration present in ≥20% of metaphase cells; NCCA, 
non-clonal chromosome aberration present in <20% of metaphase cells.  H, Shannon Index of karyotypic 
heterogeneity; H' Shannon index of karyotypic heterogeneity normalized for maximum population variability. 
† transformative stage significantly different from adjacent time point, ‡ different from day 528. 
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3.6  Variability within sub-populations identified by clonal chromosome aberrations 
To determine if the presence or absence of a marker clonal chromosome translocation 
was linked to variability of whole chromosome counts, data from day 450 cells were divided into 
subpopulations based on the presence or absence of the clonal 4;3 translocation (34% of day 
450 cells, Figure 8A).  Variability of whole chromosome copy number is shown to exist in 
karyotype tables showing the genomes of four CCA t4;3 cells (Figure 8A).  Among these four 
karyotypes, 18/20 possible chromosome positions demonstrate variability of whole chromosome 
copy number.  Additionally, an example of a non-clonal chromosome translocation is provided 
which additionally contributes to the genomic heterogeneity of the CCA t 4;3 line (Figure 8A). 
Presence of the clonal chromosome marker t 4;3 was not linked to variability of chromosome 
count as measured by standard deviation of the mean for each chromosome ID. Additionally, H' 
value for each group by total chromosome count approached the theoretical maximum (1 for 
each chromosome) and indicated slightly higher variability in the subpopulation carrying the 
clonal marker compared to the remaining day 450 cells (H' CCA t4;3 = 0.96 versus H' CCA none 
= 0.91, Figure 8B).   
 
3.7   Analyses of differential mRNA transcript abundance from key transformative stages 
3.7.1   Time course analysis and biological significance for mRNA temporal expression profiles 
of key transformative stages 
To determine the gene expression corresponding to each key transformative stage and 
its karyotype profile, genome wide analysis of mRNA transcript abundance was performed.  
Time course analysis was implemented with EDGE software as a robust method for determining 
differential gene expression over time and discovered 599 of the 18,000 candidates genes 
represented on the Illumina MouseRef-8 v2.0 chip.  The following exclusionary criteria were 
used: maximum signal >3x background, >2.5 fold change during the time course, and statistical 
significance q <0.01 to reject the null hypothesis of constant gene expression over time.  Rather 
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than arbitrarily grouping the 599 significant genes based  increase versus decrease between 
consecutive time points, the gene list and corresponding expression values were input into 
short-time course-expression-miner (STEM) software which tests gene expression profile for 
each gene to determine the relative goodness of fit to a randomly generated profiles of fold 
change over time versus constant expression.  STEM software matched 530/599 differentially 
expressed genes to 8 unique profiles, where the maximum allowable correlation coefficient 
between profiles was <0.9.  Unmatched gene sets comprise the remaining 69 genes at the 
bottom of the heat map (white block, Figure 9A).  Fold change and enrichment for cluster 
membership and the defining characteristics of each color-coded cluster and its corresponding 
heat-map intensity plot are summarized (Figure 9B).  Figure 9C shows plots (y-axis-fold change, 
x-axis=days) for the genes matched to each profile (red lines), which ranged in number from 
(12-181) and are plotted as red lines against the normalized median profile (black line) as a 
function of days in culture (Figure 9C).  The biological significance of enriched genes from each 
profile was determined using GO enrichment analysis for biological process, molecular function, 
and cellular component.  These were significant for functional gene enrichment in profile 2 and 
profile 5 where corrected p <0.05 (Figure 9D).  Profile 2 enrichment lists categories relating to 
chromatin, chromosome, protein-DNA complex assembly, nucleosome organization and 
assembly, cellular macromolecular complex assembly and subunit organization, RNA 
processing and others.  Profile 5 is enriched for cholesterol biosynthetic processes, metabolic 
processes, microsome and vesicular formation.  Both profiles with functional gene enrichment 
show a net increase in gene expression during transformation, but differ in the magnitude of 
their slopes (450-528).  Additionally, profile 2 genes slightly decrease expression between days 
450 and 528, whereas profile 5 genes continue to increase, (Figure 9C, D).  A compliation of 
matched and unmatched genes lists genes by membership in each fold change by profile (Table 
4). 
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Table  4.  Differentially expressed genes during tumorigenesis       
(1) genes=181 (2e-129)  170  245  450  528  (2) genes=78(5e-39)  170  245  450  528   
1110033j19RIK  0  -1.9  -4.0  -3.8  1110067d22RIK  0  0.8  1.4  1.3   
1200013b22RIK  0  -0.6  -2.2  -1.9  2410008j05RIK  0  1.9  2.2  2.0   
1700011h14RIK  0  -0.9  -2.9  -2.3  2610318c08RIK  0  1.5  1.8  1.4   
1700019e19RIK  0  -1.1  -1.6  -1.3  2610510j17RIK  0  1.4  1.7  1.5   
1700088e04RIK  0  -1.2  -2.2  -1.6  2610524h06RIK  0  1.2  1.5  1.1   
1810015a11RIK  0  -2.5  -3.6  -3.3  4832406c22  0  2.0  2.2  1.4   
2300002d11RIK  0  -2.0  -2.6  -2.3  Asf1b  0  1.3  1.8  1.3   
2310044g17RIK  0  -0.5  -1.4  -1.2  Birc5  0  2.1  2.2  1.6   
2700055k07RIK  0  -1.1  -3.7  -3.6  Bub1b  0  1.5  1.8  1.7   
2810003c17RIK  0  -1.6  -3.2  -2.4  Ccl7  0  2.8  4.4  4.0   
2810417j12RIK  0  -2.1  -3.2  -3.2  Cdc42ep2  0  1.7  2.3  2.3   
3110004l20RIK  0  -0.8  -1.7  -1.6  Cdkn2a  0  1.3  2.2  2.0   
4732481h14RIK  0  -1.0  -1.7  -1.8  Cldn1  0  2.0  2.5  2.4   
4930402h24RIK  0  -1.4  -2.2  -1.8  Col5a1  0  1.0  1.9  1.5   
4933405a16RIK  0  -1.5  -2.5  -1.8  Copg  0  1.1  1.4  1.3   
5133400g04RIK  0  -0.8  -1.8  -1.4  Cyp7b1  0  3.2  4.6  4.0   
5730469m10RIK  0  -0.8  -1.3  -1.1  Drctnnb1a  0  1.0  1.8  1.6   
5830467p10RIK  0  -2.6  -4.2  -4.0  Eg433923  0  0.7  1.4  1.0   
6330580j24RIK  0  -1.5  -2.0  -2.0  Emp3  0  1.4  2.0  1.8   
9130213b05RIK  0  -0.6  -3.1  -2.6  Espl1  0  1.5  2.2  1.8   
9830002i17RIK  0  -1.4  -3.1  -2.9  Exosc8  0  1.1  1.6  1.4   
Acvr2b  0  -0.2  -1.5  -1.1  Fkbp2  0  1.7  2.0  1.9   
Agtrap  0  -0.9  -1.5  -1.6  Gap43  0  3.7  5.3  2.8   
Akap12  0  -0.9  -2.2  -1.7  Gnb4  0  1.2  1.4  1.0   
Aldh1a1  0  -2.1  -6.0  -4.5  H2afz  0  1.4  2.0  1.8   
Ankrd1  0  -1.9  -2.8  -3.1  Hey1  0  1.2  2.3  1.8   
Anxa11  0  -0.6  -1.5  -1.0  Hist1h2ad  0  1.8  2.6  2.3   
Anxa6  0  -0.7  -1.5  -1.5  Hist1h2af  0  1.5  2.2  2.0   
Apg10l  0  -0.7  -1.5  -1.3  Hist1h2ag  0  2.0  2.7  2.6   
Aplp1  0  -1.9  -3.5  -3.6  Hist1h2ah  0  1.7  2.5  2.3   
Atp6v0e2  0  -0.8  -3.1  -2.2  Hist1h2ak  0  1.8  2.6  2.3   
Aw146242  0  -0.9  -1.6  -1.6  Hist1h2an  0  1.5  2.2  2.1   
Aw555464  0  -0.8  -2.0  -1.6  Hist1h2ao  0  1.2  1.5  1.5   
Axin2  0  -1.4  -2.8  -2.5  Hist1h4f  0  1.5  2.0  1.3   
B430104h02RIK  0  -1.1  -2.7  -2.7  Hist2h2ab  0  1.9  2.7  2.7   
B930041f14RIK  0  -2.7  -3.7  -3.7  Hist2h2ac  0  1.3  1.6  1.5   
Bc024814  0  -1.2  -1.9  -1.5  Hmgb2  0  2.2  3.1  2.4   
Bc031181  0  -0.8  -1.6  -1.3  Hnrpa1  0  1.1  1.6  0.9   
Bc036718  0  -1.7  -2.4  -2.2  Hnrpa2b1  0  1.3  1.6  1.2   
Bc056929  0  -1.2  -5.3  -3.9  Irf1  0  1.3  1.8  1.7   
Bicc1  0  -0.8  -1.7  -1.4  Irs2  0  2.6  3.5  3.5   
Bicd2  0  -0.3  -1.4  -1.3  Kdelr2  0  1.5  2.1  1.6   
Blcap  0  -1.0  -1.6  -1.5  Klra18  0  2.2  3.5  3.3   
Bok  0  -1.0  -3.1  -2.8  Klra33  0  1.7  3.3  2.8   
Btbd6  0  -1.2  -2.1  -1.6  Klra4  0  2.3  3.6  3.4   
Bzrap1  0  -2.5  -3.8  -4.3  Kpna2  0  1.6  1.9  1.3   
Camk2n1  0  -1.5  -2.9  -2.8  Loc381795  0  3.0  3.5  3.2   
Carhsp1  0  -0.3  -1.7  -1.5  Lsm2  0  1.3  1.5  1.2   
Ccbl1  0  -1.9  -2.4  -2.1  Ly6a  0  2.3  4.1  3.9   
Cd59a  0  -1.2  -3.6  -3.3  Ly6e  0  1.1  1.8  1.6   
Cd97  0  -2.0  -3.2  -3.5  Mcm5  0  1.1  1.4  1.2   
Cdc23  0  -1.1  -1.8  -1.7  Mettl9  0  1.1  1.4  1.3   
Cdc42bpb  0  -1.2  -1.9  -1.5  Ncapd2  0  1.5  1.8  1.6   
Ceecam1  0  -1.8  -2.6  -2.5  Nsbp1  0  1.1  1.5  1.3   
Cib2  0  -0.8  -2.3  -1.9  Odz3  0  2.0  3.0  3.0   
Ckb  0  -5.5  -8.5  -8.4  Otx1  0  2.3  2.8  2.5   
Cln2  0  -1.3  -2.1  -1.7  Pak3  0  1.2  1.4  1.1   
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Table  4.  Differentially expressed genes during tumorigenesis (continued)       
(1) genes=181 (2e-129)  170  245  450  528  (2) genes=78(5e-39)  170  245  450  528   
Col4a1  0  -1.7  -6.7  -5.1  Pfn2  0  1.1  1.5  1.4   
Col4a2  0  -1.4  -5.5  -4.1  Prdx4  0  1.7  1.9  1.9   
Col4a5  0  -1.0  -1.6  -1.2  Rab32  0  1.0  1.4  1.4   
Creb3  0  -0.7  -1.4  -1.3  Rbm3  0  0.9  1.5  0.8   
Creld1  0  -0.8  -1.8  -1.6  Rfc3  0  0.9  1.5  0.9   
Crim1  0  -0.6  -1.3  -1.4  Rfc5  0  0.8  1.4  1.1   
Crip2  0  -2.0  -4.8  -4.3  Ris2  0  0.9  1.6  1.3   
Csrp1  0  -1.5  -2.2  -2.3  Skp2  0  0.8  1.4  1.0   
D14ertd449e  0  -1.3  -2.4  -2.6  Slc29a1  0  1.3  1.5  1.5   
D430039n05RIK  0  -0.7  -2.1  -1.9  Smoc1  0  3.6  4.9  4.1   
D4bwg0951e  0  -0.8  -1.3  -1.4  Snx8  0  1.0  1.5  1.5   
D630003m21RIK  0  -1.0  -3.0  -2.4  Spc25  0  1.4  1.5  1.2   
D930001i22RIK  0  -0.9  -1.7  -1.5  Sprr2g  0  2.2  4.2  3.6   
Dcp1b  0  -1.0  -2.1  -1.9  Ssbp2  0  0.9  1.7  1.5   
Ddah1  0  -0.9  -1.9  -2.0  Thoc4  0  1.3  1.6  1.4   
Dnaja4  0  -1.1  -1.6  -1.7  Tk1  0  1.4  1.6  1.2   
Dos  0  -2.0  -2.9  -2.7  Twist1  0  1.2  1.8  1.7   
Dtnb  0  -1.0  -2.0  -1.5  Tyms  0  1.7  2.1  1.5   
Dusp2  0  -1.1  -2.5  -2.6  Tyms-ps  0  1.4  1.7  1.4   
Dyrk3  0  -1.4  -2.2  -2.4  Uaca  0  0.7  1.4  1.0   
Edn1  0  -0.5  -1.7  -1.5  Zfp326  0  1.2  1.6  1.3   
Efna5  0  -0.6  -1.7  -1.6   
Eno3  0  -1.4  -2.8  -2.5  (3) genes=65 (5e-17)  170  245  450  528   
Enpp5  0  -0.8  -2.4  -1.6  1190002h23RIK  0  0.4  1.4  1.0   
Entpd4  0  -0.7  -1.4  -1.3  1810014l12RIK  0  0.6  1.5  1.1   
Eppk1  0  -0.9  -2.2  -2.3  2610019i03RIK  0  1.0  2.2  2.2   
Etfb  0  -1.1  -1.5  -1.4  5430420c16RIK  0  1.0  2.3  2.1   
Fblim1  0  -1.1  -2.4  -1.9  Aa467197  0  0.1  4.3  4.0   
Fos  0  -0.4  -1.5  -1.5  Acsl3  0  0.9  2.1  2.1   
Fst  0  -3.1  -6.1  -6.0  Adh7  0  2.7  7.8  8.0   
Fxyd5  0  -1.3  -2.8  -2.3  Ank  0  0.1  1.3  1.4   
Galntl4  0  -2.7  -4.2  -3.6  Aqp5  0  1.3  4.1  4.3   
Garnl4  0  -0.8  -2.0  -2.1  Arhgdib  0  1.0  5.9  5.3   
Gdf15  0  -3.0  -6.1  -4.6  Avpi1  0  -0.3  1.4  1.5   
Ghr  0  -0.5  -1.4  -1.4  Bc029169  0  1.2  4.1  4.0   
Gnaz  0  -1.2  -2.2  -1.8  Bgn  0  0.4  4.2  4.3   
Golph2  0  -0.6  -1.7  -1.7  Ccl25  0  0.7  1.4  1.3   
Gstk1  0  -2.1  -4.8  -4.1  Col1a1  0  1.1  7.6  7.4   
H13  0  -0.9  -1.4  -1.2  Col3a1  0  0.3  4.9  4.4   
Havcr1  0  -1.2  -3.4  -3.2  Col6a1  0  0.7  2.3  2.3   
Hemk1  0  -1.6  -2.2  -1.8  Col6a2  0  0.3  2.9  2.8   
Hint2  0  -1.2  -2.2  -1.6  Cxcl12  0  2.1  5.0  4.7   
Hist1h1c  0  -1.9  -3.5  -3.4  Cyp51  0  1.0  2.6  2.5   
Hist1h2bc  0  -1.5  -3.3  -3.4  Dap  0  0.3  1.8  2.0   
Hist1h2bj  0  -1.1  -1.8  -2.0  E030003n15RIK  0  0.2  1.5  1.7   
Hist2h2aa1  0  -2.1  -3.3  -2.8  Elovl6  0  0.6  1.5  1.5   
Hk2  0  -0.5  -1.7  -1.5  Emilin1  0  0.9  3.4  3.3   
Hr  0  -1.0  -3.3  -3.0  Esm1  0  1.4  3.9  4.0   
Hyal1  0  -2.0  -3.1  -2.5  Fdps  0  0.0  1.5  1.8   
Igfbp2  0  -1.3  -3.5  -3.0  Fgf7  0  -0.2  3.7  3.2   
Igsf4a  0  -1.1  -2.9  -2.7  Fmnl3  0  0.6  1.8  1.7   
Il11  0  -3.1  -4.1  -3.7  Foxq1  0  0.2  4.3  3.9   
Impact  0  -1.1  -2.4  -1.8  G431001e03RIK  0  0.8  1.9  2.0   
Krt1-18  0  -1.5  -2.8  -1.6  Hmgcs1  0  0.3  1.4  1.3   
Lims2  0  -2.6  -4.5  -4.2  Igf2bp3  0  1.6  4.7  4.4   
Llglh2  0  -2.0  -4.1  -3.7  Lsp1  0  1.1  2.9  2.7   
Loc239102  0  -1.1  -1.9  -1.7  Ly6c  0  0.9  3.8  3.4   
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Table  4.  Differentially expressed genes during tumorigenesis (continued)       
(1) genes=181 (2e-129)  170  245  450  528  (3) genes=65 (5e-17)  170  245  450  528   
Loc381297  0  -0.8  -2.0  -2.1  Tinagl  0  -1.2  -3.8  -3.4   
Loc386486  0  -0.8  -1.4  -1.5  Tnc  0  -0.7  -1.6  -1.6   
Lrrc28  0  -0.9  -1.5  -1.4  Mglap  0  1.2  9.3  9.6   
Lzf  0  -1.0  -1.6  -1.5  Mgst1  0  0.7  2.1  2.0   
Man2b2  0  -1.2  -1.8  -1.4  Mgst2  0  -0.4  4.0  4.3   
Mocos  0  -1.4  -2.4  -1.8  Mnd1  0  0.7  1.5  1.4   
Mscp  0  -1.1  -1.4  -1.3  Mvd  0  0.1  2.0  2.0   
Mt1  0  -1.3  -3.6  -2.6  Mxra8  0  -0.3  3.0  3.4   
Mvp  0  -0.9  -1.7  -1.3  Nr2f1  0  0.2  5.5  5.9   
Ndfip2  0  -0.9  -1.5  -1.4  Nrn1  0  1.7  4.0  3.9   
Nek9  0  -0.7  -1.5  -1.1  Nupr1  0  0.4  1.6  1.3   
Nipsnap1  0  -0.6  -1.7  -1.6  Ottmusg00000010673  0  1.4  5.0  5.0   
Nme4  0  -1.1  -2.5  -2.5  Padi1  0  0.2  4.7  4.9   
Nme5  0  -0.8  -4.0  -3.7  Pcolce  0  1.1  4.2  4.1   
Nppa  0  -2.1  -3.6  -3.9  Pdgfra  0  0.4  5.4  6.2   
Nppb  0  -3.1  -5.8  -6.0  Pem  0  0.2  3.3  2.8   
Nt5e  0  -0.5  -1.6  -1.1  Pmvk  0  0.7  1.9  2.0   
Nudt7  0  -0.9  -2.2  -1.9  Ppbp  0  1.4  4.6  4.3   
Ostm1  0  -0.9  -1.6  -1.4  Ptn  0  1.2  3.6  2.5   
Oxr1  0  -0.6  -1.5  -1.0  Rcn3  0  1.1  2.4  2.2   
Pde4dip  0  -2.1  -3.3  -3.6  S100a4  0  0.6  3.1  3.7   
Pea15  0  -0.5  -1.5  -1.4  Scd2  0  1.0  2.7  2.6   
Peg3  0  -1.5  -4.1  -3.8  Sec24d  0  0.7  1.6  1.6   
Picalm  0  -0.7  -1.7  -1.3  Sfrp1  0  0.4  2.9  3.0   
Pld3  0  -1.3  -1.8  -1.4  Siat4a  0  0.3  1.2  1.3   
Plekhb2  0  -1.0  -1.7  -1.7  Slc1a3  0  1.6  4.1  4.0   
Plekhc1  0  -0.9  -2.0  -1.6  Sqle  0  0.7  2.5  2.4   
Plekhg3  0  -1.1  -1.7  -1.9  Stard4  0  0.6  1.5  1.4   
Ppp1r9a  0  -0.8  -2.1  -1.6  Tnfrsf11b  0  1.2  3.0  2.1   
Ppt1  0  -1.0  -1.5  -1.4  Twist2  0  2.0  5.0  4.8   
Prnp  0  -0.8  -1.6  -1.3  Ugt1a10  0  0.3  2.3  2.8   
Ptpn21  0  -0.7  -1.4  -1.1  Vamp5  0  0.6  1.5  1.1   
Ptprk  0  -0.6  -1.5  -1.3  Zfp537  0  0.8  2.3  2.3   
Pwwp2  0  -0.5  -1.5  -1.3   
Rab3d  0  -1.0  -2.1  -1.9   
Rab3ip  0  -1.0  -1.7  -1.6   
Rab7l1  0  -0.5  -1.6  -1.5   
Rbpms  0  -0.6  -1.7  -1.2   
Rhob  0  -0.9  -2.2  -2.0   
Rin3  0  -0.4  -1.5  -1.3   
Rras  0  -0.6  -1.5  -1.4   
Rras2  0  -1.1  -2.0  -1.9   
Rusc2  0  -1.0  -1.7  -1.5   
S100a1  0  -1.2  -2.3  -1.4   
Scin  0  -3.3  -5.9  -6.3   
Slc7a4  0  -2.1  -3.4  -3.3   
Slc7a7  0  -1.6  -2.5  -2.5  (1) continued…   
Slco2a1  0  -1.7  -3.6  -2.8   
Sptlc1  0  -0.9  -1.4  -1.4  (1) genes=181 (2e-129)  170  245  450  528   
Srd5a1  0  -1.3  -2.5  -2.6  Tnfaip3  0  -0.6  -2.3  -2.1   
Tagln  0  -2.3  -5.6  -5.8  Tspyl3  0  -2.2  -3.2  -3.4   
Taldo1  0  -1.1  -1.5  -1.2  Ttc5  0  -0.9  -1.5  -1.2   
Tcf2  0  -0.5  -1.4  -1.3  Unc13b  0  -2.5  -4.6  -3.5   
Tgfb1i1  0  -1.4  -4.1  -4.2  Zdhhc14  0  -1.3  -3.2  -3.2   
Tgfb1i4  0  -1.2  -2.4  -2.6  Zfhx2  0  -1.1  -2.0  -1.7   
Tgfb3  0  -0.7  -2.0  -1.6  Zfp219  0  -0.7  -1.8  -1.4   
Timp3  0  -1.5  -2.8  -2.2  Zfp354a  0  -0.8  -2.1  -1.8   
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Table  4.  Differentially Expressed Genes During Tumorigenesis (continued)       
(4) Genes=58(1E-25)  170  245  450  528  (5) Genes=53(9E-22)  170  245  450  528   
0610041g09RIK  0  -0.4  -1.0  -1.3  1190005i06RIK  0  0.9  2.0  2.2   
1300014i06RIK  0  -0.4  -1.4  -1.5  2310022b05RIK  0  1.0  1.9  1.9   
1500031h04RIK  0  -0.7  -2.4  -3.5  2610027c15RIK  0  0.5  1.0  1.3   
2010004a03RIK  0  -1.0  -1.7  -2.2  2810428i15RIK  0  0.9  1.6  1.7   
2310067e08RIK  0  -0.6  -1.9  -2.2  2810471m23RIK  0  1.3  2.0  3.1   
Acta2  0  -1.3  -2.6  -3.2  4930504e06RIK  0  0.1  1.0  1.4   
Actn1  0  -0.8  -1.6  -2.1  9230117n10RIK  0  0.5  1.4  2.4   
Agrn  0  -0.7  -2.3  -2.6  Acat2  0  0.2  1.3  1.6   
Akr1c19  0  -1.5  -3.2  -4.5  Adamts2  0  0.3  3.1  4.1   
Arhgdig  0  -0.9  -3.0  -3.5  Ai467484  0  0.9  1.5  2.2   
Bc003236  0  -0.3  -1.2  -1.4  Aldh3a1  0  0.4  3.8  5.0   
Bc011487  0  -0.7  -3.5  -4.5  Antxr1  0  0.9  2.3  3.1   
Bc058638  0  -1.2  -3.5  -4.0  Apbb2  0  0.8  1.5  1.5   
Bin1  0  -0.8  -1.3  -1.5  Arfgap3  0  0.4  1.0  1.4   
Cd44  0  -0.9  -1.5  -1.8  Bteb1  0  0.5  1.1  1.6   
Clcf1  0  -0.9  -1.7  -1.9  C3  0  0.6  2.2  4.8   
Cltb  0  -0.6  -1.1  -1.6  Cacna2d1  0  0.3  1.1  1.5   
Col4a3  0  -1.0  -2.8  -3.9  Card4  0  0.4  1.4  1.7   
Col4a4  0  -1.2  -2.3  -3.0  Casp4  0  1.3  2.6  3.0   
D330037a14RIK  0  -0.5  -1.1  -1.4  Cd14  0  0.5  0.9  1.6   
Dbn1  0  -0.7  -1.2  -1.6  Chst2  0  0.9  1.7  1.7   
Dtr  0  -0.7  -1.8  -2.6  Efna1  0  0.5  1.5  1.9   
Dusp1  0  -0.5  -1.5  -1.7  Eif4b  0  0.5  1.2  1.4   
Fbln2  0  -0.6  -1.8  -2.7  Emb  0  0.7  1.3  1.9   
Fhl1  0  -0.6  -1.4  -2.1  Fbxo31  0  0.6  1.4  1.6   
Flrt3  0  -0.9  -2.7  -3.2  Figf  0  2.0  4.8  5.3   
Gjb4  0  -0.3  -1.5  -2.0  Gypc  0  0.7  1.4  1.5   
Hes1  0  -0.1  -1.0  -1.7  Il13ra1  0  0.6  1.5  1.9   
Hist1h2bf  0  -1.0  -1.7  -2.1  Lss  0  0.6  1.7  2.0   
Hist1h2bh  0  -1.1  -1.7  -2.0  Man2a1  0  1.1  1.7  1.9   
Hist1h2bk  0  -0.4  -0.8  -1.3  Mknk2  0  0.8  0.9  1.5   
Hist1h2bm  0  -1.1  -1.8  -2.1  Msln  0  0.4  1.5  2.3   
Hist1h2bn  0  -0.7  -1.2  -1.5  Ntrk3  0  1.6  2.1  3.2   
Igsf9  0  -0.6  -1.7  -2.3  Olfml2b  0  1.2  2.2  2.2   
Inhba  0  -1.2  -1.8  -3.0  Olfml3  0  0.4  2.8  4.0   
Klf5  0  -0.8  -1.4  -1.8  Pde1a  0  0.3  3.1  4.2   
Lad1  0  -0.7  -2.5  -2.6  Pdk1  0  0.3  0.8  1.7   
Lamb3  0  -1.5  -3.0  -4.1  Phka2  0  0.7  1.1  1.4   
Mcam  0  -0.7  -2.6  -3.3  Prrx1  0  1.4  2.5  3.2   
Mett11d1  0  -0.6  -1.3  -1.4  Rev3l  0  0.4  0.8  1.4   
Nes  0  -0.9  -1.3  -1.9  Rgl1  0  0.3  1.3  1.9   
Ngfb  0  -0.8  -2.7  -2.9  Sc4mol  0  0.1  1.2  1.5   
Panx1  0  -0.3  -0.9  -2.0  Scara3  0  1.8  3.3  3.5   
Pbp2  0  -0.3  -1.0  -1.7  Scara5  0  0.7  2.9  4.6   
Pdlim7  0  -0.7  -1.1  -1.8  Sdh1  0  0.4  0.9  1.7   
Ptprb  0  -1.5  -2.7  -3.8  Sesn1  0  0.3  1.0  1.9   
Raet1b  0  -0.9  -1.7  -1.9  Socs3  0  0.7  1.7  2.3   
Reprimo  0  -1.7  -4.1  -4.7  Spp1  0  0.6  1.4  1.7   
S100a15  0  -1.1  -2.2  -2.7  Stard5  0  0.6  0.8  1.6   
Scamp5  0  -0.9  -1.3  -2.1  Tgfbi  0  1.9  3.7  4.6   
Sdc3  0  -0.2  -1.5  -3.0  Tgfbr3  0  0.7  1.5  2.2   
Slc7a3  0  -1.7  -2.5  -3.2  Tnfaip8  0  0.8  1.4  1.6   
Snrpn  0  -1.3  -3.0  -4.1  Vdr  0  0.4  1.3  2.1   
Taf9b  0  -0.6  -2.3  -3.1   
Ugcg  0  -0.5  -1.9  -2.3   
Wnt7a  0  -2.3  -5.4  -6.2   
Wnt7b  0  -1.3  -5.7  -6.1   
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Table  4.  Differentially Expressed Genes During Tumorigenesis (continued)       
(6) genes=36(9e-4)  170  245.0  450.0  528.0  (7) genes=34(6e-4)  170  245  450  528   
0610006i08RIK  0  -0.4  -2.2  -2.4  1110012d08RIK  0  -1.2  -1.4  -0.8   
1110032e23RIK  0  0.4  -0.8  -1.0  1500005a01RIK  0  -1.6  -2.0  -1.6   
2610001e17RIK  0  0.1  -1.5  -1.2  2210008i11RIK  0  -1.1  -1.4  -1.0   
4930422j18RIK  0  0.0  -1.5  -1.7  2310005e10RIK  0  -1.1  -1.5  -1.0   
A230050p20RIK  0  0.8  -1.4  -2.0  2610020h15RIK  0  -1.1  -1.5  -1.2   
Al024069  0  -0.6  -3.8  -3.5  Abhd4  0  -1.6  -2.4  -1.7   
Axud1  0  0.4  -0.5  -0.9  Aldh4a1  0  -1.6  -2.2  -1.4   
Bdnf  0  -0.1  -1.8  -1.5  Aldh6a1  0  -1.8  -2.3  -0.9   
Card10  0  -0.3  -1.4  -1.4  Atp6v1d  0  -1.1  -1.6  -1.0   
Cav1  0  0.2  -0.9  -1.4  Bc031853  0  -1.2  -1.8  -1.2   
Chrnb1  0  0.0  -0.9  -1.4  Ccnd2  0  -1.0  -1.8  -1.0   
Clca4  0  0.0  -2.6  -3.5  Ccng1  0  -2.3  -2.7  -2.4   
Ctsw  0  -0.1  -2.0  -3.2  Clu  0  -2.3  -3.3  -2.1   
F2rl1  0  -0.5  -2.3  -2.6  Cox6a2  0  -1.7  -2.2  -1.6   
Gadd45g  0  -0.2  -1.9  -2.5  Cyp2d22  0  -1.8  -2.9  -1.3   
Greb1  0  -0.2  -1.5  -1.3  Cyp4f13  0  -1.7  -2.2  -1.9   
Hspb1  0  -0.4  -1.8  -1.8  Dgka  0  -2.3  -2.6  -2.3   
Nbl1  0  1.0  -1.2  -1.5  Ganc  0  -1.4  -2.0  -1.5   
Ndn  0  -1.9  -3.6  -6.3  Ghitm  0  -1.3  -1.8  -1.2   
Nox4  0  0.3  -1.0  -1.4  Gm2a  0  -1.2  -2.0  -1.3   
Pdgfb  0  0.3  -2.3  -2.3  Gns  0  -1.0  -1.5  -0.9   
Pdlim4  0  -0.2  -1.4  -1.6  Grcc10  0  -0.9  -1.5  -0.8   
Plk2  0  -0.3  -1.5  -1.5  H2-dmb1  0  -0.8  -1.4  -0.7   
Pvr  0  0.1  -1.3  -1.0  Itm2b  0  -1.2  -1.7  -1.2   
Pvrl2  0  0.2  -2.0  -1.7  Lbh  0  -1.4  -2.4  -1.4   
Rasgrp3  0  -0.6  -2.6  -2.7  Mgc18837  0  -1.9  -2.3  -1.7   
Rasl12  0  -0.5  -3.4  -3.4  Rpl22  0  -1.4  -1.6  -1.1   
Rassf1  0  0.5  -0.8  -1.1  Sdsl  0  -2.9  -3.5  -3.1   
Rtn1  0  0.1  -3.2  -3.1  Slc9a3r2  0  -1.2  -1.6  -1.0   
S100a3  0  -0.1  -1.2  -1.4  Tgm2  0  -1.0  -1.7  -0.8   
Samd10  0  0.0  -1.8  -1.6  Tmem141  0  -1.6  -2.0  -1.5   
Sema4f  0  -0.6  -4.9  -5.8  Trp53inp1  0  -3.3  -3.7  -3.1   
Slc39a6  0  0.0  -1.3  -1.4  Trp53inp2  0  -1.1  -1.4  -0.7   
Smtn  0  0.2  -1.4  -1.5  Wars  0  -1.3  -1.7  -1.4   
Sox8  0  0.3  -1.4  -1.3   
Tuft1  0  0.1  -1.7  -2.0   
Wfs1  0  -0.1  -1.9  -1.5   
(8) continued…   
(8) genes =25 (9e-4)  170  245  450  528  (8) genes =25 (9e-4)  170  245  450  528   
1810009n02RIK  0  1.9  2.6  2.7  Rfxap  0  1.1  1.4  1.4   
2610002m06RIK  0  1.0  1.6  1.6  Rgs10  0  1.8  2.2  2.7   
Abcb1b  0  1.5  1.8  2.0  Slco1a5  0  2.0  2.6  3.3   
Car13  0  1.0  1.3  1.6  Slit2  0  1.3  1.8  2.2   
Ccl9  0  2.8  3.7  4.3  Smpdl3b  0  1.6  2.2  2.6   
Cdca3  0  1.7  2.0  2.1  Snx25  0  1.1  1.4  1.6   
Cdkn2c  0  1.4  1.9  2.0  Vcam1  0  0.8  1.0  1.3   
Cox7b  0  1.0  1.2  1.4   
Cxcl1  0  2.4  3.8  3.9   
Ednra  0  3.3  4.7  5.2   
Frda  0  1.2  1.5  1.7   
Ifitm3  0  1.1  1.6  1.7   
Lsm6  0  1.0  1.5  1.5   
Mad2l1  0  1.3  1.4  1.5   
Mcrs1  0  0.8  1.1  1.4   
Ogn  0  3.0  4.3  5.2   
Pdk3  0  1.4  1.8  1.8   
Pold2  0  1.3  1.6  1.6   
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Table  4.  Differentially Expressed Genes During Tumorigenesis (continued)       
(Ns) genes=68  170  245  450  528  (ns) genes=68 (ns)  170  245  450  528   
1110058a15RIK  0  -4.8  -5.6  -5.8  Gstm2  0  -0.3  2.0  3.0   
1700024k14RIK  0  -0.7  0.9  2.9  Igfbp4  0  -0.6  2.3  3.4   
2010323f13RIK  0  -1.0  1.1  2.0  Inmt  0  1.2  1.7  5.1   
4432405b04RIK  0  -0.6  -1.3  -0.8  Jam4  0  -1.3  -1.7  -2.2   
5430435g22RIK  0  -0.7  1.5  1.6  Khdrbs3  0  0.5  1.5  0.7   
Ai429612  0  -0.7  -1.6  -0.9  Kif3c  0  -1.0  -1.4  -1.4   
Aqp1  0  0.9  1.5  3.2  Lrrfip1  0  -1.7  -2.2  -2.5   
Arl4c  0  0.9  0.7  -0.5  Man2c1  0  -1.2  -1.7  -2.0   
Arrdc3  0  -0.8  0.1  0.9  Manea  0  0.0  -1.3  -0.8   
Bc013481  0  -0.4  1.3  1.7  Mgat3  0  0.1  1.0  1.9   
Cd248  0  -0.8  1.3  1.5  Mmp2  0  -0.7  2.3  3.0   
Cdkn1a  0  -5.1  -6.0  -5.5  Msc  0  2.6  -0.6  -2.4   
Cds1  0  0.6  -1.9  -1.5  Mybl2  0  1.4  1.3  0.7   
Cebpb  0  0.0  0.7  1.9  Myd116  0  -0.4  -1.9  -1.3   
Cmtm8  0  -0.5  -3.1  -2.0  Nnmt  0  -0.1  -1.9  -1.0   
Cnnm2  0  -0.5  0.4  1.5  Palmd  0  3.0  2.4  1.1   
Cobl  0  -0.3  -1.7  -0.7  Prelp  0  -0.5  0.8  3.2   
Cp  0  0.9  1.1  2.3  Prickle1  0  0.4  -0.4  -1.1   
Csrp2  0  0.8  1.9  1.2  Rad52b  0  -0.6  -1.4  -0.3   
Ctgf  0  -0.4  -0.5  -1.5  Rasl11b  0  0.5  -3.3  -2.5   
Ctsh  0  -0.2  -3.4  -1.0  Rem2  0  -3.5  -4.3  -4.3   
Cx3cl1  0  -0.5  1.3  1.4  Rgs17  0  -1.2  0.6  1.4   
Cxadr  0  0.0  -1.6  -1.0  Sars1  0  0.0  -1.5  -1.1   
D19wsu12e  0  0.0  0.9  1.5  Serpinf1  0  -0.6  1.6  2.9   
D330024h06RIK  0  -0.6  0.1  1.0  Stxbp2  0  -1.3  -1.9  -2.1   
D430044g18RIK  0  -0.6  -2.1  -1.3  Sytl2  0  -0.5  -1.9  -1.3   
Enpp2  0  0.8  4.7  2.6  Tacstd2  0  0.6  -2.3  -1.7   
Epb4.1l3  0  0.6  -0.4  -0.8  Tcn2  0  -2.2  -2.8  -2.8   
Fbxo2  0  -0.8  0.1  1.0  Tm4sf3  0  0.4  2.4  5.2   
Gjb3  0  1.1  -0.4  -1.9  Tm4sf6  0  0.8  -0.1  -0.8   
Gnb5  0  -1.1  -1.4  -1.4  Trib3  0  -1.1  -1.7  0.2   
Gpx3  0  -1.5  -3.7  -2.1  Tspan7  0  1.2  1.6  0.7   
Gstm1  0  -1.1  -0.5  0.6  Uchl1  0  1.1  -0.1  -1.0   
       
Whrn  0  0.0  -1.6  -1.0   
 
Table 4. Gene symbols, fold change, and profile assignment for each of four key transformative stages during 
tumorigenesis.  Differentially expressed genes over time were assigned to each profile by maximization of the 
correlation coefficient between the actual and randomly generated model profiles.  Fifty theoretical profiles were 
tested with a maximum correlation of 0.9 among profiles and a maximum allowable change of 5 units. The statistical 
significance of the number of assigned versus expected genes for each profile is shown and profiles were assigned 
by relative expression for the list of differentially expressed genes from time course gene discovery analysis.  Genes 
were included in a given profile where p <0.05. 
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3.7.2   Traditional gene analysis by paired comparisons of consecutive transformative stages 
In addition to the time course analysis for microarray data, pair wise analyses using 
Significance Analysis of Microarrays (SAM) on consecutive samples were performed in 
biological triplicate (Figure 10).  Gene lists, definition, location, and fold change are provided for 
each paired analysis (Table 5).  The largest list of differentially expressed genes was generated 
between Early=170:245= 319 genes.  Despite using the same statistical cut-points and fold 
change of 2.5 for all pair wise analysis, the lists of differentially expressed genes became 
progressively shorter as transformation progressed, with Mid=245:450=102 genes and 
Late=450:528= 30 genes.  Gene lists between consecutive transformative stages were similarly 
subjected to GO enrichment analysis to determine the functional significance of the differentially 
expressed genes (Table 6).  Several significant categories were returned for functional 
enrichment at between each pair of stages.  Of note are several categories relating to 
extracellular matrix and collagen components, as well as several relating to cell cycle, mitosis, 
and development were enriched for altered gene expression (Table 6). 
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Table 5.  Differentially expressed genes between consecutive transformative stages  
170:245 gene definition cytoband fold change 
1110031b06RIK synaptosomal-associated protein, 47 11qB5 -2.9 
1110033j19RIK ribosomal protein S4, Y-linked 2 10qC1 -4.3 
1110036o03RIK RIKEN cDNA 1110036O03 gene 11qB5 -3.5 
1110058a15RIK late cornified envelope 1G 11qC -109.3 
1700088e04RIK RIKEN cDNA 1700088E04 gene 15qE3 -2.5 
1810009n02RIK RIKEN cDNA 1810009N02 gene 1qC3 4.2 
1810015a11RIK YdjC homolog  5qF -6.8 
1810054o13RIK transmembrane protein 86A 2qE3 12.8 
1810073e21RIK trafficking protein particle complex 6A 3qE3 -5.0 
2300002d11RIK TMF1-regulated nuclear protein 1 10qD3 -5.4 
2310061n23RIK interferon, alpha-inducible protein 27 like 2A 10qA4 36.2 
2410008j05RIK transmembrane protein 121 1qD 4.2 
2810003c17RIK allograft inflammatory factor 1-like 8qB3.3 -3.0 
2810004a10RIK interleukin 17 receptor D 12qA1.1 -3.1 
4833421e05RIK isoamyl acetate-hydrolyzing esterase 1 homolog  12 -3.3 
4930418p06RIK rhomboid domain containing 1 13qA3.3 -3.3 
4933405a16RIK sphingomyelin synthase 2 3 -2.9 
5830467p10RIK fermitin family homolog 1  16qC4 -10.2 
6330406i15RIK RIKEN cDNA 6330406I15 gene 18qB3 7.8 
9830002i17RIK spinster homolog 3  12qC3 -3.0 
Abhd4 abhydrolase domain containing 4 14 -3.2 
Ai427138 frizzled homolog 5  4qD3 -3.9 
Ai449441 PIF1 5'-to-3' DNA helicase homolog  8qA2 3.9 
Ai450948 AHNAK nucleoprotein 2 11qB5 -5.0 
Ak1 adenylate kinase 1 4qC7 -19.1 
Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 11qD -5.3 
Amid apoptosis-inducing factor, mitochondrion-associated 2 7qA3 -2.6 
Ankrd1 ankyrin repeat domain 1  1qC1.3 -3.3 
Aplp1 amyloid beta  precursor-like protein 1 11qB2 -4.7 
Arhgap24 Rho GTPase activating protein 24 5qE5 4.4 
Ass1 argininosuccinate synthetase 1 1qA5 -47.0 
Atp6v0a1 ATPase, H+ transporting, lysosomal V0 subunit A1 5qG2 -3.9 
B930041f14RIK RIKEN cDNA B930041F14 gene 6qB1 -7.1 
Bc022687 cDNA sequence BC022687 9qF1 -2.9 
Bc024814 cDNA sequence BC024814 7qB2 -2.6 
Bc036718 nudix -type motif 18 13qB3 -3.4 
Bc046331 cDNA sequence BC046331 4qE2 3.0 
Bc049806 family with sequence similarity 126, m B 7qF5 -3.0 
Birc5 baculoviral IAP repeat-containing 5 11 4.1 
Bmp3 bone morphogenetic protein 3 XqC3 17.9 
Bscl2 Bernardinelli-Seip congenital lipodystrophy 2 homolog  9qA5.2 -3.3 
Btbd3 BTB  domain containing 3 XqA3.3 5.0 
Bub1b budding uninhibited by benzimidazoles 1 homolog, beta  8qB3.1 3.1 
Bzrap1 benzodiazapine receptor associated protein 1 17qA3.3 -9.1 
 
  
56 
 
 
Table 5.  Differentially expressed genes between consecutive transformative stages 
170:245 gene definition cytoband fold change 
C630013n10RIK kelch-like 26  10qC2 -2.6 
Cask calcium/calmodulin-dependent serine protein kinase XqA1.1 3.1 
Ccbl1 cysteine conjugate-beta lyase 1 8qE1 -4.3 
Ccnb1 cyclin B1 13qD1 2.9 
Ccnd1 cyclin D1 5qF -3.7 
Ccng1 cyclin G1 XqA5 -5.2 
Cd97 CD97 antigen 4qA5 -4.5 
Cdc20 cell division cycle 20 homolog  8qC5 3.8 
Cdca3 cell division cycle associated 3 6qF2 3.2 
Cdca8 cell division cycle associated 8 4qD2.2 4.6 
Cdkn1a cyclin-dependent kinase inhibitor 1A  11qB3 -41.7 
Cdsn corneodesmosin 14qC3 -4.2 
Ceecam1 cerebral endothelial cell adhesion molecule 9qF4 -3.9 
Cenpa centromere protein A 5 7.2 
Cenpi centromere protein I 13qB3 4.2 
Ckb creatine kinase, brain 19qA -49.3 
Cldn4 claudin 4 5 -75.3 
Cln2 tripeptidyl peptidase I 7 -2.7 
Clu clusterin 8qD3 -5.3 
Col18a1 collagen, type XVIII, alpha 1 11qB3 -3.0 
Col4a1 collagen, type IV, alpha 1 2qE5 -3.3 
Crip2 cysteine rich protein 2 15qA1 -4.1 
Csrp1 cysteine and glycine-rich protein 1 1 -2.9 
Cxcl1 chemokine  ligand 1 5qE1 5.6 
Cyp2d22 cytochrome P450, family 2, subfamily d, polypeptide 22 15 -4.3 
Cyp4a12 cytochrome P450, family 4, subfamily a, polypeptide 12a 6qE3 -71.4 
Cyp4f13 cytochrome P450, family 4, subfamily f, polypeptide 13 2qE1 -3.7 
Cyp7b1 cytochrome P450, family 7, subfamily b, polypeptide 1 19qC3 10.5 
D11ertd18e solute carrier family 46, m 1 2qB -7.3 
Dab2 disabled homolog 2  12qD2 4.8 
Dbf4 DBF4 homolog  11qC 4.1 
Dcn decorin 10qC3 13.2 
Dcxr dicarbonyl L-xylulose reductase 13qA5 -14.1 
Ddit4 DNA-damage-inducible transcript 4 1qC1.1 -3.6 
Dgka diacylglycerol kinase, alpha 2qE3 -6.7 
Dos downstream of Stk11 10qD3 -4.6 
Dusp6 dual specificity phosphatase 6 14qD3 -3.9 
Dyrk3 dual-specificity tyrosine--phosphorylation regulated kinase 3 4qB3 -2.7 
E130306d19RIK RIKEN cDNA E130306D19 gene 4 3.6 
Ednra endothelin receptor type B 7qB1 24.0 
Eno3 enolase 3, beta muscle 5qF -3.0 
Ephx1 epoxide hydrolase 1, microsomal 4qA3 -4.4 
Ercc5 excision repair cross-complementing rodent repair deficiency,  10qC1 -3.2 
Etv4 ets variant gene 4  11qB4 -3.4 
Fez1 fasciculation and elongation protein zeta 1  2qA1 -4.6 
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 Table 5.  Differentially expressed genes between consecutive transformative stages  
170:245 gene definition cytoband fold change 
Fibp fibroblast growth factor  intracellular binding protein 2qH1 -5.5 
Fignl1 fidgetin-like 1 11qA1 2.8 
Foxd1 forkhead box D1 13 6.9 
Foxm1 forkhead box M1 6qF3 3.5 
Fst follistatin 13 -8.8 
Galntl4 polypeptide N-acetylgalactosaminyltransferase-like 4 10qC1 -8.1 
Ganc glucosidase, alpha; neutral C 2qH3 -3.1 
Gcnt2 glucosaminyl  transferase 2, I-branching enzyme 17qA3.3 -2.8 
Gdf15 growth differentiation factor 15 15qD1 -8.2 
Grem1 gremlin 1 7qB1 -18.5 
Gspt2 G1 to S phase transition 2 12qC1 -32.9 
Gsta4 glutathione S-transferase, mu 2 18qE3 -6.6 
H2afz H2A histone family, m Z 3qG3 2.6 
Hes6 hairy and enhancer of split 6  1 -3.3 
Hist1h1c histone cluster 1, H1d 13 -3.6 
Hist1h2ad histone cluster 1, H2ad 13qA3.1 3.5 
Hist1h2ag histone cluster 1, H2ag 13 4.2 
Hist1h2bc histone cluster 1, H2bc 11qB3 -3.1 
Hist1h3a histone cluster 1, H3a 5qB1 6.0 
Hist1h3d histone cluster 1, H2ad 11qB1.3 3.9 
Hist1h3e histone cluster 1, H3e 13qA3.1 4.6 
Hist1h4f histone cluster 1, H4d 13qA3.1 3.3 
Hist2h2aa1 histone cluster 2, H2aa1 17qA3.3 -6.1 
Hist2h2ab histone cluster 2, H2ab 11qE2 3.9 
Hmgb2 high mobility group box 2 7qF3 4.6 
Hmgn2 high mobility group nucleosomal binding domain 2 4qD3 3.0 
Hmox1 heme oxygenase  1 7qA3 -3.7 
Hoxb7 homeobox B7 5qG2 -2.9 
Hs3st3a1 heparan sulfate  3-O-sulfotransferase 3A1 5qB1 -3.2 
Hsd3b7 hydroxy-delta-5-steroid dehydrogenase 11qD -4.0 
Htatip2 HIV-1 tat interactive protein 2, homolog  6qG1 -5.8 
Idb1 inhibitor of DNA binding 1 17qB1 -2.6 
Igf1 insulin-like growth factor 1 2qC1.1 9.4 
Igf2bp2 insulin-like growth factor 2 mRNA binding protein 2 5qC3.1 -14.8 
Igfbp2 insulin-like growth factor binding protein 2 1qG2 -2.6 
Il11 interleukin 11 11qC -14.3 
Ilvbl ilvB -like 12qA3 -3.1 
Immp2l IMP2 inner mitochondrial membrane peptidase-like  9qE3.3 -3.6 
Ing1l inhibitor of growth family, m 2 8B2 2.6 
Iqgap3 IQ motif containing GTPase activating protein 3 19qA 4.6 
Irs2 insulin receptor substrate 2 11qB3 12.5 
Itga3 integrin alpha 3 4qE2 -3.4 
Jam4 immunoglobulin superfamily, m 5 6qD1 -2.7 
Kif2c kinesin family m 2C 4qD1 3.1 
Kif4 kinesin family m 4 6qE3 3.9 
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 Table 5.  Differentially expressed genes between consecutive transformative stages  
170:245 gene definition cytoband fold change 
Klra18 killer cell lectin-like receptor, subfamily A, m 18 11qE1 4.5 
Klra4 killer cell lectin-like receptor, subfamily A, m 4 6qF3 5.3 
Kntc1 kinetochore associated 1 5qF 3.2 
Krt1-18 keratin 18 15qE1 -3.0 
Lbh limb-bud and heart 13qD1 -2.8 
Lims2 LIM and senescent cell antigen like domains 2 16qC3.3 -8.0 
Lin54 lin-54 homolog  5qE4 3.1 
Llglh2 Mus musculus lethal giant larvae homolog 2  11E2 -4.3 
Loc381795 11qC 9.6 
Lrrfip1 leucine rich repeat  interacting protein 1 1 -3.5 
Ly6a lymphocyte antigen 6 complex, locus A 10qB4 4.6 
Mapkapk3 mitogen-activated protein kinase-activated protein kinase 3 17qA2 -4.0 
Mdm2 transformed mouse 3T3 cell double minute 2 2qA3 -7.1 
Mgc25972 4qD1 -53.5 
Mgmt O-6-methylguanine-DNA methyltransferase 11qB1.3 -7.0 
Mocos molybdenum cofactor sulfurase 18 -3.1 
Msc musculin 1qA3 6.6 
Myo7a myosin VIIA 16qA1 3.2 
Ncapd2 non-SMC condensin I complex, subunit D2 6qF3 2.8 
Ndc80 NDC80 homolog, kinetochore complex component  18qD3 3.4 
Ndg2 coiled-coil-helix-coiled-coil-helix domain containing 10 3qF1 -27.4 
Ndn necdin 15qD3 -3.9 
Nid1 nidogen 1 13 -22.8 
Nppa natriuretic peptide precursor type A 4 -5.1 
Nppb natriuretic peptide precursor type B 11qC -9.5 
Oact1 membrane bound O-acyltransferase domain containing 1 13 3.3 
Oasl2 2'-5' oligoadenylate synthetase-like 2 17qA3.3 17.7 
Ogn osteoglycin 15qB2 13.1 
Otx1 orthodenticle homolog 1  9qA4 5.8 
Palmd palmdelphin 12qA1.1 18.1 
Pbxip1 pre-B-cell leukemia transcription factor interacting protein 1 3qF1 -4.2 
Pde4dip phosphodiesterase 4D interacting protein  2qA3 -5.3 
Phf17 PHD finger protein 17 11qB1.3 3.7 
Phlda3 pleckstrin homology-like domain, family A, m 3 17qE1.1 -4.8 
Pi4k2b phosphatidylinositol 4-kinase type 2 beta 17qB1 3.2 
Pkn2 protein kinase N2 3qH1 2.8 
Plk1 polo-like kinase 1  3qH2 4.3 
Plk4 polo-like kinase 4  3 3.5 
Pole polymerase , epsilon 5qF 3.4 
Prc1 protein regulator of cytokinesis 1 7qD3 2.8 
Prdx4 peroxiredoxin 4 XqF3 3.2 
Prss19 kallikrein related-peptidase 8 16qB2 -37.5 
Psen2 presenilin 2 6qB3 -3.7 
Rab27a RAB27A, m RAS oncogene family 14qD3 -8.7 
Rab6b RAB6B, m RAS oncogene family XqA4 -4.5 
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Table 5.  Differentially expressed genes between consecutive transformative stages 
170:245 gene definition cytoband fold change 
Rasl11a RAS-like, family 11, m A 5qG3 7.1 
Rbmx RNA binding motif protein, X chromosome 16qA3 3.4 
Reprimo reprimo, TP53 dependent G2 arrest mediator candidate 7qA1 -3.6 
Rgs10 regulator of G-protein signalling 10 9qB 3.5 
Rutbc1 small G protein signaling modulator 2 11 -6.0 
Scin scinderin 16qA1 -10.8 
Sdsl serine dehydratase-like 5qC3.1 -15.2 
Serpinb6b serine  peptidase inhibitor, clade B, m 6b 4qB3 10.8 
Slc19a2 solute carrier family 19 , m 2 1 -5.6 
Slc24a3 solute carrier family 24 , m 3 2qG1 3.3 
Slc25a1 solute carrier family 25 , m 1 11qA3.1 -2.5 
Slc7a3 solute carrier family 7 , m 3 12qC2 -3.6 
Slc7a4 solute carrier family 7 , m 4 19qB -5.2 
Slco1a5 solute carrier organic anion transporter family, m 1a5 6qG2 5.4 
Slco2a1 solute carrier organic anion transporter family, m 2a1 7qF3 -3.5 
Sprr2g small proline-rich protein 2K 2qH1 5.1 
Srpx2 sushi-repeat-containing protein, X-linked 2 7qB4 11.3 
Ssx2ip synovial sarcoma, X breakpoint 2 interacting protein 3qH2 2.7 
Stk6 aurora kinase A 2 3.4 
Stmn1 stathmin 1 4 3.4 
Tagln transgelin 9 -5.2 
Timp3 tissue inhibitor of metalloproteinase 3 10 -3.0 
Tle6 transducin-like enhancer of split 6, homolog of Drosophila E 11qA1 -4.6 
Tmem141 transmembrane protein 141 1qG2 -3.3 
Tmem150 transmembrane protein 150A 7qE3 -3.3 
Tmem205 transmembrane protein 205 9A3 -3.8 
Tmem53 transmembrane protein 53 11qD -3.6 
Tob1 transducer of ErbB-21 12qD2 -5.0 
Trp53inp1 transformation related protein 53 inducible nuclear protein 1 5qG2 -20.1 
Tspyl3 TSPY-like 3 XqA7.1 -6.0 
Tyms thymidylate synthase 5qB1 3.4 
Tyms-ps thymidylate synthase, pseudogene 10qC1 2.6 
Unc13b unc-13 homolog B 7qF1 -7.3 
Vgf VGF nerve growth factor inducible 6qE3 -87.4 
Vkorc1l1 vitamin K epoxide reductase complex, subunit 1-like 1 5qG1.3 3.2 
Vps25 vacuolar protein sorting 25 11qE2 -3.4 
Wig1 zinc finger matrin type 3 3 -4.0 
Wisp2 WNT1 inducible signaling pathway protein 2 15qE1 22.2 
Wnt7a wingless-related MMTV integration site 7A 6 -5.5 
Zfp365 zinc finger protein 365 17qB1 -6.2 
 
 
Table 5.  Differentially expressed genes between consecutive transformative stages 
245:450 gene definition location change 
0610006i08RIK transmembrane protein 223 19qA 3.2 
1200013b22RIK NUAK family, SNF1-like kinase, 2 1qE4 2.9 
2310047c17RIK AHNAK nucleoprotein  19 2.8 
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Table 5.  Differentially expressed genes between consecutive transformative stages 
245:450 gene definition location change 
2310067e08RIK endonuclease domain containing 1 9qA1 2.7 
2610001e17RIK coiled-coil domain containing 80 16 2.8 
2810003c17RIK allograft inflammatory factor 1-like 2qB 2.9 
4930422j18RIK splA/ryanodine receptor domain and SOCS box containing 1 4qE2 3.3 
9130213b05RIK prostate androgen-regulated mucin-like protein 1 5 6.1 
A230050p20RIK RIKEN cDNA A230050P20 gene 9qA3 5.8 
Aa467197 expressed sequence AA467197 2qE5 -26.4 
Adh7 alcohol dehydrogenase 7 , mu or sigma polypeptide 3qG3 -43.7 
Agrn agrin 4 3.4 
Aqp5 aquaporin 5 15qF1 -8.7 
Avpi1 arginine vasopressin-induced 1 19qC3 -4.0 
Bc056929 doublecortin-like kinase 3 9qF3 18.9 
Bok BCL2-related ovarian killer protein 1 5.4 
Bst2 bone marrow stromal cell antigen 2 8qB3.3 3.0 
Btbd3 BTB  domain containing 3 2 3.1 
Calr calreticulin 8qC3 -3.0 
Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 4qD3 2.7 
Cd59a CD59a antigen 2qE2 6.4 
Cdh16 cadherin 16 8 5.9 
Cds1 CHK2 checkpoint homolog  5qE4 5.5 
Cish cytokine inducible SH2-containing protein 9 3.3 
Clca4 chloride channel calcium activated 1 3qH2 6.8 
Col1a1 collagen, type I, alpha 1 11 -162.6 
Col4a1 collagen, type IV, alpha 1 8qA1.1 31.2 
Col4a2 collagen, type IV, alpha 2 8qA1.1 16.3 
Col6a1 collagen, type VI, alpha 1 10 -3.2 
Col6a2 collagen, type VI, alpha 2 10qC1 -8.7 
Crip2 cysteine rich protein 2 12qF1 7.8 
Ctsh cathepsin H 9qE3.1 9.7 
Cxadr coxsackie virus and adenovirus receptor 16qC3.1 3.1 
Cxcl1 chemokine  ligand 1 5qE1 -2.6 
Cyp51 cytochrome P450, family 51 5 -3.5 
Cyp7b1 cytochrome P450, family 7, subfamily b, polypeptide 1 3 -2.7 
D430044g18RIK SH3 domain and tetratricopeptide repeats 2 18 3.0 
Dap islet amyloid polypeptide 15qB2 -3.2 
Dcn decorin 10 2.5 
Ddit4 DNA-damage-inducible transcript 4 10qB4 -3.9 
Dhrs6 3-hydroxybutyrate dehydrogenase, type 2 3qG3 -4.4 
Ednra endothelin receptor type B 14 -2.5 
Enpp5 ectonucleotide pyrophosphatase/phosphodiesterase 5 17qB3 2.8 
Etv4 ets variant gene 4  11 -4.2 
F2rl1 coagulation factor II  receptor-like 1 13qD1 2.9 
Fdps farnesyl diphosphate synthetase 3 -3.0 
Figf c-fos induced growth factor XqF5 -10.4 
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 Table 5.  Differentially expressed genes between consecutive transformative stages  
245:450 gene definition location change 
Fkbp11 FK506 binding protein 11 15 -4.3 
Flrt3 fibronectin leucine rich transmembrane protein 3 2qF3 3.2 
Gadd45g growth arrest and DNA-damage-inducible 45 gamma 13qA5 3.6 
Gdf15 growth differentiation factor 15 8qB3.3 7.7 
Gp38 podoplanin 4 2.8 
Gpx3 glutathione peroxidase 3 11qB1.3 4.0 
Hist1h1c histone cluster 1, H1d 13qA3.1 2.9 
Hspb1 heat shock protein 1 5 2.6 
Igf2bp2 insulin-like growth factor 2 mRNA binding protein 2 16qB1 -9.1 
Igf2bp3 insulin-like growth factor 2 mRNA binding protein 3 6qB2.3 -11.1 
Igfbp2 insulin-like growth factor binding protein 2 1qC3 3.9 
Impact imprinted and ancient 18 2.5 
Kcnk1 potassium channel, subfamily K, member 1 8qE2 22.2 
Klra4 killer cell lectin-like receptor, subfamily A, member 4 6qF3 -2.6 
Lsp1 lymphocyte specific 1 7qF5 -4.0 
Lss lanosterol synthase 10 -2.6 
Ly6a lymphocyte antigen 6 complex, locus A 15qD3 -3.7 
Manea mannosidase, endo-alpha 4qA3 2.7 
Mcc mutated in colorectal cancers 18qB3 3.0 
Mglap matrix Gla protein 6 -379.7 
Mgst2 microsomal glutathione S-transferase 2 3 -23.5 
Mmp2 matrix metallopeptidase 2 8 -9.6 
Mt1 metallothionein 1 8qC5 4.7 
Mvd mevalonate  decarboxylase 8qE1 -4.7 
Nbl1 neuroblastoma, suppression of tumorigenicity 1 4qD3 4.6 
Ndn necdin 7 3.6 
Neu1 neuraminidase 1 17 3.6 
Nipsnap1 4-NPP domain and non-neuronal SNAP25-like protein homolog 1  11 2.6 
Nnmt nicotinamide N-methyltransferase 9qA5.3 3.5 
Npr2 natriuretic peptide receptor 2 4 5.5 
Npr3 natriuretic peptide receptor 3 15qA1 3.9 
Nrn1 neuritin 1 13qA3.3 -5.3 
Nup210 IQ motif and Sec7 domain 1 6qD1 5.0 
Orf63 open reading frame 63 16qC3.3 7.1 
Pcolce procollagen C-endopeptidase enhancer protein 5 -10.0 
Pdgfb platelet derived growth factor, B polypeptide 15 5.4 
Plekhf2 pleckstrin homology domain containing, family F  member 2 4qA1 3.0 
Plk2 polo-like kinase 2  13qD2.2 2.6 
Ppbp pro-platelet basic protein 5qE1 -11.6 
Prkcdbp protein kinase C, delta binding protein 7qE3 -2.7 
Pvrl2 poliovirus receptor-related 2 7qA3 4.5 
Rasl11b RAS-like, family 11, member B 5 17.1 
Rasl12 RAS-like, family 12 9qC 8.7 
Slpi secretory leukocyte peptidase inhibitor 2qH3 -33.1 
Sprr2g small proline-rich protein 2K 3qF1 -4.2 
Sqle squalene epoxidase 15 -4.0 
Stc2 stanniocalcin 2 11 3.0 
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 Table 5.  Differentially expressed genes between consecutive transformative stages  
245:450 gene definition location change 
Tacstd2 tumor-associated calcium signal transducer 2 6 8.0 
Tagln transgelin 9 11.2 
Tgfbi transforming growth factor, beta induced 13qB1 -3.7 
Tinagl 4qD2.2 4.5 
Tnfaip3 tumor necrosis factor, alpha-induced protein 3 10qA3 3.3 
Twist2 twist homolog 2  1 -8.8 
Ugcg UDP-glucose ceramide glucosyltransferase 4qB3 2.6 
Wfs1 Wolfram syndrome 1 homolog  5 3.3 
 
 
450:528 definition location change 
Aqp1  aquaporin 1  6qB3 3.3 
Arc  activity regulated cytoskeletal-associated protein  15qD3 -3.0 
Bc056929  doublecortin-like kinase 3  9qF3 2.9 
C3  complement component 3 17E1.3 7.1 
Cdh16  cadherin 16  8qD3 3.5 
Cdo1  cysteine dioxygenase 1, cytosolic  18qC 12.3 
Clip4 CAP-GLY domain containing linker protein family, m 4 17qE2 4.7 
Col4a1  procollagen, type IV, alpha 1  8qA1.1 3.4 
Col4a2  collagen, type IV, alpha 2  8qA1.1 2.7 
Ctsh  cathepsin H  9qE3.1 5.5 
Dcn  decorin  10qC3 3.0 
Enpp2  ectonucleotide pyrophosphatase/phosphodiesterase 2  15qD1 -5.4 
Fmo1  flavin containing monooxygenase 1  1qH2.1 3.4 
Gap43  growth associated protein 43  16qB4 -7.8 
Gdf15  growth differentiation factor 15  8qB3.3 2.9 
Gpx3  glutathione peroxidase 3 , transcript variant 2 11qB1.3 2.8 
Gsta4  glutathione S-transferase, alpha 4  9qE1 3.6 
Inmt  indolethylamine N-methyltransferase  6qB3 9.9 
Kcnk1  potassium channel, subfamily K, m 1  8qE2 9.6 
Ndn  necdin  7qC -20.2 
Nid2  nidogen 2  14qA3 2.8 
Osmr  oncostatin M receptor  15qA1 2.8 
Prelp  proline arginine-rich end leucine-rich repeat  1qE4 6.1 
Rasl11a  RAS-like, family 11, m A  5qG3 3.4 
Scara5  scavenger receptor class A, m 5   14qD1 3.6 
Sdc3  syndecan 3  4qD2.3 -3.3 
Slc7a11  solute carrier family 7, m 11  3qC 2.7 
Trib3  tribbles homolog 3   2qG3 3.9 
Tspan8  tetraspanin 8 10D2 8.2 
Wisp2  WNT1 inducible signaling pathway protein 2  2qH3 3.8 
 
Table 5.  Gene description, location, and fold change for genes with differential expression of mRNA transcript abundance by pair 
wise SAM analysis Total RNA was extracted from biological triplicates of each stage and analyzed on Illumina MouseRef-8 v2.0 
expression bead chips.  Gene analysis by paired comparisons of consecutive time points was performed on genes with significant 
signal elevation over background p >0.1, exceeding 3x background ( >420, 11,817 genes), and yielded 317 genes with differential 
expression where p<0.05 and fold change >2.5.  Cytoband information and gene name obtained from Illumina Mouse Ref-8 v2.0 
annotation file or secondarily from Mouse Genome Informatics (MGI, http://www.informatics.jax.org/).  
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Table 6.  Functional enrichment analysis for genes discovered by paired comparisons 
 
170:245  A  B  C  D  E  F 
Category  BP_ALL  SPPIR  SPPIR  BP_ALL  SPPIR  BP_ALL 
GO:Number  278.000  22402  22403 
Term  mitotic cell cycle  cytoplasm  mitosis 
cell cycle 
process  cell division  cell cycle phase 
Count  16  43  10  21  12  15 
%  0.09  0.25  0.06  0.12  0.07  0.09 
PValue  5.40E‐09  3.10E‐07  1.14E‐06  1.36E‐07  9.82E‐07  3.20E‐07 
List Total  128  143  143  128  143  128 
Pop Hits  260  2169  121  596  192  306 
Pop Total  14977  16241  16241  14977  16241  14977 
Fold Enrichment  7.2  2.3  9.4  4.1  7.1  5.7 
Benjamini  2.80E‐05  2.69E‐04  3.30E‐04  3.53E‐04  4.25E‐04  5.54E‐04 
FDR  1.03E‐05  4.82E‐04  1.77E‐03  2.59E‐04  1.52E‐03  6.11E‐04 
Genes  Ndc80  Dusp6  Kntc1  Ak1  Kntc1  Ndc80 
 Ccng1   Sprr2g   Birc5   Ndc80   Birc5   Bub1b 
 Bub1b   Pkn2   Ccnb1   Ccng1   Prc1   Ccng1 
 Cdca8   Kif2c   Ndc80   Bub1b   Ccnb1   Cdca8 
 Ncapd2   Ak1   Ccng1   Trp53inp1   Ndc80   Ncapd2 
 Cdca3   Prc1   Bub1b   Cdca8   Ccng1   Cdca3 
 Stmn1   Myo7a   Cdca8   Ncapd2   Bub1b   Kntc1 
 Kntc1   Bub1b   Ncapd2   Cdca3   Cdca8   Gspt2 
 Gspt2   Trp53inp1   Cdca3   Stmn1   Ncapd2   Birc5 
 Birc5   Ndn   Cdc20   Cxcl1   Ccnd1   Plk1 
 Plk1   Cdca8      Kntc1   Cdca3   Ccnb1 
 Ccnb1   Ncapd2   Gspt2   Cdc20   Htatip2 
 Htatip2   Tagln   Birc5      Dbf4 
 Dbf4   Cdca3   Plk1   Mdm2 
 Mdm2   Kntc1   Ccnb1   Cdc20 
 Cdc20   Birc5   Dbf4    
    Gsta4   Htatip2 
 Ckb   Cdkn1a 
 Cask   Ccnd1 
 Htatip2   Mdm2 
 Pbxip1   Cdc20 
 Fez1    
1810009n02RIK 
 5830467p10RIK 
 Aldh1a1 
 Pde4dip 
 Lrrfip1 
 Stmn1 
 Prdx4 
 Ddit4 
 Vps25 
 Igf2bp2 
 Ccnb1 
 Ccbl1 
 Mapkapk3 
 Aplp1 
 Cdkn1a 
 Unc13b 
 Scin 
 Mdm2 
 Eno3 
 Bzrap1 
 Pi4k2b 
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Table 6.  Functional enrichment analysis for genes discovered by paired comparisons 
170:245  G  H  I  J  K  L  M  N 
Category  BP_ALL  BP_ALL  BP_ALL  BP_ALL  BP_ALL  BP_ALL  BP_ALL  BP_ALL 
GO:Number  87  32502  7067  7049  48856  74  51726  30154 
Term 
M phase of mitotic 
cell cycle 
develop‐
mental 
process 
mitosis  cell cycle 
anatomical 
structure 
development 
regulation of 
progression 
cell cycle 
regulation of 
cell cycle 
cell differen‐
tiation 
Count  12  51  12  22  39  15  15  36 
%  0.07  0.29  0.07  0.13  0.22  0.09  0.09  0.21 
PValue  7.42E‐07  5.23E‐07  7.04E‐07  1.02E‐06  1.64E‐06  3.15E‐06  3.46E‐06  2.73E‐06 
List Total  128  128  128  128  128  128  128  128 
Pop Hits  193  3028  192  740  2058  371  374  1847 
Pop Total  14977  14977  14977  14977  14977  14977  14977  14977 
Fold Enrichment  7.3  2.0  7.3  3.5  2.2  4.7  4.7  2.3 
Benjamini  6.42E‐04  6.79E‐04  7.31E‐04  7.53E‐04  1.06E‐03  1.48E‐03  1.49E‐03  1.58E‐03 
FDR  1.42E‐03  1.00E‐03  1.35E‐03  1.94E‐03  3.13E‐03  6.02E‐03  6.60E‐03  5.22E‐03 
Genes  KNTC1  HOXB7  KNTC1  AK1  HOXB7  AK1  AK1  SPRR2G 
Birc5  Ndn  Birc5  Prc1  Sprr2g  Bub1b  Bub1b  Fst 
Plk1  Nppb  Plk1  Ndc80  Fst  Ccng1  Ccng1  Myo7a 
Ccnb1  Foxm1  Ccnb1  Ccng1  Myo7a  Trp53inp1  Trp53inp1  Bub1b 
Ndc80  Tagln  Ndc80  Bub1b  Foxd1  Cxcl1  Cxcl1  Trp53inp1 
Ccng1  Hes6  Ccng1  Trp53inp1  Nppb  Kntc1  Kntc1  Foxd1 
Bub1b  Dab2  Bub1b  Cdca8  Ndn  Gspt2  Gspt2  Ndn 
Htatip2  Dyrk3  Htatip2  Ncapd2  Tagln  Birc5  Birc5  Foxm1 
Cdca8  Birc5  Cdca8  Cdca3  Foxm1  Plk1  Plk1  Dab2 
Ncapd2  H2afz  Ncapd2  Stmn1  Igfbp2  Ccnb1  Ccnb1  Hes6 
Cdca3  Crip2  Cdca3  Cxcl1  Otx1  Htatip2  Htatip2  Birc5 
Cdc20  Htatip2  Cdc20  Kntc1  Dab2  Dbf4  Dbf4  Dyrk3 
Grem1  Gspt2  Hes6  Cdkn1a  Cdkn1a  Phf17 
Nid1  Birc5  Dyrk3  Ccnd1  Ccnd1  Etv4 
Irs2  Plk1  Crip2  Mdm2  Mdm2  Htatip2 
Stmn1  Ccnb1  Etv4  Itga3 
Psen2  Dbf4  Htatip2  Ccnd1 
Aplp1  Htatip2  Itga3  Il11 
Scin  Cdkn1a  Grem1  Wnt7a 
Tob1  Ccnd1  Il11  Igf1 
Clu  Mdm2  Wnt7a  Col18a1 
Sprr2g  Cdc20  Wisp2  Aldh1a1 
Fst  Igf1  Rab27a 
Bub1b  Col18a1  Stmn1 
Myo7a  Aldh1a1  Bmp3 
Trp53inp1  Nid1  Psen2 
Foxd1  Irs2  Ednra 
Igfbp2  Stmn1  Ddit4 
Otx1  Bmp3  Mgmt 
Phf17  Psen2  Atp6v0a1 
Etv4  Ednra  Arhgap24 
Itga3  Atp6v0a1  Cdkn1a 
Ccnd1  Arhgap24  Aplp1 
Il11  Aplp1  Scin 
Wnt7a  Scin  Tob1 
Wisp2  Palmd  Clu 
Igf1  Tob1  Scin 
Col18a1  Vgf  Tob1 
Aldh1a1  Nppa  Vgf 
Rab27a  Nppa 
Bmp3 
Ednra 
Ddit4 
Mgmt 
Atp6v0a1 
Cdkn1a 
Arhgap24 
Ercc5 
Palmd 
Vgf 
Nppa 
 
  
65 
 
Table 6.  Functional Annotation for Significant Pairwise Gene Analysis 
170:245  O  P  Q  R  S  T  U 
Category  BP_ALL  BP_ALL  BP_ALL  SPPIR  BP_ALL  BP_ALL  BP_ALL 
GO:Number  48869  51301  279  48731  7275  48513 
Term 
cellular 
developmental 
process  cell division  M phase  cell cycle 
system 
development 
multicellular 
organismal 
development 
organ 
development 
Count  36  12  12  14  33  39  29 
%  0.21  0.07  0.07  0.08  0.19  0.22  0.17 
PValue  2.73E‐06  7.81E‐06  1.14E‐05  1.98E‐05  1.73E‐05  1.71E‐05  1.64E‐05 
List Total  128  128  128  143  128  128  128 
Pop Hits  1847  246  256  366  1749  2270  1416 
Pop Total  14977  14977  14977  16241  14977  14977  14977 
Fold Enrichment  2.3  5.7  5.5  4.3  2.2  2.0  2.4 
Benjamini  1.58E‐03  3.11E‐03  4.21E‐03  4.28E‐03  5.27E‐03  5.54E‐03  5.68E‐03 
FDR  5.22E‐03  1.49E‐02  2.17E‐02  3.07E‐02  3.31E‐02  3.27E‐02  3.14E‐02 
Genes  Sprr2g  Kntc1  Kntc1  Prc1  Hoxb7  Hoxb7  Hoxb7 
 Fst   Birc5   Birc5   Ndc80   Sprr2g   Sprr2g   Sprr2g 
 Myo7a   Prc1   Plk1   Bub1b   Fst   Fst   Fst 
 Bub1b   Ccnb1   Ccnb1   Ccng1   Myo7a   Myo7a   Myo7a 
 Trp53inp1   Ndc80   Ndc80   Cdca8   Ndn   Foxd1   Foxd1 
 Foxd1   Ccng1   Ccng1   Ncapd2   Foxd1   Nppb   Foxm1 
 Ndn   Bub1b   Bub1b   Cdca3   Foxm1   Ndn   Tagln 
 Foxm1   Cdca8   Htatip2   Kntc1   Tagln   Tagln   Otx1 
 Dab2   Ncapd2   Cdca8   Birc5   Hes6   Foxm1   Dyrk3 
 Hes6   Ccnd1   Ncapd2   Ccnb1   Otx1   Otx1   Crip2 
 Birc5   Cdca3   Cdca3   Htatip2   Dyrk3   Dab2   Htatip2 
 Dyrk3   Cdc20   Cdc20   Cdkn1a   Crip2   Hes6   Etv4 
 Phf17         Ccnd1   Etv4   Birc5   Grem1 
 Etv4   Cdc20   Htatip2   Dyrk3   Il11 
 Htatip2      Itga3   H2afz   Wnt7a 
 Itga3   Grem1   Crip2   Igf1 
 Ccnd1   Il11   Etv4   Col18a1 
 Il11   Wnt7a   Htatip2   Aldh1a1 
 Wnt7a   Igf1   Itga3   Nid1 
 Igf1   Col18a1   Grem1   Irs2 
 Col18a1   Aldh1a1   Il11   Bmp3 
 Aldh1a1   Nid1   Wnt7a   Psen2 
 Rab27a   Irs2   Igf1   Ednra 
 Stmn1   Stmn1   Col18a1   Atp6v0a1 
 Bmp3   Bmp3   Aldh1a1   Arhgap24 
 Psen2   Psen2   Nid1   Aplp1 
 Ednra   Ednra   Irs2   Scin 
 Ddit4   Atp6v0a1   Stmn1   Tob1 
 Mgmt   Arhgap24   Bmp3   Vgf 
 Atp6v0a1   Aplp1   Psen2    
 Arhgap24   Scin   Ednra 
 Cdkn1a   Tob1   Atp6v0a1 
 Aplp1   Vgf   Arhgap24 
 Scin      Aplp1 
 Tob1   Ercc5 
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Table 6.  Functional Annotation for Significant Pairwise Gene Analysis 
245:450 A B C D E F 
Category CC_ALL CC_ALL CC_ALL SPPIR SPPIR SPPIR 
Number 5615 44421 5576 - - - 
Term extracellular space 
extracellular region 
part extracellular region signal Secreted triple helix 
Count 35 35 36 36 21 4 
PValue 6.79E-12 3.84E-11 6.82E-11 2.24E-09 9.83E-07 9.46E-06 
List Total 76 76 76 81 81 81 
Pop Hits 2064 2195 2375 2551 1200 9 
Pop Total 15845 15845 15845 16241 16241 16241 
Fold Enrichment 3.5 3.3 3.2 2.8 3.5 89.1 
Benjamini 5.32E-09 1.50E-08 1.78E-08 1.94E-06 4.26E-04 1.64E-03 
FDR 1.04E-08 5.88E-08 1.04E-07 3.47E-06 1.52E-03 1.47E-02 
Genes Cd59a Cd59a Cd59a Cd59a Enpp5 Col4a1 
 Tacstd2  Tacstd2  Tacstd2  Tinagl  Tinagl  Col1a1 
 Nbl1  Nbl1  Nbl1  Nbl1  Nbl1  Col6a1 
 Col4a2  Col4a2  Col4a2  Col4a2  Col6a1  Col4a2 
 Figf  Figf  Figf  F2rl1  Col4a2 
 Col6a2  Col6a2  Col6a2  Figf  Figf 
 Igfbp2  Igfbp2  Igfbp2  Col6a2  Col6a2 
 Npr3  Npr3  Npr3  Nup210  Cxadr 
 Cxcl1  Cxcl1  Cxcl1  Cxadr  Igfbp2 
 Gdf15  Gdf15  Gdf15  Igfbp2  Cxcl1 
 Pcolce  Pcolce  Pcolce  Npr3  Slpi 
 Dcn  Dcn  Dcn  Cxcl1  Stc2 
 Cyp7b1  Cyp7b1  Cyp7b1  Gdf15  Gdf15 
 Aqp5  Aqp5  Aqp5  Pcolce  Dcn 
 Col1a1  Col1a1  Col1a1  Dcn  Pcolce 
 Calr  Calr  Calr  Col1a1  Gpx3 
 Tgfbi  Tgfbi  Ppbp  Calr  Col4a1 
 Pdgfb  Pdgfb  Tgfbi  Tgfbi  Col1a1 
 Enpp5  Enpp5  Pdgfb  Npr2  Tgfbi 
 Pvrl2  Pvrl2  Enpp5  Pdgfb  Pdgfb 
 Manea  Manea  Pvrl2  Enpp5  Mmp2 
 Col6a1  Col6a1  Manea  Pvrl2   
 Fkbp11  Fkbp11  Col6a1  Col6a1 
 Clca4  Clca4  Fkbp11  Fkbp11 
 Slpi  Slpi  Clca4  Slpi 
 Stc2  Stc2  Slpi  Stc2 
 Ugcg  Ugcg  Stc2  Ednra 
 Sqle  Sqle  Ugcg  Nrn1 
 Gpx3  Gpx3  Sqle  Cdh16 
 Col4a1  Col4a1  Gpx3  Gpx3 
 Agrn  Agrn  Col4a1  Col4a1 
 Cyp51  Cyp51  Agrn  Ly6a 
 Ctsh  Ctsh  Cyp51  Ctsh 
 Mmp2  Mmp2  Ctsh  Mmp2 
 9130213b05RIK  9130213b05RIK  Mmp2  Neu1 
     9130213b05RIK  9130213b05RIK 
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Table 6.  Functional Annotation for Significant Pairwise Gene Analysis 
245:450 G H I J K L M N 
SPPIR SPPIR SPPIR SPPIR CC_ALL SPPIR CC_ALL CC_ALL CC_ALL 
- - - - 5581 - 5578 31012 44420 
cell 
binding hydroxyproline glycoprotein 
extracellular 
matrix collagen collagen 
proteinaceous 
extracellular 
matrix 
extracellular 
matrix 
extracellular 
matrix part 
4 4 32 8 5 6 9 9 6 
9.46E-06 6.33E-06 1.84E-05 4.15E-05 3.03E-05 6.51E-05 7.51E-05 9.05E-05 1.21E-04 
81 81 81 81 76 81 76 76 76 
9 8 3012 190 38 86 295 303 102 
16241 16241 16241 16241 15845 16241 15845 15845 15845 
89.1 100.3 2.1 8.4 27.4 14.0 6.4 6.2 12.3 
1.64E-03 1.83E-03 2.65E-03 5.13E-03 5.91E-03 7.04E-03 1.17E-02 1.18E-02 1.35E-02 
1.47E-02 9.82E-03 2.85E-02 6.43E-02 4.63E-02 1.01E-01 1.15E-01 1.38E-01 1.85E-01 
Col4a1 Col4a1 Cd59a Dcn Col4a1 Pcolce Dcn Dcn Col4a1 
 Col6a1  col6a1  tinagl  col4a1  col1a1  col4a1  col4a1  col4a1  col1a1 
 Col4a2  col4a2  col4a2  col1a1  col6a1  col1a1  col1a1  col1a1  col6a1 
 Col6a2  col6a2  f2rl1  col6a1  col4a2  col6a1  col6a1  col6a1  agrn 
   Figf  Col4a2  Col6a2  Col4a2  Agrn  Agrn  Col4a2 
 Col6a2  Col6a2  Col6a2  Col4a2  Col4a2  Col6a2 
 Nup210  Tgfbi  Col6a2  Col6a2   
 Cxadr  Mmp2  Tgfbi  Tgfbi 
 Npr3  Mmp2  Mmp2 
 Gdf15 
 Pcolce 
 Dcn 
 Aqp5 
 Col1a1 
 Bst2 
 Npr2 
 Pdgfb 
 Enpp5 
 Pvrl2 
 Col6a1 
 Stc2 
 Kcnk1 
 Ednra 
 Nrn1 
 Cdh16 
 Col4a1 
 Ly6a 
 Ctsh 
 Mmp2 
 Neu1 
 Klra4 
 9130213b05RIK 
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Table 6.  Functional Annotation for Significant Pairwise Gene Analysis 
245:450 O P Q R S T U 
SPPIR SPPIR SPPIR MF_ALL SPPIR BP_ALL BP_ALL BP_ALL 
- - - 5201 - 6694 7275 48513 
heterotrim
er 
structural 
protein hydroxylation 
extracellular 
matrix structural 
constituent 
cell adhesion 
steroid 
biosynthetic 
process 
multicellular 
organismal 
development 
organ 
development 
4 6 5 5 7 71 39 29 
1.66E-04 1.92E-04 1.65E-04 2.29E-04 7.08E-03 7.30E+01 1.71E-05 1.64E-05 
81 81 81 79 81 14977 128 128 
22 108 56 63 345 14.44819603 2270 1416 
16241 16241 16241 16377 16241 1 14977 14977 
36.5 11.1 17.9 16.5 4.1 0.5 2.0 2.4 
1.43E-02 1.50E-02 1.58E-02 2.67E-01 4.01E-01 CYP7B1 5.54E-03 5.68E-03 
2.57E-01 2.97E-01 2.56E-01 4.07E-01 1.04E+01  CYP51 3.27E-02 3.14E-02 
Col1a1 Sprr2g Col4a1 Col4a1 Cdh16  mvd Hoxb7 Hoxb7 
 Col6a1  col4a1  col1a1  col1a1  pvrl2  fdps  sprr2g  sprr2g 
 Col4a2  col1a1  col6a1  col6a1  col6a1  lss  fst  fst 
 Col6a2  col6a1  col4a2  col4a2  col6a2  ndn  myo7a  myo7a 
   Col4a2  Col6a2  Col6a2  Tgfbi  Foxd1  Foxd1  Foxd1 
 Col6a2  Cxadr  Foxm1  Nppb  Foxm1 
 Klra4  Tagln  Ndn  Tagln 
 Hes6  Tagln  Otx1 
 Otx1  Foxm1  Dyrk3 
 Dyrk3  Otx1  Crip2 
 Crip2  Dab2  Htatip2 
 Etv4  Hes6  Etv4 
 Htatip2  Birc5  Grem1 
 Itga3  Dyrk3  Il11 
 Grem1  H2afz  Wnt7a 
 Il11  Crip2  Igf1 
 Wnt7a  Etv4  Col18a1 
 Igf1  Htatip2  Aldh1a1 
 Col18a1  Itga3  Nid1 
 Aldh1a1  Grem1  Irs2 
 Nid1  Il11  Bmp3 
 Irs2  Wnt7a  Psen2 
 Stmn1  Igf1  Ednra 
 Bmp3  Col18a1  Atp6v0a1 
 Psen2  Aldh1a1  Arhgap24 
 Ednra  Nid1  Aplp1 
 Atp6v0a1  Irs2  Scin 
 Arhgap24  Stmn1  Tob1 
 Aplp1  Bmp3  Vgf 
 Scin  Psen2   
 Tob1  Ednra 
 Vgf  Atp6v0a1 
 Arhgap24 
   Aplp1 
 Ercc5 
 Scin 
 Vgf 
 Nppa 
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Table 6.  Functional annotation for significant pair-wise gene analysis 
450:528 A B C D E F G 
Category SPPIR SPPIR SPPIR CC_ALL CC_ALL CC_ALL SPPIR 
GO:Number - - - 44421 5615 5576 - 
Term glycoprotein Secreted signal 
extracellular 
region part 
extracellular 
space 
extracellular 
region 
extracellul
ar matrix 
Count 16 10 14 13 13 13 5 
% 0.59 0.37 0.52 0.48 0.48 0.48 0.19 
p-value 9.89E-06 6.29E-05 4.72E-05 7.07E-05 3.80E-05 1.54E-04 2.22E-04 
List Total 27 27 27 27 27 27 27 
Pop Hits 3012 1200 2551 2195 2064 2375 190 
Pop Total 16241 16241 16241 15845 15845 15845 16241 
Fold Enrichment 3.2 5.0 3.3 3.5 3.7 3.2 15.8 
Benjamini 8.53E-03 1.80E-02 2.03E-02 2.73E-02 2.94E-02 3.96E-02 4.69E-02 
FDR 1.53E-02 9.75E-02 7.32E-02 1.08E-01 5.82E-02 2.36E-01 3.43E-01 
Genes Wisp2 Wisp2 Wisp2 Wisp2 Wisp2 Wisp2 Dcn 
 Sdc3  Gdf15  Sdc3  Enpp2  Enpp2  Enpp2  Col4a1 
 Enpp2  Dcn  Enpp2  Col4a2  Col4a2  Col4a2  Prelp 
 Col4a2  Gpx3  Col4a2  C3  C3  C3  Col4a2 
 C3  Col4a1  C3  Osmr  Osmr  Osmr  Nid2 
 Osmr  Prelp  Osmr  Gdf15  Gdf15  Gdf15   
 Kcnk1  Enpp2  Gdf15  Dcn  Dcn  Dcn 
 Scara5  Col4a2  Dcn  Gpx3  Gpx3  Gpx3 
 Gdf15  C3  Cdh16  Col4a1  Col4a1  Col4a1 
 Dcn  Nid2  Gpx3  Prelp  Prelp  Prelp 
 Cdh16    Col4a1  Nid2  Nid2  Nid2 
 Col4a1  Prelp  Ctsh  Ctsh  Ctsh 
 Prelp  Nid2  Aqp1  Aqp1  Aqp1 
 Nid2  Ctsh       
 Ctsh   
 Aqp1 
 
 
Table 6.  Functional enrichment analyses and biological significance of differentially expressed genes 
from paired comparisons of consecutive time points in spontaneous transformation.  Differentially 
expressed genes were determined using paired comparisons analysis at a significance level p <0.05.  All 
available categories offered through NIH DAVID were tested for significance based on the observed 
versus expected number of genes in each category.  Uniprot keywords (SP_PIR), Kyoto Encyclopedia of 
Genes and Genomes pathways (KEGG), Gene Ontologies biological processes (BP), molecular function 
(MF) and cellular componentry (CC) were determined at a depth of three annotation levels and requiring 
a minimum of five genes per annotation where p <0.05 after correction for multiple hypothesis testing by 
randomization. 
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3.7.2   Identifying putative oncogenes or tumor suppressor genes 
 As oncogene up regulation or tumor suppressor down regulation has been suggested as 
drivers for tumorigenesis, we cross referenced the early, mid, and late lists of genes to 
determine which are differentially expressed across at least three of the four key transformative 
stages.  Area proportional Venn diagrams show the intersection of these gene lists, and their 
relation to the findings from the longitudinal time course analysis (Figure 10A).  Considering the 
possible 18,000 genes referenced on the array, relatively few genes belonged to each category.  
Sixteen genes were found in the intersection of early: middle (170:245:450=16), and two were 
found in the intersection of intermediate: late (245:450:528=2).  A single gene, Necdin (NDN), 
was the only gene shared in the intersection of all three sets (170:245:450:528=1).  STEM 
analysis places NDN, a gene expressed in terminally differentiated neurons in cluster 6.  NDN 
fits a profile of continuous down regulation (1, -1.92, -3.56, -6.32).  Together, the intersection of 
the combined significant gene lists from the SAM pair wise analysis included 135 SAM genes U 
599 STEM genes (Figure 10A).  The first in the series of numbers reflects the fold change from 
the upper term in the column header, the second number for the lower term (Figure 10).  
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3.8  Whole chromosome copy number change versus total mRNA transcript abundance by 
chromosome.    
By design, this study afforded the unique opportunity to compare the relationship 
between changes in chromosome copy number, and changed gene expression level for that 
chromosome.  Additionally, we evaluated if this relationship was different in early transformation 
compared to late stages.  Some chromosomes underwent large changes in copy number while 
others remained relatively static (chromosomes 12, 1), we sought to define the relationship (if 
any) between chromosome copy numbers and average mRNA transcript from that 
chromosome.  The relationship between chromosome gains and transcriptome gains and how 
these values change from one stage to the next (Figure 11 A-D).  When expressed as fold 
change from one transitional stage to the next, correlation and significance decreased with time 
across key transformative stages.  The correlation from day 170 cells to day 245 cells was the 
highest, but still only accounted for one-third of the variability between whole chromosome and 
transcriptome (170:245 R2=0.12, correlation=0.35, b=0.27).  Comparing fold change for days 
245:450 and 450:529, the correlation became progressively lower (day 245:450, R2=0.06, 
correlation=0.24, slope=0.23; day 450:528 R2=0.02, correlation=0.14, and slope=0.08).  These 
findings suggest that the shift away from high-fidelity genome transfer and system homogeneity 
is related to the reduced correlation between chromosome: transcriptome. 
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3.9 Tumorigenicity of select key transformative stages in vivo 
  Cells from two key transitional stages (day 245 versus 450) were selected based on 
karyotype and in vitro phenotypic differences for in vivo tumorigenicity evaluation in both 
syngeneic C57BL6 and nod-SCID-gamma immune compromised mice (Table 1, 7).  Data for 
the 16 syngeneic mice and 4 nod-SCID-gamma mice are found in Table 7.  Each C57BL6 
mouse was injected in 3 sites.  As intraperitoneal tumor formation was usually apparent only at 
the latest stages, injections on the left and right back served as sentinel markers to detect tumor 
progression.   Day 245 cells were very weakly tumorigenic, resulting in a single 1.5 mm  low 
grade subcutaneous nodule at day 70 in 1/7 C57BL6 mice (Table 7, Figure 12A).  Day 528 cells 
were significantly more efficient at tumor formation and formed subcutaneous tumors in all (7/7) 
C57BL6 mice, totaling 10/14 positive subcutaneous sites.  These tumors were of higher grade, 
larger size, and were more invasive than the single tumor found to arise from day 245 cells 
(Table 7, Figure 12B).  Day 528 cells in syngeneic BL6 mice resulted in one of two phenotypes.  
Either multiple diffusively invasive sites were established on the peritoneal fat with atypical 
nuclei (arrows, C), or immunoreactive B-cell clusters were found approximating the 
intraperitoneal fat (not shown).  Isolated intraperitoneal injections in nod-SCID-gamma mice 
gave rise to diffuse nodular intraperitoneal tumors in 2/2 mice.  ID8 cells served as positive 
controls in both types of mice and revealed a similar phenotype to day 528 cells in nearly all 
measures, with exception of slightly increased subcutaneous tumor size in ID8 cells (Table 7, 
image not shown).  Negative control mice injected with matrigel vehicle occasionally showed a 
~1mm acellular collagen deposit at the site of the subcutaneous injection resembling scar tissue 
(image not shown).  
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3.10 Characterizing the extent of karyotype heterogeneity in late stage, Brca1Δ5–13 and 
harvested tumor cells. 
MOSEC with Brca1Δ5–13 had very high H' and H values despite only 50 days in primary 
culture and 25 days in culture post AdCre recombination.  When comparing the karyotype 
profile of the injected day 528 cells to each of the harvested tumors, many features of the 
karyotype were altered between the in vitro and in vivo karyotype profiles (Figure 13).  The 
Shannon index increases significantly in both Tumor 1 and Tumor 2 over the level of the 
injected cells.  The 4;3 clonal translocation seen in the day 528 cells is present in both tumors at 
approximately the same frequency (day 528: 32%, Tumor 1: 32%, Tumor 2: 42%).  Tumors 1 
and 2 additionally had a very high frequency of translocations that were not seen previously in 
this cell line at 4;5 ~95% of tumor cells, and 5;4 in ~90% of tumor cells.  Additionally, several 
shared minute chromosomes were seen in these tumor cell lines that contributed to their 
increased variability.  NCCA frequency was much greater (essentially 100% of cells contained 
more than one non-clonal aberration).  Chromosome rearrangements were significantly more 
complex in tumor 2, involving several chromosomes in most single aberrations.  Tumor 2 had an 
increased whole chromosome karyotype heterogeneity by Shannon Index H' compared to tumor 
1, (Figure 13, Table 2). 
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3.11 DNA copy number analyses for variability, large aberrations, and whole chromosome 
counts using array competitive genomic hybridization.   
  To determine the reliability of SKY karyotype analyses, whole genome DNA was 
extracted from frozen cell stocks grown for 48-72 hours in culture.  Cells at transformative 
stages 245, 450, 528 were harvested as entire cell populations (control, left (Figure 14 A-C)), or 
mitotic enriched following 12 hour colcemid treatment  0.1 μg/ μl and mitotic shake off (mitotic, 
Figure 14, right (A-C)).  Using PopLowess normalization procedures, data were clustered by k-
means and normalized based on the largest single copy number population that could be 
tracked.  This is more appropriate for cancer genomes where chromosome copy number is 
known to vary from one chromosome to the next.  Data were centered by the median of the 
largest cluster to account for count variability among chromosomes and to allow for universal 
zeroing.  These regions were checked against SKY data for chromosome aberrations and 
values within one standard deviation of the median for each cluster (colored points) and those 
that were outside one standard deviation (black points).  Colored plots were used to compare 
counts between control and mitotic enriched fractions (>0.9).  The number of probes on each 
chromosome with copy number >1 SD ouside the cluster median increased with days in culture 
for both control and mitotic fractions p=0.032 as was less in mitotic fractions compared to 
controls. This is thought to relate to synchronization of ploidy of these cells as colcemid has 
been shown to induce DNA synthesis as well as metaphase arrest.  As the SKY data was 
gathered using the same colcemid treatment, comparisons were made between the cytogenetic 
data and the mitotic aCGH populations.  Derivative features that were clonal in spectral 
karyotype data (CCAs) and also found in the colcemid treated mitotic fraction where a second 
cluster spans more than 20% of a single chromosome (aCGH (CCA)).  The aCGH plots 
normalized by PopLowess show copy number expansion on within a chromosome where more 
than one color is assigned within a single chromosome.  Overlap between Poplowess and SKY 
data show agreement in copy number change for t 4;3 and for 11min (Figure 14D). f 
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Table 7.  In vivo tumorigenicity analyses of mouse ovarian surface epithelial cells  
Cell Type (days) 245 528 ID8 
Subcutaneous Tumors
C57BL6 Positive Mice * 1/ 7 7/ 7 2/ 2 
C57BL6 Positive Sites 1/ 14 10/ 14 2/ 4 
Tumor Size (mm) 1.5 11.1 (10.2-11.9) 9.7 (7, 13) 
Invasiveness 2/ 5 4.3 (3.7-4.9)/ 5 4.0 (3, 5)/ 5 
  
IP Tumors
C57BL6 Positive Mice 0/ 7  2/ 7  1/2  
Organ involvement - 3.5 2 
nod-SCID-gamma  IP Tumors 0/ 2 2/ 2 1/ 1 
Organ involvement - 4/ 10 4/ 10 
  
Total IP Positive Mice 0/9 4/9 * 2/ 3 
Average organ Involvement - 3.8 (3.3 - 4.3)/ 10 3/ 10 
Day 245 vs. day 528 vs. ID8 cells (100,000/ site) were injected into sixteen syngeneic C57BL6 mice and 
five nod-SCID-gamma mice at three sites (left and right subcutaneous flank and intraperitoneal).   
Summary data for are presented from gross and microscopic histopthology  analyses of tumors 
harvested 70 days post allograft injection of day 245, day 528, ID8, or vehicle alone. 
Invasiveness was scored by assigning 1 point for each of the following reported as mean (range):  
Subcutaneous scoring: dermis, subcutaneous fat, muscle, diffuse, necrotic (max= 5 each side).   
Intraperitoneal scoring: pancreas, liver, peritoneal fat, reproductive organs, lymph node, spleen, small 
intestine, large intestine, diaphragm, hemorrhagic ascites (max=10). 
*Significant between day 245 and day 528 cells by two-tailed Fisher’s exact test p <0.05 
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4. DISCUSSION 
4.1. Overview 
 The results of the current study emphasize the significance of karyotype heterogeneity in 
transformation and tumorigenesis.  Specifically, the influence of karyotype heterogeneity on 
generating genomic diversity that facilitates selection of cancer phenotypes and the differential 
effects of whole chromosome copy number change on gene expression during the key 
transformative stages of spontaneous tumorigenesis. Considering cancer cell populations to be 
complex-adaptive systems that are characterized integrative regulatory systems and by linear 
and non-linear genotype-phenotype relationships.  Therefore, multi-level analyses were 
performed longitudinally on data from whole genome microarrays, population karyotype profiles, 
and cell phenotype.  Variability of a sufficient magnitude to shift cell populations from 
homogeneous diploid cells to a mosaic of structural and numerical chromosome alterations 
reflects low-fidelity genome transfer that began well before the morphologic and behavioral 
change to the transformed phenotype.  Karyotype heterogeneity was quantified by an 
adaptation of the Shannon Index, and reached a maximum at day 528.  After only 50 days in 
culture, the parallel MOSEC line with conditional Brca1 inactivation had significantly greater 
population diversity than the spontaneously transforming MOSEC at day 528.  This 
demonstrates how cancer-associated genes can link micro-evolutionary gene-level change to 
macro-evolutionary change in karyotype that rapidly facilitates the generation of unique 
genomes within a cell population.  Day 528 cells with heterogeneous karyotypes were 
tumorigenic and rapidly shifted from the karyotype of the injected line to population karyotypes 
of increased variability in response to the shift from in vitro to in vivo environments.  Multiple 
unique fold change profiles characterized the differential expression of ~600 differentially 
expressed genes throughout spontaneous transformation.  Functional enrichment for these 
genes was significant for DNA/ nucleosome / chromosome related, and cholesterol synthesis/ 
microsome related categories.  The multi-level longitudinal data presented support genomic 
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instability as a means for increasing population diversity by increasing  cell-to-cell variations in 
karyotype.  Thus, genomic instability would also be permissive for rapid adaptation of 
populaitons of late stage transformed cells.  Together, these findings support a genome-
centered evolutionary framework for cancer progression that emphasizes cell-to-cell genomic 
variability as the basis for macro-evolutionary selection and rapid phenotypic switching by whole 
chromosome copy number change.  These data demonstrate the significance, methodologies 
and rationale for quantifying karyotype heterogeneity in transformation and tumorigenesis. A 
foundation is provided for incorporating these concepts and techniques into clinical and 
research based applications for improved cancer detection and treatment strategies. 
4.2. Adapting the Mouse ovarian surface epithelial cell model 
 Similar to previous studies using the mouse ovarian surface epithelial cell (MOSEC) model, 
we have identified four key transformative stages based on the appearance and disappearance 
of key phenotypic and behavioral characteristics during spontaneous transformation [54-55, 63].  
Several groups have utilized the MOSEC model with attention to a specific hypothesis or with 
emphasis on a certain feature of the transformation process.  These include but are not limited 
to studies of specific processes (cytoskeletal remodeling [55]), selected gene modifiers of 
transformation and tumorigenicity (Brca1, p53, and Rb [48]), and pathway modification by 
specific compounds (alpha-lipoic acid and NF-KB pathway) [100].  Others have taken a 
genome-wide approach including array based studies that compare genome-wide aCGH 
analysis of DNA copy number with microarray data for gene expression to compare an early 
stage MOSEC line and with harvested MOSEC tumor lines [57, 61].  Rather than focus on a 
specific pathway or stage, the current study provides a global assessment of genome content 
and gene regulation in relation to cell phenotype throughout the transformation process.  The 
levels studied range from cell behavior to measurements of karyotype heterogeneity for cell 
populations at key transformative stages and include cell phenotype assays, mRNA transcript 
abundance, DNA copy number change, the characterization of structural and numerical 
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chromosome change, and the in assessment of tumorigenic capabilities and tumor 
histopathology.  The design allows for the comparison of a single variable over time as well as 
an integrative analysis of the interactions between variables.  The current study design is unique 
in this regard and additionally in its characterization of cell populations while preserving 
resolution at the level of the individual cell. 
Several specific changes to the experimental design and methodologies were made to 
previous publications using the MOSEC model with the following rationale:  previous studies 
using  batched surface epithelial cells from more than ten mice to initiate the primary culture 
demonstrated significant karyotype heterogeneity ranging from 2n – 6n at the earliest time point 
in this study [55].  The culture was initiated only with cells from a single mouse ovary to 
minimize the possibility that early stage heterogeneity could be attributed to the batching of cells 
from many different mice.  The key transitional stages of MOSEC transformation have been well 
defined in previous studies [55] and emerged with predictable sequence in the current study, 
albeit with a longer timeline.  MOSEC displayed slow contact-inhibited growth with low invasion 
and proliferation capabilities until day 170 and gradually progressed to acquire the capacity for 
rapid growth, increased migration, invasion with upward stratification, and three- dimensional 
branching from day 245 onwards.  These acquired traits are well established hallmarks of the 
malignant phenotype and, as previously reported, the current MOSEC transformation shows 
that a strong correlation exists between these behaviors in vitro and tumorigenic potential in 
vivo.  Therefore, the genome-wide multi-variate assessment performed is useful not only for 
time course analysis, but also to evaluate changes in a pair-wise fashion associated with the 
acquisition of key characteristics leading to the tumorigenic phenotype.   
 Additional noteworthy differences should additionally be highlighted between our SKY data 
collection and reporting that extend beyond current standards for cancer cytogenetics.  These 
differences are important because, in addition to reporting the aneusomies found in high 
frequency in a cell population, this study emphasizes the quantification of low frequency events 
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and variability from cell to cell.  Therefore, high quality metaphases for SKY analysis were 
selected with minimal overlap and clearly defined borders for each metaphase.  This minimizes 
the possibility that artifactual numerical change or improper chromosome assignment would 
occur.  Additionally, to thoroughly quantify karyotypic variability of cell populations for 
comparison across different ploidy levels, a high number of complete metaphases (n=50) are 
counted and reported. 
 
4.3. Stress Induced Senescence as an Incomplete Mechanism of Tumor Suppression 
Even when the primary culture was initiated from a single mouse ovary, day <40 cells 
displayed chromosome copy number change as well as nuclear and cytogenetic morphological 
abnormalities. These were visualized in images of DAPI stained and SKY painted interphase 
nuclei and in metaphase spreads.  In this earliest evaluation of karyotype change, aneuploidy 
ranged from loss of a single chromosome, doubling of the entire genome with multiple 
chromosome fragments and functional defects in extreme cases.  Based on the senescence 
and karyotype data, we can speculate as to possible causes of this early aneuploidy as it relates 
to ovarian cancer in humans.  The incessant ovulation hypothesis is the dominant theory for 
ovarian cancer causation in humans and suggests that repeated rupture-repair cycles 
eventually lead to transformation and increased ovarian cancer incidence.  According to this 
hypothesis, successive bouts of apoptosis and regenerative repair of OSE cells at the ovulation 
site induces genetic instability via oxidative DNA damage, over expression of p53 at the rupture 
site and anti-apoptotic Bcl-2 at the rupture margin, and replication of cells at the margin and 
their migration to the wound [101].  Survival and subsequent expansion of OSE cells with 
unrepaired genomic damage and heightened survival potential is theorized to predispose the 
epithelial cell layer to tumorigenesis [28].  The early genomic instability seen in the current study 
cannot be due to the inherent MOSEC instability caused by repeated rupture-repair cycles.  This 
is because the first estrus cycle of the mouse occurs at 4-6 weeks of age [102], so harvested 
85 
 
cells from six-week-old mice possibly could have been exposed only to a single cycle of follicle 
rupture and repair.  Therefore, the genomic instability seen in the MOSEC model reflects growth 
and regeneration occurring as a function of days in culture.  As the cells are passaged before 
reaching confluency and therefore continually divide. 
4.2  Cell Senescence 
Cellular stress likely accounts for early aneuploidy and is evidenced by the majority of 
the cell population (>95%) undergoing senescence at day <40.  Cellular senescence has been 
correlated with aneuploidy [103], and is thought to function as a tumor suppressive mechanism 
in genomically unstable cells [104-106].  The findings that the small minority of dividing cells 
display aneuploidy with nuclear and cytogenetic abnormalities suggests that, as a potential 
tumor suppressive mechanism, the halting of genomically unstable cells through cellular 
senescence is an incomplete mechanism of tumor suppression.  Another possibility recently 
described is the escape of senescence by neosis.  Briefly, this process involves the formation of 
several daughter cells with viable genomes from giant polyploid cells via nuclear budding and 
asymmetric cytokenesis [107].   The finding that the day 170 culture contained almost no 
senescent cells suggests incompatibility of the senescent cell phenotype with MOSEC 
tumorigenesis.  Possible mechanisms for this shift include senescence escape mechanisms 
such as neosis, or progressive replacement due to differential attachment, replication, or death 
of the senescent versus mitotic cell fractions.  Aneuploidy was present in ~32% of cells by small 
alterations in whole chromosome copy number change and by the prevalence of linked 
chromosomes.  Interestingly, among 50 metaphases, tetra-ploid genomes such as that detected 
in the day <40 cells were not seen.  This suggests that doubling of the genome in the early 
stages of transformation is linked to reduced viability of cells with 4n genomes. 
The increased frequency of murine cell immortalization is attributed to the substantial 
increase in telomere length in the mouse compared to the human (40-60 Kb, 10 Kb 
respectively).  Additionally, mice have constitutively active telomerase activity in contrast with 
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the re-activated telomerase activity responsible for transformation of human cells [108-109].  
The short time in culture before the majority of MOSEC became senescent combined with the 
properties of constitutively active telomerase and longer primary telomeres reduces significantly 
the possibility of telomere associated senescence.  The increased stability and maintenance of 
rodent telomeres could account for spontaneous transformation and tumorigenesis in these 
lines.  However, the ability of the MOSEC to overcome high frequency senescence based arrest 
suggests that differential entry of human versus mouse cells into senescence is not responsible 
for their contrasting abilities to immortalize.  By comparison, this suggests that telomere induced 
senescence may be sufficient to prevent tumorigenesis; whereas stress induced senescence 
may be a less tightly controlled process.  Some evidence suggests that different patterns of 
telomerase activity may be linked to the differing cytogenetic profiles of mouse versus human 
epithelial tumor cells.  For example, the frequency of clonal non-reciprocal translocations is 
greatly increased in telomerase deficient compared to control Trp53 mutant mice, reaching at 
least one translocation in each chromosome after only a short time in culture [110].  The 
acrocentric mouse chromosome morphology may therefore be differentially subject to specific 
aberration patterns compared to human chromosomes.  The mouse chromosome centromere is 
almost directly adjacent to one telomere reducing the physical space in which translocation 
events might occur by one half [111].  Despite these differences in telomere structure and 
function, the fact that high-degrees of genomic instability are reported in ovarian cancer cell 
lines and tumors from both species [87] supports the validity of this model. 
 
4.3 Quantifying Genomic Instability in Cellular Transformation 
 The application of SKY analysis to early stage cells provides insight into a number of 
questions regarding early transformative events.  Several types of nuclear and cytogenetic 
abnormalities were detected in both interphase and mitotic cells, which implicates structural and 
functional pathologies as early contributors to the transformation process.  Evidence for both 
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gene and chromosome based causes of cellular transformation has been provided by 
experiments in which genes or chromosomes and the rate and frequency of cellular 
transformation that follows are tracked [112-115].  Unlike other published data, the current 
methodologies did not alter the cellular chromosomal content or any specific gene(s).  Rather, to 
more closely mimic the majority of human cancers, we observed the process of spontaneous 
transformation from the normal diploid phenotype over time.  Due to the large body of evidence  
associating multiple checkpoint  [116-118] and mitotic associated proteins [119] with 
chromosomal instability and aneuploidy, all of which may contribute to chromosomal instability 
in various systems, we sought to determine the effect and extent of early instability rather than 
determine its specific cause.  Evidence for mitotic instability are provided by the images of 
abnormal nuclear morphologies [120] such as the blebs and nuclear bridges seen in day <40 
cells.  Cells with the ability to pass through the colcemid induced pro-metaphase block and 
proceed through mitosis in the presence of colcemid without spindle fibers [99] are identified by 
two separated centromeres per chromosome. The chromosomes then decondense coalesce 
and form micronucleated restitution nucleus. Cells in colcemid-telophase or forming a restitution 
nucleus have been described as those shown here with two separated centromeres per 
chromosome.  This suggests that even in this early stage, the cells have lost the ability to 
maintain arrest at the spindle checkpoint.  Other abnormalities include rare cells with highly 
aneuploid karyotypes, multiple breaks and structural abnormalities.  The fate of these cells is 
not known, but it has been suggested that for the most part, their viability is reduced compared 
to diploid cells [121].  This could possibly account for the reduced frequency of day 170 
polyploid cells. 
 Early in the study of cancer, the visualization and experimental manipulation of 
chromosomes led scientists to postulate that misdistribution of chromosomes might cause tumor 
development [112].  Since this time, it has become clear that many tumors are not only 
aneuploid, but also have acquired mutations in oncogenes and tumor suppressor genes, fuelling 
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the debate over whether genomic instability is the cause or consequence of cellular 
transformation [122-125].  Independent of the cause for cellular transformation, the implications 
of genetic heterogeneity as the basis for increased variability, selection, and genetic adaptation 
are generally underestimated by most in the field [126].  Therefore, to track the effects of early 
genomic instability during spontaneous transformation of near-normal diploid cells, population 
based karyotype analysis was performed at each key transformative stage.  The level of cell-to-
cell genomic heterogeneity is believed to provide a snapshot of chromosomal instability and 
allows the assessment of cancer progression from an evolutionary perspective by tracking 
patterns of change at the level of the entire karyotype [127-130].  These data are the first to 
evaluate karyotype heterogeneity in a longitudinal model that begins from a near-normal 
relatively homogeneous karyotype where chromosomal instability has not been specifically 
induced by gene or chromosome manipulation.   
The mosaic of cellular karyotypes common to solid tumors and blast-phase hematologic 
neoplasms are often ignored or filtered to emphasize clonality within a population of cells.  
Despite the emphasis on pattern detection inherent in most data collection and interpretation, 
the true biological variability resulting from low-fidelity genome transfer remains apparent in 
many data sets [131].  As high-throughput molecular technologies allow us to explore the 
genome at finer molecular resolution, emphasis is placed on filtering and normalizing data so 
that signal detection is maximized at the expense of variability.  In this way, most investigators 
hope to find common, clinically-relevant mutations in cancer causing genes, over the variable 
background of intra-tumor genomic noise.  Rather than filter or minimize the effect of such 
genomic variability, our approach for collecting and reporting genomic data adopts concepts 
from information theory and calculates variability on the basis of whole chromosome copy 
number data, translocations, minute chromosomes, deletions and structural defects.  Using 
these inclusive criteria, a striking difference is seen in the karyotype variability between day 170 
cells and later stage cells, between allografted cell lines and harvested tumors, and between 
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spontaneously transformed versus Brca1 conditional knockout MOSEC.  The karyograph format 
provides a clear picture of cell-to-cell variability for comparison with the variability induced by the 
conditional inactivation of Brca1 in this model. 
Quantification of genomic heterogeneity over time provides significant challenges.  
Nevertheless, we sought to characterize and quantify genomic heterogeneity throughout 
spontaneous transformation, with the concept that heritable variability at the level of the entire 
genome system is the basis for evolutionary selection.  Though not intuitive in the context of 
linear outcome prediction, we have chosen to incorporate the reporting of cell-to-cell genomic 
variation at multiple levels into our experimental design, as we believe it to be inextricably linked 
to the emergent properties of cancer cell populations.  We encourage the development of high 
throughput technologies that comparatively will provide cellular resolution rather than molecular 
resolution.  Population profiling of transformation, tumorigenesis, drug resistance, and variable 
responses to therapy will be more easily employed.  We have provided a basis for quantifying 
karyotypic heterogeneity in cancer cell populations which is intuitive and describes the extent of 
genomic variability by whole chromosome, derivative chromosome, and as a total population 
index.  Taken together, these data demonstrate the significance, methodologies and rationale 
for quantifying karyotype heterogeneity in transformation, tumorigenesis, and clinical cancers, 
with hope towards incorporation of these features into prognostic and therapeutic applications. 
 The mechanism leading to such genomic mosaicism is, for most clinical cancers, not as 
significant as the magnitude and extent of this phenomenon.  Cell-to-cell variability within a 
population of cells in culture, or from clinical tumors has been estimated in a number of ways by 
different groups [72].  Some algorithms for quantifying chromosomal or karyotype instability are 
based on the mechanisms by which they are thought to arise.  Most support two sets of 
calculations for the contributions of whole versus translocations or marker chromosomes.  
Recently, in an set of papers by Castro et. al., the concept for quantifying inter-tumor karyotype 
heterogeneity among data from the Mittleman database was put forth using concepts based on 
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Shannon Entropy [80].  By this measure, tumor heterogeneity among samples was paired with 
data from SEER and showed that lower diversity of total chromosome number across samples 
correlated with better survival statistics.  Additionally, the stochastic nature of chromosome 
change was shown by the relationship between global spread of numerical and structural 
chromosome abnormalities with sample number.  If chromosomal instability is a necessary and 
ongoing characteristic of solid tumors, continuing to increase sample size in search of recurrent 
patterns of derivative chromosomes linked with cancer phenotype tumors [132-138] seems 
illogical.  Independent of the mechanism, if random aberrations are produced at an increased 
rate and population size increases, some aberrations may appear more frequently if they confer 
a relative increase in fitness in that environment [125, 139]. 
 The clonal selection theory describes the dynamics of a population of cells that, after 
undergoing random mutations, environmental pressures eliminate the least viable genotypes. If 
we assume that viable mutant phenotypes are rare, the degree of karyotype heterogeneity 
would be expected to decrease over time [140].  Our data, most clearly shown by the 50-cell 
karyographs characterizing each transformative stage or condition, suggest that unique and 
viable mutant genotypes are much larger in number than previously expected.  By our measure, 
each of the fifty cells is unique by SKY analysis once it has diverged from the diploid genome, 
providing evidence for at least 50 different viable phenotypes per flask.  As the literature 
suggests, a significant amount of additional variability likely exists in each cell that is too small to 
be detected with SKY analysis [141].  Our SKY data show that more than half (25/50) of the 
karyotypes are unique even in the earliest stages of transformation.  When combining this 
finding with the concept that clinical tumors are detected when comprised of approximately 12 
billion cells, we suggest that change at many levels including the whole chromosome, derivative 
chromosome, indels, loss of heterozygosity, and base mutation contribute to clinical tumors in 
which each cell, by its genome, is most likely unique.  Although some may consider the 
measurement of genomic heterogeneity to be without clinical significance, we suggest that the 
91 
 
opposite may be true.  This is because the resulting mosaic of cellular genomes provides the 
large-scale variability by which different phenotypes can be selected by drug treatment, or can 
adapt to a new environment during metastasis.  By acknowledging the rate and magnitude of 
the heterogeneity formed in spontaneous versus gene-based transformation models (such as 
the conditional Brca1 conditional inactivation model), we demonstrate the necessity for 
measuring karyotype heterogeneity and stability of cancer cell lines as outcomes variables in a 
wide variety of cancer research projects.   These data suggest at least in the case of Brca1 
inactivation, this genetically induced model of cellular transformation is significantly different in 
terms of its ability to generate heterogeneity.  As the variability seen in our allografted cell line 
and in the work of others [142] affords cell populations the ability to readily undergo rapid 
phenotypic shift, it seems that karyotype data should be included in experimental design and 
data interpretation using unstable cell lines. 
The findings of a small Shannon Index value for chromosomes within the day 170 cells 
was not surprising considering  the small variation in count for each chromosome.  From day 
245 onwards, the increased cell-to cell variability as indicated by the rise in the Shannon Index 
for each chromosome and for summed whole and aberrant chromosomes within that transitional 
stage, suggests an extremely low fidelity process for genome transfer.  The small but significant 
reduction in Shannon Index values with the onset of several clonal chromosome translocations 
suggests decreased variability from the previous passages.  As a unique event occurring in the 
late stage cells, we conclude that cells with this t4;3 translocation most likely have descended 
from a common cell, and now account for ~30% of the cell population.  Interestingly, when these 
cells were isolated into subpopulations the variability of the remaining chromosomes was 
greater in cells with the 4;3 translocation than in those without, implying that selection may have 
occurred for this translocation, but low fidelity transfer of the remainder of the genome persisted. 
Clonal and sub-clonal evolutionary processes have been previously described in 
induced cellular transformation [143-145].  In the current model, karyotype change is tracked 
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beginning from a normal diploid cell as might occur in a typical cancer patient without an 
inherited aneusomy or known heritable gene linked to increased cancer risk.  In our 
spontaneous transformation model, cells demonstrated a weakly positive tumor phenotype after 
245 days, and displayed high-grade tumorigenesis in 100% of injected animals at day 528.  Our 
data support that by whole-genome analysis, clonal and sub-clonal evolutionary processes as 
described in the literature do not occur.  When chromosome copy number changes, data for 
derivative chromosomes, and phenotypic data are taken into account, the evidence for clonal 
and/or sub-clonal populations of cells is largely nonexistent.  However, when measuring 
clonality by emphasis on a single translocation and ignoring other variability, it appears ~30% of 
the day 450 cells may have originated from a common predecessor cell as marked by the 4;3 
translocation. Background heterogeneity of the cells with the 4;3 translocation was the same as 
those cells without the translocation, suggesting that this marker of clonality may be fairly 
insignificant on the background of genomic variability. 
 The reason why clonal expansion is more clearly defined in other models probably extends 
beyond simple differences in reporting methodologies.  Typically, induced transformation 
requires colonies to be picked that are all directly descended from a single cell.  The fastest 
growing are the most likely to be picked and, as the cells in that colony recently descended from 
one cell with the same genomic disruption leading to its increase growth rate is more likely to be 
clonal.  Other studies measure lower numbers of cells, typically only ~10 metaphase cells which 
are then subjected to pre-analysis filters to remove events with frequencies less than 20%.  The 
concept that heterogeneity in the current study is created by artifact is unlikely based on the 
uniformity of the day 170 cells and the consistency in median gains, losses, and distributions of 
specific chromosomes over time.  Few have studied karyotype change over time, but it has 
been suggested that following induced transformation and over 60 passages in culture, newly 
derived clones with “quazi-stable” karyotypes could be maintained in culture for 10 subsequent 
generations [146]. 
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4.5 Genomic variability in spontaneous versus genetically induced models for transformation 
By comparing the genomic mosaicism of MOSEC with conditional inactivation of Brca1 
(Brca1Δ5–13) at day 79 with spontaneously transformed MOSEC, we provide insight into some of 
the unexplained features of clinical and laboratory findings relating to ovarian cancers in 
patients with inherited BRCA1 mutations.  Previous attempts to transform human ovarian 
epithelial cells by similar means have failed to spontaneously generate tumorigenic cells.  
Therefore, we find the MOSEC model well suited to investigate the role of genomic instability in 
spontaneous transformation and tumorigenesis. 
Additionally we can shed some light on the confusion between genes as causative agents for 
cancer, and the difference between micro and karyotypic macro-scale evolutionary change.  
Among carriers of the BRCA1 mutation with family histories of breast and or ovarian cancer, the 
lifetime risk of developing ovarian cancer has been estimated to range from 11-66% [147-148].  
This six-fold spread in the range of ovarian cancer risk has been attributed to a number of 
environmental factors and detail regarding specific gene mutation.  The current findings of rapid 
and widespread genomic mosaicism shown by the Brca1Δ5–13 MOSEC suggest that 
environmental and other factors likely all contribute to promotion of the malignant phenotype by 
selection from a genomically heterogeneous cell population.  The data also may explain why, in 
contrast to sporadic disease, BRCA1-related familial ovarian cancers are more frequently 
multifocal, with genetically distinct clones involving multiple sites [149].  The inherent 
heterogeneity of these Brca1Δ5–13 cells gives rise to the possibility that certain karyotypes may 
be well matched for specific microenvironments or niches within the peritoneum in which the 
local environment would provide the basis for selection.  The findings that the Shannon Index 
for each chromosome in the Brca1Δ5–13 MOSEC was significantly elevated over the most 
variable of the MOSEC stages suggests that genetically distinct subtypes may arise more 
frequently and to more rapidly adapt to new environments (multifocal nature, drug resistance, 
94 
 
progression).  As a functional Brca1 protein is required for reliable DNA double strand break 
repair by homologous recombination, we expected increased non-homologous end joining 
events [150-151] to be marked by increased translocation frequencies.  Increased translocation 
frequencies were seen to some extent, but low numbers of translocations prevented thorough 
analysis.  This phenomenon may become more prominent with increased time in culture 
following conditional Brca1 inactivation.  The data suggest that a large increase in whole 
chromosome counts due to improper segregation events precedes the emergence of instability 
caused by translocation events.  It has been suggested that the gene expression profiles in 
sporadic ovarian cancers have been reported to fall into two categories that resemble the 
ovarian cancer gene expression from patients carrying either BRCA1 or BRCA2 mutations 
[152].  This seems to conflict with the early widespread heterogeneity documented in the 
Brca1Δ5–13 line, but may be resolved by the different selective pressures created by differing 
environments and clinical phenotypes of BRCA1 versus BRCA2 tumors compared to early 
stage cells in vitro that have a relatively homogeneous and constant cell culture environment.  
These data can be used as an example of how microevolution can facilitate and predict of the 
onset of macroevolution in certain types of cancer.  BRCA1 and likely other widely accepted 
oncogenes or tumor suppressor genes have profound and swift impact on genomic instability 
compared to spontaneously occurring transformation.  This demonstrates a link between micro-
evolutionary alteration in a single gene and the jump to macro-evolutionary large scale 
rearrangement of the entire cellular genome.  The current data support a theory for cancer 
causation by genetic alteration that occurs through widespread genomic instability.  This 
instability begins as early as day 40, far ahead of the emergence of specific traits of the cancer 
phenotype supposedly linked to growth or invasiveness.  Conditional inactivation of Brca1 in 
MOSEC in situ by AdCre recombination within the bursa results in the development of 
preneoplastic changes, such as hyperplasia, epithelial invaginations, and inclusion cysts but 
failed to yield epithelial ovarian cancer even after a one year follow up.  The lack of expression 
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of known human ovarian cancer genes suggests that BRCA1 mediated transformation may 
occur differently in mouse versus man.  Additionally, it is possible that the time was not sufficient 
for the pre-neoplastic changes to develop into tumors [48]. 
The findings that certain chromosome counts remained relatively stable (e.g. 
chromosome 1, 12), while others were highly unstable (e.g. chromosome 2, X) is noteworthy, 
but the mechanisms and significance of these findings is not well understood.  The differential 
variability of certain chromosomes could be related to an inherent stability of each chromosome 
in the segregation or selection process.  In this case, if the experiment were repeated, as in the 
Brca1 conditional knockout model, these may again emerge as most and least stable.  The 
second and more likely possibility is that an early random expansion or imbalance in copy 
number increases the likelihood of persistent or worsening change.  It is possible that the 
variability seen in chromosome count reflects the ability to regulate gene expression from genes 
on that chromosome.  This is supported by data from the X chromosome, which consistently 
displayed the greatest amount variability in whole chromosome copy number.  This hyper-
variability may relate to its ability to its ability to repress transcription from the entire 
chromosome as a Barr body, a phenomenon that is not appreciated when chromosomes are 
condensed at metaphase.  However, several studies have found that ovarian cancer cells lack a 
normal inactivated X chromosome (Xi) and manifest at least two active X chromosomes (Xa), 
suggesting a selection for multiple Xas that may be linked to over expression of X-linked genes 
[153-155].  These findings regarding dysregulation of heterochromatin at the X chromosome 
may mark a broad dysregulation of the nuclear hetero-chromatic compartment responsible for 
global perturbations of gene-expression promoting tumorigenesis. 
4.5  Array analyses for gene expression  
The majority of short time series expression data analyses do not utilize the scale and 
sequence information inherent in time-series data sets.  Some of the typically used methods for 
analysis are hierarchical clustering [156], k-means clustering [157], self-organizing maps [158], 
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and sets of paired comparisons [159].  It is important to understand that these commonly used 
methods do not test for differential expression based on event sequence, and so random 
permutation of the order of time points would not change the results of these analyses.  As 
phenotype data from the current study clearly suggest a progressive transformation over time, a 
more appropriate and robust method for time course data analysis was performed using 
extraction and analysis of differential gene expression (EDGE)  [92] coupled with time-course 
based cluster analysis with gene Ontologies using the short time series expression miner 
(STEM) [95] software.  Nearly 600 genes were identified and clustered by profile according to 
each gene’s fold-change pattern of significant differential expression over time.  This analysis 
was ideally suited for the sequential analysis of key transitional stages, as the time between key 
transitional stages was relevant to the accumulation of changes in cell phenotype, but time 
points were not equally spaced. 
4.5.1 Longitudinal Gene Expression Analysis Suggests that Six Hundred Genes and a Variety of 
Fold Change Profiles  Play a Role in Tumorigenesis 
 Tests for functional enrichment of the genes linked to each profile were significant for Gene 
Ontologies annotation categories in two of the eight profiles.  Differential expression in profile 2 
was characterized by increasing transcript abundance of ~3-4 fold (170:0; 245:3; 450:4; 528:3) 
and this profile was enriched in functional categories concerning chromatin, DNA packaging, 
conformational change, chromosome and nucleosome organization, RNA processing, 
macromolecular complex assembly and subunit and spliceosomal complexes.  This profile 
summary fits directly with the dramatic changes seen in chromosome copy number and 
transcription profiles throughout transformation and may be particularly relevant to trends in 
chromosome number and distribution as well as in karyotype heterogeneity and altered 
differential gene expression patterns over time.  The second significant profile (5) shows a trend 
of increasing transcript abundance across all transformative stages (fold change: 170:0; 245:1; 
450:2; 528:3).  This profile was significantly enriched for cholesterol biosynthetic and metabolic 
97 
 
processes and genes associated with microsomal and vesicular fractions.  A wide range of 
integral and lipid membrane associated protein types are contained within the microsomal and 
vesicular fractions including pores, channels, pumps, transporters, trans membrane receptors, 
and cell-adhesion proteins.  The functional enrichment of genes linked to cholesterol 
biosynthesis and metabolism support emerging evidence of off-target anticancer effects of 
commonly prescribed Statin drugs (HMG-CoA reductase inhibitors) [160].  By reducing available 
mevalonic acid, this class of drugs exerts pleiotropic effects including blockade of the G1-S 
transition effecting cell proliferation and on many essential cellular functions including 
differentiation, survival, and the regulation of cell shape and motility [161-162]. 
 Pair wise analysis using significance analysis of microarray (SAM) identified specific lists of 
differentially expressed genes for comparison with morphological and behavioral change.  The 
largest changes in mRNA transcript abundance occurred in the early transition (170:245), which 
parallels the largest shift in karyotype diversity and chromosome count.  The day 245:450 mid 
transition had relatively small changes in expression despite over 200 days of continuous 
culture.  Phenotypic change included the acquisition of a diffusively invasive phenotype and a 
large increase in cell  branching morphology in 3 dimensional culture.  Day 245 cells produced 
low-grade locally confined tumors at low frequency (1/14 sites).  Significant functional 
enrichment for GO categories, included categories relating to the extracellular space/ matrix, 
glycoprotein related cell signaling, and changes in cell binding and adhesion.  These gene 
expression array results are concordant with previous work by Roberts et. al. [55], who used 
immunohistochemistry on various MOSEC transformative stages and demonstrated alterations 
in focal adhesion complexes and cytoskeletal elements.  These categories for functional 
enrichment generally are well matched with changing MOSEC phenotype including increased 
growth capabilities, acquired focal invasiveness, and the loss of contact inhibited growth.  
Approximately half of the differentially expressed genes determined in each SAM pair wise 
analysis overlapped with genes detected using STEM time series analysis.  Genes in the null 
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set (Ф) are significant for that specific transitional stage, but are outside the time course 
analysis. As fold change cut offs were the same across both types of expression, Ф genes likely 
reflect the increased power to detect change following normalization only for that specific pair 
wise analysis. 
4.5.2 Driving genes in transformation as anti-cancer targets 
Due to the large numbers of studies attempting to find cancer causing genes through the 
high-throughput screening of large numbers of patient samples, we sought to determine the rate 
at which early up-regulated genes were detectable in the transformed late stage cells.  To 
identify these putative “driving genes” in transformation, the intersection of gene lists generated 
from SAM pair wise analyses were evaluated.  Three lists were generated that consisted of 
genes from the intersection of each paired comparison (170:245, 245:450, 450:528).  The 
number of differentially expressed genes on each pair-wise analysis list became smaller as 
transformation progressed.  This suggests that later stage samples are more closely related to 
each other than earlier stage samples.  Accordingly, genes found in the intersections of these 
were few in number (170:245=16; 245:4501=6; 450:528=2).  In fact, only a single gene, Necdin 
(NDN), met criteria for significant differential expression across the three paired comparisons.  
NDN shows current major associations with neuronal migration and the human disease Prader-
Wili Syndrome.  A lone entity among 600 genes, the role of Necdin in cellular transformation is 
developing and others report NDN as a target of P53 with a role in hematopoetic stem cell 
senescence.  Combined with evidence for NDN-mediated down regulation of p53 and other 
diverse roles for NDN in tumorigenesis, data from the current study provide further rationalle for 
continued investigation of NDN as a potential tumor suppressor gene [163]. 
 
4.6 Chromosome Copy Number Change Influences Gene Expression in Late Stage 
Tumorigenic Cells 
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 Karyograph and Shannon Index data provide qualitative and quantitative evidence for 
differential chromosome instability and karyotype heterogeneity across the key transitional 
stages.  The concept of, “gene-dosage effect” is familiar to most geneticists, as is the notion in 
cancer genomics that that gene-dosage might contribute to the malignant phenotype.  As of yet, 
gene regulation by this mechanism has not been evaluated across various transformative 
stages.  In the early transformative stages (170:245) chromosome count (5% per chromosome) 
is not related to mRNA transcript abundance (range: 3-8% per chromosome).  However, when 
this phenomenon is tracked over time, the strength of this relationship becomes less and less 
clear.  Fold change in chromosome copy number and mRNA transcript abundance are largely 
unrelated, reaching a minimum between 450:528.  Unlike our late transition findings between 
day 450:528, a close relationship between chromosome copy number and transcriptome has 
been reported in sub-clone derivatives of previously established cancer cell lines in culture 
[164].  Oppositely, in the case of chromosome gains on the background of a normal diploid 
karyotypes, such as human autosomal trisomies, dosage compensation for individual genes can 
be stage- and tissue-specific [84, 165-166].  The susceptibility of cells to gene dosage effect or 
their ability to compensate for altered gene dosage is mediated presumably by feedback at the 
level of transcription or mRNA stability; however, similar translational and post-translational 
effects might exist that would not be detected.  Gene dosage effect by whole chromosome 
count is not a feature of the late transitional stages of spontaneously transforming MOSEC 
(245:450:528), as chromosome copy number and gene expression are unrelated.  Subcloned 
MOSEC lines recently derived from a single transformed progenitor may exhibit such features, 
however this did not occur under the spontaneous transformation model used in the current 
study.  The current data are unique in that they resolve the discrepancy between gene-dosage 
effects in normal diploid versus transformed cells by taking a whole genome multi-level 
approach to understanding cancer genomics.  The data suggest that gene-dosage effect may 
be a characteristic of early stage cancer cells and that the relationship may exist when 
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chromosome copy first depart from diploid status and vary over a large range from one 
transformative stage to the next.  This provides further support for the theory that karyotype 
based evolution is significant to cancer cell populations in that low fidelity genome transfer and 
high variability from cell to cell is linked to dysregulation of mRNA transcript abundance and 
uncoupling of the gene-doseage effect [164].  Karytype evolutionary patterns that have 
previously been linked to a tight genome: transcriptome relationship have significantly less 
variability from cell to cell and less change in chromosome copy numbers over all.   
 
4.7  Linking Changes in Tumor Karyotype Profiles to Environmental Shift 
 By continuing to evaluate the key transformative stages during in vivo tumorigenicity assays, 
several interesting findings emerged.  The weak tumorigenicity of the day 245 cells that were 
allografted into C57BL6 mice was expected based on in vitro data and link relatively low 
Shannon indices to low tumorigenicity.  The findings that day 528 cells formed subcutaneous 
and intraperitoneal tumors of larger, and higher grade than day 245 cells concur with previously 
published characteristics of allografted cells using this model system [54].  These tumorigenicity 
rates for late stage MOSEC are somewhat lower than previously reported rates [55], but match 
the tumorigenic potential of these cells as assessed in vivo.  The invasion and proliferation 
assays from the current study are slightly less aggressive at all transformative stages despite 
longer transformation times [55], which could be attributed to the small number of seeded and 
early stage mitotic cells.  Considering the genomic instability and karyotype variation in this 
longitudinal transformation model, previous “runs” beginning from primary cells could likely have 
different end phenotypes.  The variable karyotypes of the late stage injected MOSEC and the 
significant phenotypic shift that occurred between cell injection and harvest, could account for 
the variable tumor formation.  Based on the findings that both tumors contain the same four to 
five high-frequency translocations these cells have likely descended from a common 
predecessor.  It is unlikely that this translocation itself increases tumorigenicity as in the 
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BCR:ABL fusion protein of CML, but rather marks a recognizable feature of a genome that at 
one point had a selective advantage over the other cells.  The significance of these markers 
may be interpreted in several ways.  Perhaps this set of markers represent a genome that 
facilitated survival in the initial transition from in vitro to in vivo environments, or if these markers 
were accumulated in a stepwise fashion and reflect cellular adaptations required to survive as a 
larger and progressively more invasive tumor.  Additionally, the contributions of gene alterations 
associated with these visible markers versus gene alterations invisible to SKY analysis is 
beyond the scope of the current studies.  This could be interpreted to mean that this clonal set 
of markers are part of a very large set of genomic, epigenetic, environmental, and population 
based variables that facilitate positive selection for the tumorigenic phenotype.  Alternatively, it 
is possible that this set of karyotype markers are unlinked to phenotype and that they 
independently arose in both tumors, and as multiple independent events in the day 450 cells.  If 
this were true, we suspect that fragile sites or other inherent features of the genome could 
account for the increased frequency and repeated appearance of this set of markers. 
 A role for the immune system in suppressing, selecting for, or eliminating injected tumor 
cells from the peritoneal cavity is of particular interest as ovarian cancer cells evade the immune 
system by creating a highly suppressive environment in the peritoneal cavity.  A recent clinical 
cohort study in of 500 ovarian cancer patients correlated intraepithelial CD8+ T-cells with 
improved clinical outcomes for all stages of ovarian cancer [167] brought importance to the 
study of immune system based therapies for ovarian cancer. The immune function of the 
C57BL6 mice was evidenced by the active aggregates of mesothelial cells with inflammatory 
cells seen in association with peritoneal fat.  Although subject numbers in the current study are 
small, the larger tumor burden in the nod-SCID-gamma mice and the occurrence of invasive 
tumors in 2/2 animals supports our current knowledge of immune regulation in tumor 
establishment and progression.  Importantly, these data suggest that the MOSEC model is well 
suited for ovarian cancer studies focused on the dynamics between the immune cells, 
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cytokines, and other regulatory molecules in cancer progression in the context of vaccine or 
other immunologic therapies. 
The population karyotype data from injected late-stage versus harvested tumor cells 
provides valuable insight into the possibility of cell selection and the significance of variability 
and low fidelity genome transfer in tumorigenesis.  The two tumors evaluated are from different 
mice injected with the same late-stage cells.  However, both share the 4;5 translocation at the 
same frequency as the day 450 cells, but both display two additional translocations at 
frequencies greater than 90%.  Based on the rates and patterns of these aberrations, it seems 
more likely that the environmental shift selected for a cell subtype that was present at low levels, 
rather than the set of translocations arising independently in both mice.   The former theory 
seems more likely, although the latter cannot be completely ruled out.  Finally, the high degree 
of complex non-clonal translocations in tumor two (T2) compared to tumor one (T1) may be 
linked to tumor histopathology.  The size and growth rate of T2 was significantly elevated over 
T1, is likely responsible for the large necrotic zone seen on histopathologic analysis.  Necrosis 
is a well known response to oxygen debt and is related to tumor size and perfusion, with cells 
adjacent to the necrotic zone subjected to low oxygen tensions [168-169].  Hypoxic cells 
continue to divide and, as they slowly proceed through the cell cycle, increase genomic 
instability and promote tumorigenesis [170].  These data warrant further investigation as they 
link genomic instability with hypoxia, a phenomenon involved in radio-resistant tumors.  The 
concept that random chromosomal change in response to hypoxia could increase variability and 
provide the basis for rapid evolution and phenotypic shift suggests a low fidelity of genome 
transfer in the larger, hypoxic tumor, suggestive of a genome based, rather than gene based 
mechanism for hypoxia in resistance to chemotherapy and radiation treatments. 
 
4.8 Future Directions and Clinical Considerations 
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 The findings of the current study raise several basic and clinical scientific questions 
regarding karyotype heterogeneity and many complications known to clinical oncology including 
metastasis, drug resistance, and immune system evasion.  Both the prognostic significance of 
chromosomal instability and its facilitative role in drug resistance and metastasis suggest that 
genomic instability may likely be a modifiable factor in clinical cancer outcomes.  We anticipate 
the key future challenges will lie in the determination of how genomic instability based therapies 
can be incorporated into the current clinical standards for cancer treatment.  The elucidation of 
the mechanisms underlying aneuploidy and genomic instability is only one piece of this puzzle.  
More important is to determine how our interventions on genomic instability change cancer cell 
evolution and clinical outcomes.  Our analyses suggest that the observed karyotype 
heterogeneity differs with key transitional stages of transformation, but leaves several 
unanswered questions.  These include our ability to alter genomic instability of cancer cells in 
vitro and in vivo with pharmacologic intervention and the outcomes of these alterations on cell 
phenotype and clinical outcome.  One mechanism by which genomic instability could be 
exploited for treatment would be by inhibiting mitotic-checkpoint signaling.  This has been 
shown to be lethal in unstable cells as the consequence of massive chromosome loss [171].  
Genomic instability additionally holds promise in the design of adjuvant chemotherapies that 
minimize new mutations that allow them to develop resistance to other cyto-toxic agents.  The 
ability to identify and interpret information contained in measurements of cellular heterogeneity 
will, within an evolutionary framework for cancer progression, provide insight that is not 
attainable by traditional analyses of genomic material.  This is because traditional analyses are 
performed on averaged over a heterogeneous population. 
 In conclusion, early genomic instability generates variation in tumor cell populations well 
before the onset of the transformed phenotype.  By reporting complete karyotype data for a 
large number of metaphase cells at key transformative stages, the contributions of population 
karyotype dynamics in tumorigenesis can be evaluated.  The fact that gene-dosage effect by 
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changes in whole chromosome copy number are most significant in tumorigenic late-stage cells 
suggests a mechanism by which genotype is differentially linked to global gene expression 
profiles between normal and cancer cells.  The magnitude and early onset of genomic 
heterogeneity in the conditionally inactivated Brca1 MOSEC demonstrate how a gene linked to 
increased cancer incidence can predictably induce rapid and widespread genomic instability at 
a much faster rate than the spontaneously transformed line.  The widespread instability of this 
population suggests that targeted therapy will likely result in selection, then expansion and 
progressive increase in the heterogeneity of resistant cells.  Finally, the late stage cells with 
heterogeneous karyotypes are shown to undergo rapid karyotypic shift from the profile of the 
injected line to a profile of increased variability following environmental shift.  Together these 
multi-level longitudinal data support genomic instability and increasing cell-to-cell variations in 
karyotype as a means to increase population diversity and permissive for rapid adaptation by 
gene-dosage effect in late stage transformed cells.  By understanding how cancer cells continue 
to generate heterogeneous karyotypes versus commit to senescence or cell death pathways 
support will be provided for the treatment designs affecting this common feature of all clinical 
cancers.  In the science of cancer complexity, a shift away from observational techniques to the 
application of quantitative measures for genomic heterogeneity is established.  Like other 
genome-wide techniques in molecular biology, the continued development of high throughput 
machinery will benefit clinicians and investigators in the field by permit the quantification of 
genomic heterogeneity by streamlining the data acquisition process while maintaining cellular 
resolution.    The universal features of within tumor genomic variation and cancer cell evolution 
can be evaluated in a wide variety of clinical and research settings and the outcomes applied to 
improve cancer detection and treatment strategies. 
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5. THEORETICAL CONSIDERATIONS 
Since the War on Cancer was officially declared nearly four decades ago, the United 
States has spent over $1.5 trillion dollars on cancer research and treatment.  A large amount of 
data has been generated through the development of high throughput genomic strategies, multi-
center collaborative efforts, and the exploration of new therapies including immunologic [172] 
and gene based  [173] therapies.  Despite these advancements, overall cancer mortality rates 
have only fallen by approximately 1% since 1975 [174].  With some rare successes in 
hematological cancers [175] and in cancers where inheritance or environmental exposure 
increases surveillance and early prophylactic removal of at-risk tissues [47, 176-177], the 
outlook for most people diagnosed with cancer today is not much different than it was a 
generation ago.  Therefore, a critical review of the assumptions inherent in the established 
paradigm currently dominant in cancer research is provided.  
Understanding the evidence for the current paradigm and the accumulation of anomalies 
against it is of utmost importance, as scientific paradigms imbue the minds of researchers in the 
field and influence numerous aspects of how science is conducted, how experiments are 
designed, and how data are interpreted.  The established paradigm defines genes as primary 
agents in cancer causation and describes a stepwise clonal evolutionary process where gene 
mutations account for the progressive acquisition of the hallmarks of the clinical cancer 
phenotype.  Oppositely, the proposed paradigm emphasizes wide-spread heterogeneity of 
cancer cell genomes within a given population.  Rather than focus on individual genes and their 
direct linkage to specific acquired characteristics of the cancer phenotype, the new paradigm 
considers genomically unstable cancer cell populations as complex-adaptive systems that are 
not governed by linear genotype-phenotype relationships.  The proposed paradigm places 
greater significance on the clinical utility and predictive power of gene-level change on a normal 
diploid genomic background, and acknowledges it as “micro-evolution.”   Cancer cell 
populations evolve by a novel mechanism that is central to the proposed paradigm.  This  rapid 
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and widespread  genomic reorganization can be monitored within a cell population and is 
termed “cellular macro-evolution.”  Central to this paradigm shift are several pertinent 
conceptualizations surrounding the magnitude and extent of the karyotype heterogeneity 
discovered within random samplings of cell populations at key stages of cellular transformation 
and tumorigenesis.  These include current working definitions of clonality in cancer, cancer cell 
populations as complex-adaptive and non-linear systems, microevolution versus 
macroevolution, cellular versus molecular resolution, genotype-phenotype linearity in stable 
versus macro-evolutionary environments. 
  
Paradigm Shifts in Cancer Research 
 Over one hundred years ago, chromosomal aberrations were linked to cancer.  At first this 
link was based on observational data by Von Hanssemann [126].  Soon after, Boveri reported 
the growth of tumor like structures in sea urchins after manipulating their chromosome numbers 
and inducing multipolar mitotic events.  This work resulted in the formulation of a theory that 
implicated unequal mitotic events and the resulting chromosome aberrations that ensued in the 
formation of cancers [178].  The significance placed on gene-level change by the established 
gene-centered paradigm is rooted in a series of exemplar experiments and has maintained 
momentum through in vitro experiments and a handful of clinical successes. Each of these 
experiments involves gene alteration of an otherwise normal genome followed by selection for 
the transfected cells with strong growth phenotype.  Each exemplar experiment which initially 
implicated a specific gene or genes in cancer causation has subsequently been tied to genomic 
instability and karyotype abnormalities [179][180]. For example, the discovery of the first gene 
(Src) that could cause cancer in normal animals [181], was soon followed by publications 
demonstrating a clear role for Src in genomic instability [179].  Similarly, in Knudson’s 2-hit 
hypothesis for inherited versus sporadic cases of retinoblastoma (Rb) [182], Rb was reported to 
cause mitotic recombination errors that lead to homozygosity of the inherited mutation [180], 
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and disruption of the Rb pathway was linked to mitotic spindle checkpoint disruption and 
aneuploidy [115].  “The clonal evolution of tumor cell populations” describes an evolutionary 
view of cancer as being caused by gene mutation mediated increases in variability that are 
subsequently followed by selection or clonal evolution of tumor cell populations tracked by 
signature karyotypic features [143].  Nowell had recognized the potential for inter-tumor 
variability by studying karyotypes cell-by-cell with relatively simple techniques.  According to the 
current data, which demonstrates unique karyotypes for each cell in a randomly selected 
population of 50 metaphases, the magnitude and extent karyotype heterogeneity has been 
grossly underestimated, as evidenced by the co-existence of numerous highly variable 
karyotypes from actively dividing cells [143].  Banding techniques for karyotyping developed in 
the 1970s led to discovery that specific chromosome aberrations could be linked to gene-based 
causes for cancer.  This shift from the microscope to the molecule marked the beginnings of the 
established gene-centered paradigm that currently dominates the field of cancer research. 
 The gene-centered paradigm for cancer research regards cancer as a disease that is 
caused by the stepwise accumulation of gene mutations and of clonal expansion from a single 
cell.  This paradigm focuses on the one-to-one relationship between alterations in cancer 
causing genes, and the acquisition of key characteristics of the cancer cell phenotype as the 
mechanism for cancer progression.  The predictability of phenotypic change resulting from 
alterations in cancer causing genes and the linear progression to reach the transformed 
phenotype highlight a major set of assumptions contributing to the gene-centered nature of the 
established paradigm.  Two theories have provided the foundation for the current paradigm that 
are not mutually exclusive: the theory of gene-mutation and the theory of somatic evolution for 
clonal cellular transformation.  Gene-mutation theory states that cancer progression is driven by 
sequential somatic mutations in five to ten specific genes, each of these accounting for a 
specific facet of the cancer cell phenotype [183-184].  This theory is also gene-centered, in that 
change at the level of entire chromosomes or karyotypes is considered epiphenomena of the 
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altered growth and metabolism.  The second theory underlying the established gene-centered 
paradigm is the theory of somatic evolution for clonal cellular transformation, which explains 
tumor progression as the result of acquired genetic instability and the sequential selection of 
variant subpopulations, the most advantageous of these leading to clonal expansion and 
transformation.  These theories are synergistic, and when integrated support the gene-centered 
paradigm by describing cancer progression according to a linear path of Darwinian 
microevolution, where clonal selection due to specific gene mutations is responsible for the 
conversion from the normal somatic cell phenotype to the eventual death of the host organism.   
 Dissidents of the current paradigm suggest that careful examination of the existing data 
regarding genetically linked oncogenic transformation contains a significant number of 
anomalies.  The first is that transfection with sets of oncogenes results in transformation in vitro 
in a very small minority of cells (1:100,000), [3, 185].  The second anomaly is that early transient 
gene alteration is sufficient to increase the rate of transformation, but is not required in later 
stages of progression where genotype-phenotype alterations are purported to continue to 
contribute to progression towards the malignant phenotype.  Following these early transient 
gene alterations, genomic instability emerges and persists into late stages despite a loss of the 
corresponding gene products [114, 186-189].  The third anomaly pertains to inherited cancers 
and transgenic animal models of cancer causation.  When cancer arises by these means, the 
gene mutation supposedly causative for oncogenesis imbues the entire organism.  However, 
such inherited mutations result in cell-type specific cancers in a small number of cells and 
frequently arise after a long time period despite the equal presence of cancer gene alterations in 
all cells [186-188, 190].  An example of this is in human cancers is in cases of inherited BRCA1 
mutation.  Ovarian cancers arise only in some women carrying the mutation, is epithelial cell 
type specific, and typically arises at approximately 50-60 years of age [191].  For reasons 
beyond our current understanding, BRCA1 mutations additionally increase the risk for breast, 
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fallopian tube, prostate, and a subset of hematologic cancers, but do not similarly effect other 
organs [192]. 
 In response to the above questions of the gene-centered approach, the proposed paradigm 
is centered on genomic heterogeneity of cancer cell populations and places gene-level 
alterations in a diminutive role and is therefore termed, “genome-centered”.  Despite a large 
body of evidence that supports the genomic instability in cancer causation, the popularity of this 
theory has been surpassed by gene-centered viewpoints in the last 25 years [83, 122-124, 128-
129, 139, 145, 193-202].  Numerous classes of non-genic causes of cancer have been reported 
and include environmental insult by non-genotoxic environmental carcinogens [193, 203], and 
failures of replication timing [204], condensation, cytokenesis, kinetechore migration, centriole 
duplication, and spindle formation [205].  These mechanisms all destabilize the genome and 
result in a massive increase in genomic variability through the unequal distribution of 
chromosomes among each generation of daughter cells.  The new “genome-centered” 
paradigm differentially defines the role of gene level changes before and after the major rise in 
population diversity by the generation of new and variable genomes.  The paradigm defines 
gene-level alterations as micro-evolutionary change which can predictably contribute to cancer 
causation through increasing the likelihood of genomic instability in stable, near-normal cells.  
Under the genome-centered paradigm, gene level alterations are much less predictably related 
to cell phenotypic change once population diversity has risen, but may be linked to phenotype 
change through karyotypic shift.   
 The genome-centered paradigm defines the genome context as follows: The entire genome 
in its orientation including all heritable modifiers of that genome.  This is significant as the 
proposed paradigm  places theoretical and functional emphasis on the genome context (rather 
than any of its individual constituents) as the main platform for evolutionary selection [86, 206].  
The conditions required for natural selection are well known to evolutionary biologists and are 
entirely dependent upon genetic variability within the population of cells.  These conditions 
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include 1) the existence of variation in the population, 2) that variation must be heritable, and 3) 
that variation must affect survival or cell fitness.  Based on these tenets, the proposed novel 
theories for cancer biology similarly regard variability as the universal feature of success for 
cancer cell populations as such variation facilitates rapid phenotypic shift of cell populations and 
rapid adaptability to new environments such as those encountered by metastatic or drug-treated 
cells.  Spontaneous and inherited clinical cancers, cancer cell lines, and tumors arising by 
oncogene transformation universally display aneuploid karyotypes and genomic instability [146, 
186, 207-211].  The association of increased population fitness with increased genetic diversity 
has been described in cancer cell drug resistance [87, 142, 212], and is linked to decreased 
patient survival times in clinical cancers [213].  On the basis of these findings and the results of 
the current data set, it seems the gene-centered paradigm and the step-wise clonal expansion 
theory for cancer causation place the investigator on a certain observational plane.  From this 
viewpoint, the extent and significance of high-level genomic variability as facilitators of rapid 
genomic and phenotypic switching are greatly underestimated.  The genome-centered paradigm 
for cancer research places emphasis on the differential predictability of genetic cause and effect 
relationships.  These are dependent on the genomic composition of the cell population.  
Specifically, the proposed paradigm calls for two sets of rationale, one of which can be applied 
to genomically stable cell populations that are homogeneous by karyotype and constrained by 
normal organismal function.  The second set of guidelines is to be applied to genomically 
unstable cells comprising the majority of clinical cancers that display high levels of genomic 
variability facilitatory for large-scale macro-evolutionary change. 
 
Clonal Misconceptions of the Gene-Centered Paradigm 
 Under the established gene-centered paradigm, a generation of cancer researchers has 
been indoctrinated with the belief that clonality is central to cancer formation.  A systematic and 
self-renewing bias favoring "clonality" is propagated by the continued use of tools and 
111 
 
techniques that systematically reduce the measurement and reporting of intra-tumor genomic 
variability.  The ramifications of introducing such a bias are reflected in our current working 
definitions of the clonality of cell populations in cancer research.  For example, clonality among 
cancer cell populations is frequently concluded on the basis of a single point mutation shared 
among populations of cells.  This working definition of clonality is readily accepted under the 
current paradigm, despite the unexplored sequence diversity and context of the other 5 billion 
bases comprising the genome [214-218].  The acceptance of cancer cell “clonality” on the basis 
of a single genetic marker is inextricably tied to concepts of classic Mendelian genetics, where 
the genotype: phenotype relationship was taught using a single locus and the resulting 
characteristic phenotype.  Thus, our fundamental understanding and working definitions of the 
genome are rooted in linear single-gene “genotype: phenotype” relationships.  The proposed 
paradigm shift dispels the belief that cancer cell populations are characterized by clonality and 
particularly emphasizes the inappropriateness of considering them as such in scientific and 
clinical settings. 
 The incorporation of, “clonal” into the vernacular of cancer cell researchers has not occurred 
by misunderstanding of meaning or definition of the term, but by the inappropriate frame of 
reference from which clonality is measured.  By their strictest definition, clones are sets of 
genetically identical organisms.  More commonly, clones are defined as a set of cells that share 
a common genotype owing to descent from a common ancestor, and genotype is defined as an 
organism's full hereditary information or genetic constitution including expressed and non-
expressed DNA.  However, high rates of genomic alteration across many levels of the genome 
have been reported and this property of cancer cells renders them incapable of high-fidelity 
genome transfer [141, 219-220].  Therefore, the term “clone” by this definition is not applicable 
to cancer cell populations as they are neither genetically identical to each other nor do they 
share the same full hereditary information.  By the alternate definition of “clonal,” meaning that a 
cell population has descended from a common ancestor, all cells comprising all normal diploid 
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and cancer cells within the same organism would be “clones” of one original zygote.  It is 
important to recognize that the misconception of clonality in cancer biology is propagated by the 
very system used to describe cancer cells.  Similar to gene-centered studies, the identification 
of recurrent or clonal chromosome aberrations in cancer cytogenetics is also systematically 
prioritized over random change.  Specifically, the International System for Human Cytogenetic 
Nomenclature (ISCN) states that a clone may be marked by a single aberration occurring at a 
frequency of only 20-30% [221], “A clone may not be completely homogenous… It will always 
mean at least two cells (out of ten) with the same aberration.”  The guidelines recommend non-
reporting of this detail, allowing the author to provide his or her own operational definition of 
“clonal”, by which all other features of the population are described.  Rather than acknowledge 
or quantify the fact that these cell lines are in a state of extreme genomic instability, the 
guidelines recommend, “Effort then should focus on describing the sub-clones so that clonal 
evolution is made evident… the composite karyotype can be created with all clonally occurring 
abnormalities combined into one karyotype” [221].   
 The ramifications of the continued search for clonality are significant to the field for several 
reasons.  Unable to define a recurrent pattern in this multi-tiered unstable system of hyper-
variable cancer genomes, many investigators have come to regard random karyotype change 
as insignificant and with limited diagnostic and prognostic value [222-224].  However, 
quantification of this universal feature of cancer phenotypes is of the utmost importance as 
genomic instability itself is known to characterize tumor development [86, 128, 206], 
immortalization, metastasis, and drug resistance [87, 142, 212].  In line with these concepts, the 
data presented in this work documents a high-degree of genomic variability by karyotype 
heterogeneity which occurs far before the acquisition of the tumorigenic phenotype.  This 
variability supports a pattern of stochastic rather than stepwise progressive evolution.  The 
dynamics of whole genome mediated macro-evolution by karyotypic heterogeneity (rather than 
micro-evolutionary change) is shown by population karyotype reports that trace micro-
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evolutionary change in spontaneous transformation by measuring the patterns of karyotypic 
heterogeneity over time.  The new, genome-centered model provides the opportunity to re-write 
the concept of clonal cellular evolution by documenting the timing and characteristics of macro-
evolutionary karyotypic change in relation to the transformation process. 
 As the implications of clonality captured at a single locus or level are assumed to have 
strong biological and clinical relevance, the term “clonal” to describe cancer cells is not simply a 
matter of parlance, but a key term with wide-spread influence on experimental design and data 
interpretation [183, 225-226].  The rationale for this supposition is that the clonality determined 
by measurement at a specific marker is conceptually extended to encompass the remainder of 
the genome.  Therefore clonal changes should be linearly predictive of phenotype.  The 
accompanying data set demonstrates by quantification of complete karyotype data that 
subpopulations of cells with a specific translocation are no more homogeneous than the 
remainder of the cells comprising that population.  Thus, the stochasticity of low fidelity genome 
transfer invalidates the assumption that any given genomic marker denotes relative genomic 
homogeneity within the marked sub-population.  With this understanding, the significance of 
these markers is greatly reduced in the acute setting, and particularly when gene products of 
these markers are challenged with targeted therapies. 
 
Reductionism and Holism in Cancer Genomics 
 The established gene-centered paradigm has been supported by data generated within the 
framework of a molecular reductionist approach to cellular biology.  Specifically, methodological 
reductionism is the position that the best strategic approach to problem solving in science 
centers on reducing explanations to the smallest possible entities.  This deductive strategy is 
inextricably tied to the gene-centered viewpoint in that the linearity of hierarchical genomic 
organization is assumed to transcend multiple hierarchical levels (phenotype, protein function, 
protein structure, amino acid residue, RNA transcript, DNA sequence).  Multiple exceptions to 
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the rule of linear, one-to-one relationships assumed by the gene-centered paradigm exist.  If 
cancer cell evolution proceeded by the stepwise acquisition of several gene-level alterations, 
then correction of a single imbalance should have only a modest inhibitory effect.  However, the 
re-introduction of a wild-type tumor suppressor gene (for example, Tp53, Rb, or APC) into 
human cancer cells where the respective endogenous gene is inactive usually promotes severe 
growth inhibition, apoptosis, or near total inhibition of tumorigenesis [227], rather than the 
predicted equal and opposite modest inhibitory effect.  A second example is that the continued 
over-expression of some genes (e.g. CCND1) seems critical for maintaining the cancer 
phenotype in several human cancer cell lines, as antisense CCND1 reversed the cancer 
phenotype towards normal.  Unpredictable and non-linear changes were demonstrated in both 
the pancreatic and esophageal cell line, which additionally developed hypersensitivity to 
chemotherapeutic agents, and phenotype reversion with persistence of elevated CCND1 levels 
[228].  The misapplication of reductionist logic becomes increasingly evident when considering 
that genotype-phenotype relationship also assumes the intermediary cellular network of actively 
transcribed genes, their regulatory elements, and the function of their gene products to be 
normally regulated, predetermined, and therefore predictable.  Considering that gene-level 
changes frequently result in variable and unpredictable phenotypes arising from complex 
combinations of genes and gene regulatory events, the assumption that predictability even of 
similar magnitude might persist is likely incorrect.  Thus, the reductionist approach is more 
reasonably applied to predict interactions between components in small groups with clear 
margins, and it offers no mechanism for the determination of how the emergent and adaptive 
properties of these cancer cell populations come to be.  From the genome-centered 
perspective, reductionist logic is misapplied because it underestimates the complex adaptive 
nature of cancer cell populations.   
 The underlying theme of complexity theory is that local interactions between parts of a 
system can lead to global properties that are neither linear nor proportional to the sum of its 
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parts.  In assuming cancer cells to be complex-adaptive systems, a genome-centered holistic 
approach is favored over reductionist logic.  Linearity and predictability assumed by the 
established paradigm underestimates the complexity of cancer cell systems because whole 
dimensions of interaction, regulation, and adaptability are overlooked.  As complex-adaptive 
systems, cancer cell populations are characterized by innumerable multi-faceted and dynamic 
interactions at the level of molecules, genomes, cells, and microenvironments, each of these 
having characteristics of a non-linear system.  Cancer cell populations also meet the criteria for 
complex-adaptive systems because of their ability to alter the strength of interactions within the 
network in a way that maximizes the average fitness of the cell population.  Examples of 
emergent properties of cancer cell systems arising from complex local interactions include:  the 
ability to organize spontaneously into different morphological patterns, the acquisition of drug 
resistance, and the rapid development phenotype alteration by karyotype shift [164, 229].  The 
significance of intra-tumor genomic heterogeneity relative to the individual cancer gene in 
facilitating these emergent properties has been demonstrated by data from our group and 
others [83, 86, 124, 128-130, 212].  The holistic approach taken by the genome-centered 
paradigm incorporates the concepts of natural and generalized Darwinian evolution with the 
regulation that cancer cell populations be considered complex-adaptive rather than linear and 
constrained by karyotype.  The appropriateness of assumed linearity between genotype and 
phenotype can be assessed by monitoring the genomic variability and stability of the cell 
population.  The complexity of many cancer cell populations allows for similar phenotypes to be 
associated with a number of alternative genome-systems or sequences of cellular events.  This 
aspect of complexity dictates that the causative events in phenotypic cellular evolution can be 
probabilistically speculated upon, but not unequivocally determined.  Within this framework, the 
proposed paradigm implicates the interplay between deterministic chaos, complexity, self-
organization, and natural selection as driving forces for conversion to the malignant phenotype.   
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 The rationale for shifting from a holistic viewpoint rather than a reductionist approach is 
largely provided by the unique features of cancer cell populations that cannot be explained by 
our current understanding of the governance of eukaryotic cells with normal genomes [230].  
Widely held viewpoints based in Darwinian evolutionary theory have established a teleological 
dogma of cause-based-on-function and emphasized a role of natural selection for the fittest 
individuals during a continuous evolutionary process.  Within the framework of Darwinian 
microevolution, the concepts of descent with modification, and the advantages provided by 
slight and successive variations, it is not possible to understand the rapidity of genotypic or 
phenotypic adaptability of cancer cell populations.  The holistic viewpoint proposes that cancer 
cell populations characterized by widespread genomic instability are precisely the irreducibly 
complex system that Darwin himself determined exceptions to his theory [231].  The widespread 
genomic heterogeneity demonstrated in the current data set also suggests a great deal or 
redundancy within the genomes of cancer cells as numerous viable karyotypes are seen.  This 
finding supports an alternative under the proposed paradigm shift and de-emphasizes any 
specific micro-evolutionary change in the determination of causality and its linkage to specific 
features of genes or genomes.  This traditional objective of Mendelian genetics, to relate cause 
and effect in a predictable manner, cannot be achieved in the case of a complex-system 
because the defining features of complex-systems are those of chaos and complexity [232-233], 
rather than constancy and linearity.  The interconnectedness (i.e., existence of multiple links 
between elements) of the system, dictates that neither the cause nor the driving force for 
evolution of the entire hierarchical system can be identified unequivocally.  The holistic 
viewpoint proposed by the genome-centered paradigm places cancer causation and 
progression at the intersection of chaos, complexity, self-organization, and selection by 
genome-system.   In understanding that entirely different conceptual frameworks pertain to 
normal versus hyper-variable genome systems, the rationale for measuring the genomic 
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variability and stability of cell populations becomes clear, is as it provides an index for weighting 
the significance of gene-level change.   
  
Macroevolution versus Microevolution 
 The genome centric paradigm clearly delineates normal micro-evolutionary change of 
normal cells from macro-evolutionary mechanisms of cancer cells on the basis of their 
respective evolutionary genomic constraints.  That is, normal diploid cells evolve by micro-
evolutionary change and transformed cells are capable of macro-evolutionary change by 
altering their entire karyotype in a single cell division.  By incorporating these differential 
mechanisms of evolutionary change under the genome-centered paradigm, it becomes clear 
how the predictability with which specific genes increase the transformation rate of diploid cells 
in culture could be far different from the predictability of such gene alterations in solid tumors.  
Even if the oncogenes purported to be the root cause of cellular transformation are discovered 
by large-scale tumor sample analyses, they will have limited potential as therapeutic targets.  
This strategy involves specific targeting of a gene or pathway in a complex-adaptive system, 
which is problematic because cancer cells are not constrained by usual growth and division 
checkpoints or by the functional roles they once held in their tissue or organ of origin [164].  In 
this setting, targeted therapy will likely selectively kill only a fraction of the cells.  It has been 
shown by karyotypic and phenotypic change that cancer cells are capable of undergoing rapid 
macro-evolutionary phenotypic shifts [164] and that the potential for drug resistance by genome 
level cell-evolutionary mechanisms is large [234].  
 Thus, gene and genome centric paradigms can be reconciled by understanding that genetic 
cancer causation can be described as micro-evolutionary to macro-evolutionary transition in 
cellular transformation and tumorigenesis.  The genes that cancer researchers believe are 
important for cancer treatment are those that function in cancer causation to bridge the gap 
between micro-evolutionary change and Macro-evolutionary change.  Whether by non-heritable 
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transient changes in protein abundance or activity, heritable gene-level molecular change such 
as sequence mutation or heritable epigenetic alteration, or large scale physical rearrangement 
of the chromosome complement by rearrangement of whole or partial chromosomes, the 
specific initiating events by which cells transform to become tumorigenic are not as significant 
as the consequence of instability  itself.  Under the genome-centered paradigm, this shift in 
focus is particularly important, as genome level change is thought to account for macro-
evolutionary adaptation of cancer cell populations.  The genome-centered paradigm considers 
cancer as a disease of odds with an almost infinite number of possible combinations of 
causative factors, whose behavior is best predicted by the acquisition of macro-evolutionary 
change and subsequently by environmental selection.  Emphasis is placed on the presence of 
macro-evolutionary genomic change, rather than on the initial destabilizing events, because the 
switch to macro-evolutionary change makes the gene alteration unpredictable, and more 
importantly, provides the variability on which selection may occur.   
 Once widespread genomic variability is evident, genome-centered logic leads to 
consideration of cancer cell populations as complex-adaptive systems with focus on intra-tumor 
rather than inter-tumor variability.  Intra-tumor variability or cell-to-cell variability within the same 
tumor exists at multiple levels.  These levels include cell phenotype and ploidy level [235], 
chromosomal aberration [136-137, 236-244], DNA copy number [245], single nucleotide 
polymorphisms [246], microsatellite shifts [247-248], base mutations [219-220], and loss of 
heterozygosity [249].  The current data demonstrate how the largest changes in gene 
expression coincide with the largest shift in karyotype. In transformed late-stage cells, change in 
whole chromosome copy numbers appears to regulate gene expression. This signifies a major 
shift in the regulatory capacity of cells to govern their genome and is marked by altered and 
heterogeneous karyotypes among cell populations which generate large-scale variability.  
Change by macro-evolution redefines the complex-adaptive system of the cancer cell 
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population by changing chromosome copy numbers and the relative orientation of genes on 
each chromosome.   
 
Measuring Signal versus Noise in Cancer Cells 
 Despite the variability known to exist in cancer cell populations, the relative importance of 
pattern identification over characterization of the true biological variability of cancer cell 
populations should be given careful consideration.  This preference is made clear by the 
majority of investigative techniques commonly utilized to test hypotheses under the gene-
centered paradigm.  For example, the widespread acceptance of techniques that average and 
batch genetic material from cell populations with high levels of genomic heterogeneity [250-251] 
is one way that the average genomic signal from a mixed population of cells is emphasized over 
the quantification of genetic diversity.  These techniques include a wide variety of extremely 
common techniques such as harvesting of extracted nucleic acids, proteins, and other cellular 
components from lysed populations of genomically heterogeneous cells.  Secondly, the 
manifestation of gene-centered logic in experimental methodologies is the significance placed 
on increasing the resolution of molecular techniques while failing to maintain resolution at the 
level of the individual cell.  Population averaged data that are reported without measure of the 
deviation from cell-to-cell certainly has earned its rightful place in molecular problem solving, but 
only when taken in the context of the present cell diversity for that population and the stability of 
the population in its environment.  For understanding the inter and intra-tumor genomic 
heterogeneity of cancer, it becomes clear that the pattern of increasing molecular resolution and 
increased scope and size of project are likely due to the difficulty in generating signal over the 
background noise of true biologic variability.  Background biological variability particularly 
presents a formidable challenge for noise reduction in epithelial cancers. For example, in the 
case of epithelial ovarian cancer heterogeneity has been reported from the level of histological 
subtype to DNA sequence [32]. Rather than focus on analytical techniques that emphasize 
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genomic signal over the true “noise” of cancer cell systems, the current data set and work by 
our group [128-130, 193] and others [115, 252-254]  have focused the experimental design and 
techniques to quantify genomic heterogeneity as it relates to macroevolution and cell 
phenotype. 
 Several large-scale projects such as The Cancer Genome Atlas (TCGA) and the Cancer 
Biomedical Informatics Grid (CABIG) are underway in cataloging the sequences of hundreds of 
patient tumor samples.  The rationale for funding such large-scale projects is that the 
identification of gene mutations common among clinical tumor specimens will yield biologically-
relevant therapeutic targets for clinical cancer treatment [255-257].  In such studies, a wide 
variety of low frequency genetic alterations have been discovered.  For example, a team of 
forty-two scientists searched for common mutations among 18,000 genes and 11 tumor 
samples.  Most of these genes were found to be mutated in less than 10% of samples.  Of the 
cancer genes selected for the validation set, 15/40 were not found to be mutated in any of the 
96 patient cancers.  In a similar vein, gene-centered rationale has also provided the impetus for 
recent sequencing of entire cancer genomes from batched extracted DNA.  This and other 
similar studies have proven to be extremely complicated.  In sequencing the melanoma 
genome, the authors describe the difficulty in mapping the genetic components correctly onto 
each chromosome [256-257].  Additionally, repeated tweaking of the bioinformatics algorithms 
and the analysis of 200 billion data points was required to determine the 33,000 mutations 
characterizing the melanoma cell line [256-257].  Genome-centered logic suggests that the 
intra-tumor (cell-to-cell) heterogeneity of this line has greater significance than the mutations 
with significant commonality among cells to generate signal above the biological noise.  
Heterogeneity of the cell population at this level was readily apparent among 10 metaphase 
cells: 6/10 metaphases have 3 Chr. 11, four of these with an additional unbalanced 
der(?)t(1p?;18q?), while 4 other metaphases have 2 Chr. 11, and one der(?)t(11;18).  Based on 
this karyotype data, it is clear that several different versions of the melanoma genome system 
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co-exist within one cell line.  This variability brings into question how the results of such 
sequencing experiments should be interpreted and the composition possibly of sequence of the 
dominant signal over the noise of the mixed genome system that was analyzed.  The proposed 
paradigm shift additionally questions the significance of these data based on the transient 
nature of any cancer genome sequence given the rate of mutation (33,000/ division) at the level 
of the DNA base.  Finally, the likelihood that targeted therapies for clinical cancers aimed at 
gene products of mutated sequence from this melanoma line will result in cancer cure is 
extremely small considering the combined heterogeneity and adaptability of the genome 
system. 
Basic scientists are beginning to measure behavior of cell populations in lower 
organisms on a global scale and on multiple levels (genome, transcriptome, metabolome) at the 
same time.  These strategies are advantageous because they provide information as to the 
regulatory control among multiple levels of cellular dynamics.  Using these techniques, a 
complex-systems based approach to data interpretation can be employed in the evaluation of 
cancer cell populations.  However, results generated from such studies must be considered in 
light of data that shows extreme cellular variability additionally occurs at the level of transcription 
and translation when such outcomes are measured at the level of the individual cell [258-259].  
For example, when comparing metaphase-CGH to SNP-CGH to array-CGH, molecular 
resolution is clearly increasing while information quantifying cellular variability is lost.  The 
strength of data recorded on the content or behavior of individual cells within a population such 
as SKY karyotype analysis, in situ hybridization, metaphase-CGH, flow cytometry, 
immunohistochemistry and others is their ability to measure outcome variable(s) while 
maintaining cellular resolution, thereby allowing for quantification of variability about signal 
strength, and position relative to other structures.  One such technology with the capacity to 
characterize heterogeneous cellular responses is histomics.  This technique involves the 
collection of proteins from a population of cells, the generation of monoclonal antibodies from 
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the batched cellular responses, and the application of these antibodies to the cell 
population/tissue from which they were collected to determine the origin, sub-cellular location, 
and cellular variability of the response in situ.  When considering the effort required to explore 
the cancer genome that involves gene-seeking or sequencing of heterogeneous populations, 
these high-throughput technologies with high molecular resolution seem less attractive.   
As high-throughput techniques continue to be developed to support cell-by-cell 
experimental methods, data from batched cellular material can be interpreted within the 
proposed genome-centered paradigm.  These data will provide information as to the variability 
of the cellular response and the predictability and permanence of the response in different 
environments.  This is particularly important in cancer research, aging, or in fields where internal 
or external exposure to genotoxic agents jeopardizes the integrity of the genome-system.  In 
these cases, the fidelity of genome transfer is likely low, and the system can transition to macro-
evolutionary genomic shift, rather than micro-evolutionary Darwinian evolution.  For example, 
the current data set displays tumors with a set of similar marker chromosomes and two different 
patterns of cytogenetic diversity.  The widespread genomic instability of the injected cell line 
suggests that this experiment, if repeated, would likely emerge to showcase a different pattern 
of high-frequency clonal translocations.  If cell survival is challenged, low-fidelity genome 
transfer suggests that the genome context under which that data set was collected is transient 
because variability and macroevolution can occur within that population of cells.  Particularly in 
the case of unstable genomes, averaged data without the reporting of intra-population variability 
provides no insight into the long term impact of the discovery. 
 
Clinical Considerations under the Genome-centered Paradigm 
 Although concepts such as paradigmatic shifts and altererd conceptualizaiton of gneomic 
variability in cancer cell biology may seem of little clinical value compared to the promise of 
successful trageter therapies, these theoretical shifts have real and practical clinical impact in a 
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number of areas.  While acknowledging the complexity of cancer cell populations and their 
propensity for differential gene regulation and signal transduction, the majority of investigators 
utilize laboratory cancer models and data interpretation within the framework of the gene-
centered paradigm.  The focus on pattern matching and noise reduction continues to generate 
short and fluid lists of targets for anti-cancer therapies and are considered suffieicnt rationale for 
the continued search for the genetic “Achilles heel” of cancer cells {Weinstein, 2006 #5446}.  
However, the empirical data generated from clinical trials of targeted therapies supports their 
use in combination with at lest one or two other chemotherapeutic agents [260].  Even when 
multiple targeted therapies are used in combination, these do not provide a cure.  From a 
clinical standpoint, the diminutive role placed on cancer cell heterogeneity by the gene-centered 
paradigm seems somewhat unique to therapeutic design for solid tumors.  Cancer cells have a 
200 fold increase in mutation rate compared to normal cells {Bielas, 2006 #2050;Bielas, 2005 
#2051;Loeb, 2008 #2049}.  Additionally, the rate of chromosome mis-segregation events (one 
out of five divisions [121]).  Each of these missegregation events offsets the DNA doseage by 
61-197 mega-base pairs, therefore further contributing to the variability of the genome within a 
single population.  Considering that clinically detectable cancers have already reached 10 x 109 
cells, a modest 10% increase yields  6.3 x 1012 new DNA base mutations coupled with 7 x 107 
abnormal chromosome segregation events.  By these measures, the genome centric viewpoint 
reasons that low-fidelity genome transfer and the ensuing multi-level genomic heterogeneity 
should be recognized as the major mechanism of drug resistance in solid tumors.  Disease with 
high-level variability should then beaddressed with first-line therapy as in the approach for 
treating many genomically heterogeneous and rapidly mutating diseases caused by prokaryotes 
and viri.  The search for targeted therapy in the face of such genomic diversity hinges upon the 
rare success of certain targeted therapeutics in clinical cancer treatment.  However, 
reconsideration of genome dynamics linked to responsive versus resistant cases actually 
highlights the importance of genomic variability over specific genes.  For example, the high 
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remission rates and low toxicity of the targeted BCR-ABL tyrosine kinase inhibitor has extended 
5-year survival rates to ~90% in chronic myelogenous leukemia (CML) patients and has 
ushered in an era of targeted therapy.  CML however is unlike most cancers in that its cause is 
believed to be a single genetic event that is visible by a high frequency 9;22 chromosomal 
translocation.  This translocation creates a fusion protein with abnormally high tyrosine kinase 
activity [132] and, like other members of the hematologic malignancies, the frequency of random 
aberrations and the karyotypic variability of CML cells is relatively low when compared to solid 
tumors [79].  Like other cancer genes, BCR-ABL has been linked to genomic instability, mitotic 
errors, and unfaithful DNA repair, perhaps aiding in the transition from chronic to blast-crisis 
phase [261-263].  These changes have been noted at diagnosis.  Therefore, it is not surprising 
that progression for patients on chronic Imatinib therapy occurs at a rate of ~15% over 54 
months.  Leukemic blasts from resistant individuals were first shown by sequence exploration to 
harbor disabling ligand association mutations [175, 264].  Subsequently, resistance 
mechanisms by chromosomal aberrations and copy number alterations of BCR-ABL tyrosine 
kinase [175, 265-267] were also revealed.  But in patients with blast-crisis, where genomic 
instability is significantly elevated, remission was unpredictable and short lived.  Patients 
typically underwent dramatic relapse just weeks after a complete cytogenetic response [268-
273].   The relative success of targeted therapy in chronic versus blast phase CML demonstrate 
that gene-centered approaches have much greater utility in the context of low genomic 
instability.  Specifically, targeted therapy was successful when the phenotype was 
homogeneous, the karyotype relatively stable, and the gene target most clearly mapped.  In 
epithelial tumors, the complexities of the predominant karyotype and high degree of clonal 
heterogeneity in the form of cytogenetically unrelated clones makes characterization by 
established means virtually impossible.  Under the gene-centered paradigm, genomic 
heterogeneity of solid tumors represents a further dimension of complexity in analytical problem 
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solving that is greatly attenuated in clinical cancer conditions still evolvolving by micro-
evolutionary change. 
 The environment of homogeneity and relative genomic stability seen in successful targeted 
therapeutic intervention is not characteristic of most clinically relevant cancers [80, 213].  
Therefore, continued application of gene-centered approaches to problem solving within a 
complex adaptive system reflects an over-extension of traditional genetics to a hyper-variable 
and rapidly evolving non-linear system.  Genome-centered reasoning suggests that continued 
investment in strategies which discount the existence of cell-to-cell variability and rapid 
phenotypic shift will likely not yield results leading to clinically successful treatment.  The 
distinction between micro versus macro-evolutionary mechanisms in normal versus cancer cells 
provides rationale for the relative predictability of the genotype: phenotype relationship in each 
type of evolutionary mechanism.  For example, in heritable gene mutations in the context of a 
normal diploid background there is a fair amount of predictive power between gene alteration 
and increased cancer risk.  Similarly, the altered BCR-ABL gene has greater predictive power in 
chronic phase CML.  This greater predictive power occurs when genomic instability is relatively 
low, and the target is clear and frequent among the cell population [79-80].  The differences 
between micro and macro-evolutionary mechanisms additionally provide contextual insight into 
why multiple studies have failed to determine significant lists of validated genes from 
heterogeneous clinical tumor samples [250, 274]. 
 Clinically, the challenges posed by the application of targeted gene-therapies to a complex 
system with multi-level heritable and non-heritable variability have been evidenced by the multi-
modal acquisition of Imatinib resistance in blast phase cells.  The variability of resistance 
mechanisms and mutability of blast-phase cells are similar to the varibility and drug resistance 
mechanisms previously documented for solid tumors.  These mechanisms include gene 
amplification of associtated proteins or pathways, such as the dihydrofolate reductactase and 
androgen receptors [275-277], the acquisition of entire chromosomes [278-280] and the shifting 
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of entire karyotypes [229].  An example of multi-modal resistance in a single cancer type is that 
of estrogen-receptor positive (ERα+) breast cancers.  In this subtype of breast cancer alone, 
known resistance mechanisms include, deletions involving estrogen receptor-α [281-282],  
altered gene expression [283],  interference or cross-talk between growth factor signaling 
pathways EGFR/HER2 [284-285], protein-protein interactions among SERM, ER, and co-
regulatory proteins [286], and the background genomic profile of the cancer patient such as 
metabiolic polymorphisms including CYP2D6.  Considering the multi-modal mechanisms of 
genomic diversity documented in solid tumors and late stage hematologic disease, the gene-
centered approach to gene-discovery for targeted therapy by analysis of late stage solid tumor 
samples seems less likely to yield long-term remission or cure.  Variability within a single tumor 
hinders targeted therapeutic approaches in two ways: 1) the biological noise truly existent in the 
sample makes pattern finding difficult, even gene alteration existing in the majority of cells can 
be difficult to find,  2) if these signals are detectable, the targeted therapeutic approach will 
select for cells able to survive, appearing as a drug resistant population that has the capacity for 
high mutation rates. 
 Under the guise of that clonal tumor populations dominate most cancers, investigators look 
toward oncogenes and tumor suppressor genes identified from solid tumor patient samples to 
provide the basis for designing targeted anti-cancer therapies.  However, within the framework 
provided by the genome-centered paradigm, the significance of measuring, controlling for, or 
reducing genomic instability must be incorporated in the development first line or adjuvant 
therapy of a logical approach to prevent further diversification of cancer cell populations is to be 
implemented.  Not surprisingly, heterogeneity exists even in the response of cancer cells to 
genome-stabilizing treatments [287].  Therefore, multi-pathway or multi-level approaches may 
be required in conjunction with genome stabilizing therapy, perhaps also reducing drug dosages 
to a safer therapeutic window [288].   
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 Several molecular approaches thus far have been proposed and are in various stages of in 
vivo and in vitro testing. An example of therapy that targets genomically unstable cells is the 
inhibition of centrosome clustering required for multipolar mitosis [289].  Additionally, the use of 
therapies such as 1,25(OH)2D3 that work at multiple regulatory levels [290-293] and potentiate 
the effects of many cytotoxic and antiproliferative therapies [290, 294] are promising therapeutic 
strategies according to the genome-centered paradigm.  In a similar vein, randomized aptamer 
libraries have been suggested to reduce tumor cell heterogeneity by allowing cancer cells select 
for RNA sequences that are then conjugated to radionuclide and cytotoxic drugs and targeted to 
many tumor cells [295].  Therapies such as these are a particularly good match for the complex-
systems adaptive view of cancer biology because they impact multiple regulatory levels and are 
therefore more likely to impact heterogeneous cell populations. 
 
Implications of Incorporating the Genome-Centered Paradigm 
 In conclusion, the tremendous research efforts put forth in the past decades have 
demonstrated cancer to be extremely complicated.  Cancer cell populations universally 
demonstrate karyotype alterations and genomic instability, signifying their ability to adapt by 
macroevolution.  The implications of the  paradigm shift to genome-centered thinking  on cancer 
research and treatment are many as they alter the significance of a large amount of past and 
present clinical and basic research.    Based on our data and the work of others demonstrating 
the extent and significance of cell-to-cell variability in cancer biology, it is anticipated that the 
measurement of outcome variables including intra-population variation will provide the context 
for data interpretation and inferences as to the repeatability of the experiments.  Investigators 
are encouraged to consider the possibility of rapid macro-evolutionary change in cancer cell 
lines and tumors, particularly when the cell population incurs cell death, selection, or 
environmental stress.  On beginning to explore how genomically unstable cell populations 
develop the emergent properties of complex systems, we are optimistic that investigators will 
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increase their utilization of genome-wide measurements of variables at multiple levels ranging 
from the gene sequence upwards to the cellular or tumor phenotype.   
 As technological advances permit the comparison of genomes, and interactome maps 
encompassing many pathways, high-throughput techniques may contribute to the systematic 
discounting of true biological noise.  Particularly in genomically unstable systems, the possibility 
of rapid macro-evolutionary phenotypic shifts should be accounted for and evaluated by 
measuring the karyotypic make-up of the cell population in each condition.  By explaining the 
complexity of cancer genomics and highlighting intra-tumor variability over inter-tumor 
variability, evidence is provided that supports a paradigm shift away from the current linear 
gene-centered approach.  The genome-centered paradigm does not dispel the significance of 
gene-level change, but considers the genomic context and relative predictability of such 
changes.  The genome-centered paradigm additionally allows for non-linearity and 
measurement of change considering cancer cell populations to be complex-adaptive systems.  
In this way the proposed paradigm incorporates the possibility of multi-level regulation and 
macro-evolutionary change.  The genome-centered paradigm shift and the supporting data 
supply an improved conceptual framework for a field currently filled with exceptions and 
paradoxes.  Moreover, the paradigm shift will alter experimental design and interpretations to 
support the advancement of cancer therapies and diagnostics, thereby improving future 
outcomes for cancer patients.  
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 The dominant paradigm for cancer research focuses on the identification of specific genes 
for cancer causation and for the discovery of therapeutic targets.  Alternatively, the current data 
emphasize the significance of karyotype heterogeneity in cancer progression over specific 
gene-based causes of cancer.  Variability of a magnitude significant to shift cell populations 
from homogeneous diploid cells to a mosaic of structural and numerical chromosome alterations 
reflects the characteristic low-fidelity genome transfer of cancer cell populations.  This transition 
marks the departure from micro-evolutionary gene-level change to macro-evolutionary change 
that facilitates the generation of many unique karyotypes within a cell population. Considering 
cancer cell populations to be complex-adaptive systems, multi-level analyses were performed 
longitudinally including whole genome microarray, population karyotype analysis, and 
determination of cell phenotype.  As heterogeneity in ovarian cancer at each of these levels is 
linked to low survival, metastasis, and resistance to chemotherapy, a syngeneic model of 
spontaneous ovarian cancer development was employed.  The significant findings of the current 
study are, 1) Genomic instability was apparent from the earliest stages of study, 2) Karyotypic 
heterogeneity was widespread, showed a pattern of expansion over time and preceded the 
acquisition of the transformed phenotype 3) a major karyotypic shift occurred between 
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transformed cells in vivo and tumors formed in vitro, documenting the formation of a new system 
induced by environmental change 4) Chromosome copy number has greater impact on gene 
expression in early-stage cell populations, where karyotypes are beginning to depart from the 
diploid genome. A genome-centered paradigm for transformation is emphasized through the 
discovery of early large-scale increases in karyotype heterogeneity.  This occurred well before 
the appearance of the transformed phenotype, arose much faster in Brca1 conditionally 
inactivated cells, was linked to the largest shift in gene expression, and was linked to the 
transition from in vitro to in vivo survival facilitating tumorigenesis.  These data demonstrate the 
significance, methodologies and rationale for quantifying karyotype heterogeneity in 
transformation, tumorigenesis, and clinical cancers.  Together, these findings support of a 
genome-centered evolutionary framework for cancer progression that emphasizes cell-to-cell 
genomic variability as the basis for macro-evolutionary selection and rapid phenotypic switching 
in response to new environments.  
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